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Ru11  r16-arene  half-sandwich complexes, [(1 6-arene)Ru(XY)Cl] where XY = 
chelating ligand, show promising anticancer activity both in vitro and in vivo, 
including activity against cisplatin-resistant cell lines. Potential biological and 
medical applications of organometallic complexes are hampered by a lack of 
knowledge of their aqueous solution chemistry. In this thesis the biological activity 
and aqueous solution chemistry of half-sandwich Os " arene complexes of the type 
[( 6-arene)Os(XY)Cl] is explored, and it is demonstrated that these properties can 
be tuned by careful choice of XY chelating ligand (N,N-, 0,0- and N,0-chelates) to 
achieve cancer cell cytotoxicity comparable to carboplatin. 
The osmium complexes containing N,N-chelates hydrolyse more slowly that 
their ,ruthenium analogues and the PKa of the resulting water is more acidic. Efforts 
to increase the rates of hydrolysis and the resulting pKa led to replacement of the 
neutral N,N-chelating ligand by an anionic 0,0-chelate. This was successful in that 
hydrolysis is more rapid (too fast to follow by NMR) and the pKa of the coordinated 
water has increased by ca. 0.8 units. However, these complexes are deactivated by 
formation of the inert and thermodynamically stable hydroxo-bridged dimers, [(71 6_  
arene)0s(p-0H)30s(i 6-arene)], the proportion of which increases with decrease in 
metal concentration (predominating at micromolar concentrations), even in the 
presence of 0.1 M saline. Although G (guanine) and A (adenine) bases bind rapidly 
to 6-arene)0s(0,O)},  and more strongly to Os" than to Ru", the Os" adduct [(1 6 {(i  
p-cym)Os(ma1)(G)] was unstable with respect to formation of the hydroxo-bridged 
dimer at micromolar concentrations. Attempts to tune the stability of complexes 
containing XY = 0,0-chelate, by replacing the 6-membered 0,0-chelate with 5-
membered analogues, was partially successful for the development of active 
complexes, but was unsuccessful in preventing hydroxo-bridged dimer formation. 
Within the class of N,N- and N,O-chelated complexes the choice of donor group is 
important. Replacing amine N-donor groups with the it-acceptor pyridine, reduced 
both the rate of hydrolysis and pKa of coordinated water, and increased the overall 
stability of the complex. This was especially the case for complexes containing N,O-
chelates, which displayed aqueous chemistry in between that of the parent 
compounds containing neutral N,N- or anionic 0,0-chelates. Within this group of 
osmium arene complexes, [(i 6-arene)Os(N,O)Cl], active cytotoxic complexes were 
obtained, and the first X-ray crystal structures of osmium bound to either G or A 
nucleobases is reported. 
This work shows that a wide range of reactivity can be obtained for 
complexes of the form [(i 6-arene)Os(XY)Cl] by careful choice of the XY chelating 
ligand, including control of hydrolysis rates, acidity of bound water, formation of 
hydroxo-bridged dimer, and this knowledge has allowed complexes with cancer cell 
cytotoxicity to be designed. 
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Chapter 1 Introduction 
1.1 Introduction 
This thesis is concerned with osmium(II) arene piano-stool type complexes and their 
potential application as anticancer agents. A strong focus of this work involves 
developing structure-activity relationships by probing their aqueous chemistry and 
reactivity, with a view to successfully designing anticancer complexes. This chapter 
introduces the chemistry of osmium and discusses metallodrugs, in particular 
focusing on the chemistry of ruthenium(II) arene piano-stool type complexes which 
show potential as anticancer agents. 
1.2 Osmium 
1.2.1 History and General 
Osmium was first discovered in 1803 by Smithson Tennant along with the element 
irididm when he was trying to purify platinum ores with aqua regia. Due to the 
pungent odour of osmium tetroxide, which is rapidly formed from the pure metal, 
Tennant wrote: 
"As the smell is one of its most distinguishing characters, I should on 
that account incline to call the metal Osmium" 
from ou-i the Greek for odor or smell. Its discovery preceded that of ruthenium by 
41 years, yet much more is known about the chemistry of ruthenium. This is most 
likely due to the high cost of osmium (ca. 2 times more expensive than ruthenium)' 
and the greater difficulty associated with the synthesis of osmium compounds. 2,3 
Osmium is a scarce metal accounting for 0.005 ppm of the earth's crust, and 
belongs to a group of metals classified as the platinum group metals, which in 
addition to osmium consists of ruthenium, rhodium, palladium, iridium, and 
2 
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platinum. These metals are classed together as they tend to have similar physical and 
chemical properties, and often occur together in the same mineral deposits. 
1.2.2 Uses and Applications 
Due to the lanthanide contraction, osmium is the densest naturally occurring metal ,4 
and therefore uses for osmium include alloys for high strength tips in pens, armour-
piercing weapon shells, instrument pivots, as well as electric light filaments, high 
temperature alloys and pressure bearings. Its tetroxide, 0s04, is used in finger 
printing and to stain biological tissues for transmission electron microscopy (TEM). 
Osmium shows some activity in homogeneous catalysis. 5,6  In particular the tetroxide 
is used in catalytic amounts in the Sharpless asymmetric dihydroxylation reaction, 
named after the 2001 Nobel prize winner Karl Barry Sharpless. 
1.2.3 Biological Role or Medicinal Uses of Osmium? 
Osmium is not thought to be a biologically relevant metal, and is often considered as 
highly toxic. This is mainly due to the ready formation of the tetroxide from the pure 
metal, which is indeed highly toxic (low airborne concentrations can cause lung 
congestion, skin or eye and other mucous membrane damage). The tetroxide was 
even thought to be a potential chemical weapon for terrorism in the foiled bomb plot 
in London in 2004. 
Osmium oxides have been employed as heavy atom markers to help solve the 
X-ray crystal structures of transfer RNA. 810  In one such example reported by Rosa 
and Sigler, an osmium bipyridyl adduct was formed with cytidine-38, which 
subsequently did not interfere with enzymatic aminoacylation." Investigation into 
the interactions of osmium with nucleobases followed. Osmium binding was 
observed through the 2'- and 3'-hydroxyl groups of the sugar residues, as well as 
addition to the 5,6 double bond in the pyrimidine rings (uridine, cytidine and 
3 
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thymidine).' 2" 3 
Work reported by Collier and Krauss in 1931 involved the testing of a 
number of heavy metal compounds, for which they found some osmium compounds 
(e.g. 0s02 in oil) to display average activity towards the Ehrlich strain of carcinoma. 
They concluded that the activity of heavy metal compounds depended not solely on 
the choice of metal but also on the choice of ligands bound to the metal. 14,11  Other 
studies on the biological activity of osmium complexes appear to have been largely 
restricted to osmium carbohydrate polymers which exhibit antiarthritic activity 16  and 
some anticancer activity has been reported by Craciunescu et al. for osmium(III) and 
(IV) neutral complexes 17,18  as well as trypanocidal activity against T b. brucei.' 9 
1.2.4 Osmium (Coordination) Chemistry 
The transition metal osmium belongs to group 8 of the periodic table, and can be 
found directly below iron and ruthenium. Osmium shows a high degree of versatility 
when it comes to the oxidation states it can possess; all the states from -II (d'°) to 
VIII (d°) are known and this is thought to be due to its position in the periodic table. 
As it is found near the centre it can adopt the d° configuration observed for elements 
to its left as well as d' °, observed in elements to its right. Belonging to the third row 
means that its outer 5d orbitals are very exposed and consequently sensitive to the 
electronic nature of coordinating ligands. 
Osmium does not demonstrate the same versatility with respect to 
coordination number. The most well known osmium complex, osmium tetroxide, is 
tetrahedral, but the vast majority of complexes are low-spin octahedral. 3 
It is possible to perform NMR on the 1870s isotope, but as its natural 
abundance is very low at 1.96% (and is very expensive ca. $25 000 per gram 20). This 
can be done using indirect X-{ 1870s} two-dimensional NMR spectroscopy (X = 'H 
or 31 P). The chemical shift range for 8( 1870s) spans more than 2500 ppm.2 ' Some 
4 
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atomic and physical properties of osmium, as well as the naturally occurring 
isotopes, are given in Table 1.1. 
Table 1.1 Atomic and Physical Properties of Osmium. 
Atomic Number 76 
Atomic Mass 190.23 
Electron Configuration [Xe] 04 5d   6s2 
Naturally Occuring Isotopes 22 
Atomic Mass Natural Abundance Nuclear 
Isotope 
(ma/u) (atom %) Spin (1) 
184 183.952488 (4) 0.02(l) 0 
1860s 185.953830 (4) 1.59(3) 0 
18705 186.955741 (3) 1.96(2) 1 /2 
18805 187.955741 (3) 13.24(8) 0 
1890s 188.958 137 (4) 16.15(5) 
189.958436 (4) 26.26(2) 0 
1920s 191.961467 (4) 40.78(19) 0 
Osmium in complete contrast to its lighter congeners (iron and ruthenium) has no 
characteristic cationic aqua ions. Efforts to synthesise [Os(OH2)6] 312 are 
ongoing. 23,24,27 
1.2.5 Reactivity of Osmium 
Third-row transition metal ions are commonly more inert than those of the first and 
second rows. For example, substitution reactions of platinum(II) complexes are 
commonly Ca. five orders of magnitude slower than those of its lighter congener 
palladium(II), 25  and as a consequence there is no palladium analogue of cisplatin 
5 
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(one of the world's most successful anticancer complexes). Similarly in the classical 
chemistry textbooks, osmium complexes have a reputation for being inert and 
unreactive "osmium(H) and osmium(III) complexes are also substitution inert" 25 
especially when compared to its lighter congener ruthenium. 2,3,25-30 
1.2.6 Osmium Arene Complexes 
1.2.6.1 Synthesis and Structure 
Though osmium arene species can be formed as either Os(0) or Os(II),31  the 
complexes investigated in this thesis consist of osmium in the more common +2 
oxidation state. 32  The dimer precursor, [( 6-arene)OsCl2]2, is most frequently 
synthesized by dehydrogenation of the cyclic-diene (reduced arene) with OsC1 3 in 
refluxing ethanol. The arene is aromatized on coordination and the Os(III) reduced to 
Os(II). The X-ray crystal structure of the common precursor dimer, [(r1 6-p-
cym)OsCl2]2, was solved in 1982 by Watkins et al.33 
The mono-arene complexes are formed by cleaving the chioro bridges of the 
dimer precursor on addition of donor ligands. 34 These complexes have been shown 
by X-ray crystallography to resemble a "piano-stool" structure, in which the arene 
forms the "seat" occupying 3 coordination sites, and the three remaining ligands are 
the "legs" of the "piano-stool". 
A search of Conquest version 1.8 (CCDC 2006) revealed that only ca. 240 X-
ray crystal structures of osmium arene complexes have been reported compared to 
ca. 4000 and 7350 structures of ruthenium and iron arene complexes, respectively. 
This is clearly indicative of the limited research to date on osmium chemistry. 
1.2.6.2 Catalysis 
Osmium arene complexes show potential for use as catalysts. Those containing 
chelated amino acids have been investigated as chiral catalysts, e.g. for 
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enantioselective hydrogen transfer reactions from 2-propanol to ketones, 35  and 
isomerization of 2-n-butyl-4,7-dihydro- 1,3 -dioxepin into 2-n-butyl-4,5-dihydro- 1,3-
dioxepin.36 The Diels-Alder condensation reaction of methacrolein and ethylacrolein 
with cyclopentadiene, has been reported using osmium p-cymene (p-cym) complexes 
as catalysts, [(i 6-p-cym)Os(L)](SbF6)2 where L = (S)-B1NAP (2,2'-
bis(diphenylphosphino)- 1,1'- binaphtalene) or (S)-B1NPO (2-diphenylphosphinyl-2' - 
diphenyl-phosphino- 1,1' -binaphtalene). 37 
1.2.6.3 Aqueous Chemistry 
The aqueous chemistry of osmium(II) arene complexes has been little investigated. 
One X-ray crystal structure has been reported by Mui et a!, of water coordinated to 
an osmium arene, [(l 5 Cp*)Os(13 C4H7)(CH3)(OH2)] + where Cp* = 11 5-05Me5, with 
an Os-OH2 bond length of 2.16 A. 38 Taube et al. investigated the aqueous solution 
chemistry of some osmium arene complexes. They found that the Os-bz (where bz 
benzene) bond resists hydrolysis, and reported pKa values of 6.3 and 6.4 for [(,q 6_  
bz)Os(en)(OH2)] 2 and [(16-bz)Os(NH3)2(0H2)] 21 , respectively, compared to a PKa of 
7.9 for [(i6-bz)Ru(en)(OH2)J2  where en = ethylenediamine. 39 The water exchange 
rate on osmium has been determined by Stebler-Rothlisberger et al. for the triaqua 
complex [(1 6-bz)Os(OH2)3 ]2 along with its ruthenium analogue, yielding kex of 11.8 
± 2.0 and 11.5 ± 3.1 s-1 at 298 K, respectively. 40 They speculate that the virtually 
identical parameters obtained for osmium and its ruthenium analogue, suggest that 
the rate of water exchange in these types of compounds is metal independent, and 
entirely due to the trans-labilizing influence of the it-acid arene, as they found the 
exchange of water in [(1 6-bz)Ru(OH2)3] 2 occurred 3 times faster than in 
[Ru(OH2)6] 2 .40 
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1.2.6.4 Anticancer Agents 
Osmium(II) arene complexes containing pta (phosphine 1 ,3,5-triazi-7-
phosphatricyclo[3.3.1.1]decane) as a ligand, [(i6-arene)Os(,ta)C12],  have been 
reported to show anticancer activity, 41,42  though the only data reported consisted of 
an IC50 value of 1430 M43 when tested against the A549 human lung cancer cell line 
(in comparison to an 10 50 of ca. 3 M for cisplatin). 44 
1.3 Metallodrugs 
Metals are often found in the active sites of metallo-enzymes and proteins, and it is 
now generally accepted that they play a crucial role in biology. Metal ions are 
generally classified as essential, non-essential or toxic, but their biological effects 
often depend on the state of the metal (oxidation state, chemical form and 
speciation). The Bertrand diagram (Figure 1.1) illustrates how the beneficial effect of 
different metals varies with concentration. Those that are essential to life have an 
optimum dose, where both deficiency and excess may be harmful. Toxic metals 
show increased negative effects with increase in concentration. Importantly for this 
work, therapeutic metals may be administered at a low dose that causes no harm, 
before the optimum dose (when they exert their therapeutic benefit), but increasing 
dosage further may still cause harm. 
Optimum dose 
- - 
0) 	 / If 






Figure 1.1 The Bertrand diagram, a schematic representation showing the 
dependences of the therapeutic benefit of a metal on its concentration. Metals can be 
classified as --- essential, - therapeutic or - - toxic. 
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1.3.1 General 
Metallodrugs, drugs that contain a metal atom, are increasingly becoming of interest 
due to their versatility. This class of compounds offer huge scope for design, 
attributable to the whole host of different metals available, the range of oxidation 
states which each can posses, the variety in coordination number and geometries, as 
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Figure 1.2 Examples of metallodrugs. The arsenic organometallic complex 
salvarsan (a mixture of the trimer and pentamer shown here), the gold complex 
auranofin, iron complex sodium nitroprusside, silver silvadene, barium baritop, 
vanadium complex BMOV and the organomercury complex, merthiolate. 
Metals have been used in medicine for thousands of years, though most due 
to their precious nature rather than an understanding of their therapeutic benefits. 
However, Paul Ehrlich demonstrated the significance of metals as therapeutic drugs 
in 1909, using organoarsenic compounds (e.g. salvarsan) for the treatment of 
9 
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syphilis. Since then many additional metal compounds have found applications as 
therapeutic agents in medicine; the gold complex auranofin is used as an 
antirheumatic agent, sodium nitroprusside as an iron cardiovascular drug, silvadene 
(silver sulfadiazine) is used to prevent and treat infections of second- and third-
degree bums (antibacterial and antifungal), baritop (barium sulphate) is used as a 
radiocontrast agent for X-ray imaging, BMOV (bis-(maltolato)oxovanadium(IV)) is 
an orally active insulin-mimetic agent used in the treatment of diabetes, 49 and 
merthiolate is a mercury compound that was used as an antibacterial and antiseptic 
product (Figure 1.2). In addition, salvarsan, sodium nitroprusside and merthiolate are 
examples of organometallic drugs (containing a metal-carbon bond). 
1.3.2 Metal Anticancer Agents 
Cancer is the second leading cause of death in the western world '50 and is a term that 
umbrella's a number of diseases that all display characteristic uncontrolled cell 
division, and the ability of these cells to invade healthy tissues. Treatment generally 
involves surgery, chemotherapy or radiation, and more commonly a combination 
approach. 
Research into metal based anticancer drugs has flourished since the discovery 
by Barnett Rosenburg in the 1960's that cisplatin [cis-PtC12(NH3)2], was a potent 
anticancer agent. 51  Cisplatin is currently the world's most successful anticancer 
complex and is a superb example of an inorganic drug, in that it contains not one 
atom of carbon (Figure 1.3). However, there are a number of problems associated 
with cisplatin. These include both developed and intrinsic resistance of certain 
cancers, as well as serious side-effects for the patient; nephrotoxicity (kidney 
damage), neurotoxicity (nerve damage), nausea and vomiting, otoxicity (loss of high 
frequency hearing) and alopecia (hair loss). These are factors which seriously limit 
the use of cisplatin. 
10 
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Figure 1.3 The chemical structures of the anticancer drug cisplatin, and some 
examples of 2 nd  generation platinum drugs; carboplatin, nedaplatin and oxaliplatin. 
Both the success of cisplatin and its limitations led to the search for other 
metal based anticancer agents. For new drugs to be successful they are required to 
either demonstrate enhanced activity over current drugs, reduced side effects or 
activity against a type of cancer currently with poor treatment success. This search 
initially resulted in the development of 2nd  generation platinum drugs like 
carboplatin, nedaplatin and oxaliplatin (Figure 1.3), which are typically less toxic 
than cisplatin (e.g. carboplatin can be administered in doses of up to 2000 mg per 
day, compared to 100 mg per day for cisplatin). 5254 Intriguingly the chemistry of 
these 2 n' generation platinum drugs is very different, for example cisplatin's mode of 
action involves hydrolysis of the Pt-Cl bond and subsequent binding to nuclear DNA. 
In contrast carboplatin does not readily undergo hydrolysis. 
r 	 1+ 
I I I Ph2P 	PPh2 I 	Ci 
'Ac( 	 Ti 
[Ph2F',PPh2j 's CI 
H2)N Me2 
Figure 1.4 The chemical structures of other metal-based potential anticancer agents. 
Gallium maltolate, gold phosphine, titanocene dichloride and hydroxy ferrocifens. 
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The potential of other metals as possible anticancer agents has also been 
explored, and some examples of these are shown in Figure 1.4. Notable are the 
examples of titanocene dichloride and hydroxy ferrocifen, as not only are these 
organometallic complexes, but the metal-carbon bond is formed between the metal 
and an aromatic carbon-based ring. 
Ruthenium(III) was thought to be a promising candidate, 55  as it exhibits a 
similar spectrum of kinetic activity as platinum(II), 56 but is generally less toxic. This 
may be due to its ability to mimic the essential metal iron (its lighter congener), and 
it has been speculated that transferrin may be a possible transport route into the 
cell. 57 Anticancer activity was reported for some ruthenium amine complexes, in 
particular fac-[Ru(III)C1 3 (NH3 )3],58 but due to solubility issues was abandoned as a 
potential drug. Since research into the possibility of ruthenium anticancer drugs 
began, two ruthenium(III) complexes have entered clinical trials, trans-
[RuC14(DMSO)(Im)]ImH (NAMI-A, where Im = imidazole) 59 and trans-
[RuC14(Ind)2]IndH (KP 1019, where Ind = indazole), see Figure 1.5 60  NAMI-A is 
relatively inactive towards primary tumours, but is instead an antimetastatic 
complex, meaning that it prevents the spread of cancer from the primary site to other 
parts of the body. It is often the spread of cancer that makes it a life-threatening 
disease. In contrast, the structurally similar KP1019 is active against primary 
tumours. 
It has been proposed by Clarke et al. and is now generally accepted, that the 
mode of action of ruthenium(III) drugs involves their in vivo reduction to the more 
reactive ruthenium(II). 56 '6 ' 
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Figure 1.5 Chemical structure of NAMI-A and KP1O19, ruthenium(III) 
antimetastatic and cytotoxic potential anticancer agents, respectively. The counter 
ions, protonated imidazole and indole, respectively, have been omitted. 
1.4 Ruthenium(II) Arene Complexes 
Based on the proposal that the active species of ruthenium(III) anticancer drugs is 
indeed ruthenium(II), work in our laboratory turned to investigating the anticancer 
activity of ruthenium complexes already in the +2 oxidation state. This was achieved 
in the form of organometallic ruthenium(II) arene complexes with a "piano stool" 
structure as depicted in Figure 1.6A. 
Ruthenium(II) arene complexes containing a chelating ligand like 
ethylenediamine (en), acetylacetonate (acac) and proline, or monofunctional pta, 
Figure 1.613, C and D, have all been reported to be cytotoxic to cancer cells. 62-65 
13 
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n+ 








(A) 	 (B) 	 (C) 	 (D) 
Figure 1.6 (A) General chemical structure of Ru(II) arene "piano stool" complexes, 
[(116-arene)Ru(X)(Y)(Z)]. Complexes (B) [( 6-bip)Ru(en)Cl] where bip = biphenyl 
and en = ethylenediamine, (C) [(ij  where p-cym = p-cymene and 
acac = acetylacetonate, and (D) [(i 6-p-cym)RuC12(pta)] where pta = 1,3,5-triaza-7-
phosphatricyclo[3 ,3,1,1 ]decane, have all been reported to be cytotoxic towards 
cancer cells. 
1.4.1 Proposed Mode of Action 
The ruthenium arene complexes containing the chelating ligand ethylendiamine, e.g. 
[(116-arene)Ru(en)Cl], are thought to have a similar mode of action to that of 
cisplatin. The intact chloro adduct is a "pro-drug" which is activated in vivo by 
hydrolysis of the Ru-Cl bond (replacement of Cl - by a water molecule). This is 
largely suppressed in the blood where high chloride concentrations are found (100 
mM), whereas in the nucleus (4 mM Cl -) the complex is predominantly hydrolysed to 
give the reactive species, {(116-arene)Ru(en)(OH2)]2.66 The aqua species is then 
believed to bind to nuclear DNA (Figure 1.7) with a high affinity for the N7 position 
of guanine (G) bases. 670  This high affinity for G has even been observed in the 
presence of 250-fold excess of glutathione. 69 
Despite similarities in the proposed mode of action there are clearly 
differences. Excitingly, ruthenium arene complexes containing chelating en, [(1 6 
arene)Ru(en)Cl], were found to be active against cisplatin-resistant cell lines. 70 
14 
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Different binding to DNA is expected as the ruthenium arene complexes can only 
form monofunctional adducts (compared to the bifunctional adducts formed by 
cisplatin), and intriguingly DNA treated with [(i 6-arene)Ru(en)Cl] was more 












Figure 1.7 Metal binding sites available on the nucleobases adenosine (A), cytosine 
(C), guanine (G) and thymidine (T), found on DNA. 73 
1.4.2 Versatility of Design 
The structure shown in Figure 1.6A offers much scope for design in terms of the 
arene and its substituents (R), leaving group (X), chelating ligand (YZ) and overall 
charge of the complex (n+). All these variables have been systematically explored in 
our laboratory and are discussed in the following sections. 74,75 
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1.4.2.1 Coordinated Arene 
The arene appears to play a major role in the activity of the type of complex shown 
in Figure 1.8, with increase in hydrophobicity correlating well with increase in 
activity (where IC 50 values are the drug concentrations that inhibit growth of cells by 
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Figure 1.8 Ruthenium complexes, [(71 6_arene)Ru(en)Cl] +, investigated with various 
arenes. 
Table 1.2 IC50 values in human ovarian A2780 
cancer cells after 24 h drug exposure 70 
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The arene provides a hydrophobic face to the molecule which may assist in crossing 
cell membranes, or be involved in biological recognition processes. The increase in 
activity with increase in hydrophobicity is primarily thought to be due to the ability 
of the extended arenes to intercalate into the DNA, thus offering further distortion to 
its structure.' 1.16  This is supported by the observations that in the crystal structures of 
9-ethylguan'ine (9EtG) adducts, [(ri 6-arene)Ru(en)(9EtG)] 2 , the extended arenes 
base-stack with the coordinated 9EtG (Figure 1.9).77  Therefore, the flexibility of the 







Figure 1.9 Extended arene base stacking and intercalating into DNA. (A) Space 
filling representation of the X-ray crystal structure for the dihydroanthracene 9-
ethylguamne adduct, [(r1 6-DHA)Ru(en)(9EtG-N7)] 2t (B) Model of the ruthenium 
complex bound to B-DNA, illustrating how the coordinated arene could intercalate 
between 0 base pairs. Figure reproduced from reference 77. 
The rate of reaction with cyclic guanosine monophosphate (cGMP) was 
found to be highly dependent on the coordinated arene, so that complexes containing 
17 
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an extended arene, bound to cGMP more rapidly than those containing an 
unsubstituted arene like benzene. 78 This suggests that binding is promoted by 
favourable arene-purine hydrophobic stacking interactions. 
In addition, the choice of arene affects both the rate of hydrolysis of the Ru-
Cl bond (hydrolysis is twice as fast when the arene is THA instead of bip), and the 
acidity of the resulting coordinated water molecule (PKa 8.01 and 7.71 when the 
arene is THA and bip, respectively). 66 The rate of hydroysis is important as this is 
thought to be the activation step for this class of complexes. The acidity of the 
coordinated water determines the speciation of [(ij  and [(,q 6 
arene)Ru(en)(OH2)] 2 at physiological pH, with the former thought to be less reactive 
than the latter. 
1.4.2.2 Leaving Group (X) 
The role of the leaving group was investigated and a detailed account reported 
recently by Wang et al.79 It was found that there is a correlation between the rate of 
hydrolysis for [(i6-arene)Ru(en)X]  and the cytotoxicity of the complex against 
cancer cells, with high activity for complexes that aquate readily (e.g. X = halide) 
and inactivity for those that do not aquate (e.g. X = pyridine). An interesting 
exception to this rule is when X = thiophenolate. This complex is active (1050 23 
xM) despite being relatively inert to hydrolysis. It has been postulated that the 
mechanism of activation is different and may initially involve oxidation of the 
thiolate, followed by hydrolysis of the sulfenate group. 69 
1.4.2.3 Chelating Ligand (YZ) 
The chelating ligand in [(TI 	appears to have the most significant 
effect on the reactivity of ruthenium(II) arene complexes. 
Replacing the neutral en chelate (Figure 1.613) with an anionic 0,0-chelator 
18 
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like acetylacetonate (acac) (Figure 1.6Q, significantly increases the rate and extent 
of hydrolysis (too rapid to measure by NMR). 80'8 ' The increased density of electronic 
charge on the ruthenium centre manifests itself in a considerable increase in the PKa  
(increase in basicity) of the coordinated water (from 8.25 to 9.41 for arene = 
cym). 80 The chelate also determines the rate of binding to DNA nucleobases (which 
is rapid when XY = acac), but more significantly also determines the nucleobase 
selectivity. When the chelate is the hydrogen-bond donor en, binding occurs to the 
N7 of guanosine, N7/NI of inosine and the N3 of thymidine, with weak and almost 
no binding to the N3 of cytidine and N7/NI of adenosine, respectively. When in 
competition, [(i6-arene)Ru(en)Cl]  binds selectively to the N7 of guanosine. This is 
thought to be due to the favourable hydrogen bonds formed between the NH protons 
of en and the exocyclic oxygen atom of guanosine, and the unfavourable steric 
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Figure 1.10 Origin of nucleobase selectivity of ftq 6-arene)Ru(en)Cl]. Favourable 
hydrogen bonding interaction in guanine adducts, [(i6-arene)Ru(en)(G)]2,  and steric 
clashes on binding to adenine in [(i6-arene)Ru(en)(A)]2.  Figure reproduced from 
reference 78. 
In contrast, complexes containing acac as chelating ligand, react with G and 
A nucleobases (though not with C or T) and when in competition react with similar 
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affinity to both G and A. The chelating oxygen hydrogen-bond acceptor atoms on 
acac form favourable interactions with the C6NH2 group in adenine. Molecular 
models of the guanine adduct suggests that binding would be stabilized if N(1)H-
C=0(6) adopts the tautomeric form, N(l)=C-0(6)-H, allowing hydrogen bonding 





















Figure 1.11 Favourable hydrogen-bonding interactions in the 9-ethyladenine (9EtA) 
and 9-ethylguanine (9EtG) adducts of {(TI  NHO hydrogen 
bonds in N7 and Ni bound 9EtA. Steric clashes in the N7 bound 9EtG as the N(1)H-
C0(6) tautomer and favourable hydrogen bonding as the N(i)=C-0(6)-H 
tautomer. 8° 
1.5 Aims 
As illustrated in section 1.4, work in this laboratory has involved the systematic 
investigation into variations of the structure of ruthenium(II) arene complexes, and 
how this affects the overall cytotoxicity of this new class of anticancer agents. To 
date the role of the arene, leaving group, chelating ligand and subsequently the 
overall charge of the complex, have been probed. This thesis is concerned with 
investigating the effects of replacing the central ruthenium metal with its heavier 
congener osmium, and relating any changes in the biological activity with changes in 
the chemistry. Therefore this thesis is concerned with the following. 
20 
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Synthesis of the osmium analogues of active ruthenium complexes, [(TI 6 
bip)Os(en)C1] and [(ij 	as well as the synthesis of new 
osmium arene complexes. 
Probing their aqueous chemistry, including rates and extent of hydrolysis, 
acidity of bound water and nucleobase binding studies, using predominantly 
'H NMR spectroscopy. Drawing comparisons with data reported for 
ruthenium analogues. 
Studying their speciation and aqueous chemistry under biologically relevant 
conditions, specifically at micromolar concentrations. 
Tuning the reactivity of osmium(II) arene complexes by variations to the 
structure of [(i 6-arene)Os(X)(Y)(Z)]. 
Testing of complexes for cytotoxicity against human cancer cells in vitro. 
Development of structure-activity relationships. The ultimate aim of this 
: thesis is to successfully design active osmium(II) arene complexes for the 
treatment of cancer. 
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Chapter 2 Experimental Methods 
General methods are described in this Chapter. More specific methods relating to 
particular experiments are described in the appropriate Chapters. 
2.1 Chemicals 
All chemicals and solvents used were obtained from commercial suppliers and were 
used without further purification except where stated otherwise. Methanol and 
ethanol were dried according to standard methods: distillation over 
magnesium/iodine. Deuterated solvents and OsC1 3 .nH20 were obtained from Aldrich 
and Alfa Aesar, respectively. 
2.2 Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy is a powerful technique, which 
involves studying the magnetic properties of an atoms nucleus (which is sensitive to 
its local chemical environment) by applying radiofrequency pulses. Only the 'H 
(natural abundance 99.985 and nuclear spin quantum number I, Y2) was studied in 
this thesis on account of its high sensitivity to detection. 1,2 
2.2.1 Experimental 
'H NMR spectra were acquired in 5 mm NMR tubes at 298 K (unless stated 
otherwise) on either a Bruker DPX 360 ('H = 360.13 MHz), DMX 500 ('H = 500.13 
MHz), AVA 600 ('H = 599.81 MHz) or AVA 800 ('H = 800.15 MHz) spectrometer, 
using TXI['H, 13C, X] or TBI['H, ' 3C, X] probe-heads equipped with z-field 
gradients. Spectra were acquired on the AVA 600 spectrometer unless stated 
otherwise. ID and 2D spectra were recorded using standard pulse sequences 
modified by Mr. Juraj Bella and Dr. Dusan Uhrin, University of Edinburgh. 'H NMR 
chemical shifts were internally referenced to 1 ,4-dioxane (3.75 ppm) for aqueous 
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solutions, (CHD2)(CD3)SO (2.50 ppm) for DMSO-d6, CHC1 3 (7.26 ppm) for 
chloroform-dl solutions, MeOH (3.34 ppm) for methanol-d 4 and toluene (7.09 ppm) 
for toluene-.d8. 3 All data processing was carried out using XWll'T-NMR version 2.0 or 
3.6 (BrukerU.K. Ltd.). 
2.2.2 Water Suppression 
Most of the experiments in this thesis were performed on samples in aqueous 
solution so as to be of biological relevance. Despite using 99.9% D20 (as opposed to 
a 90% H20/10%  D20 mixture) a large HOD signal is present and requires 
suppression. This was achieved using either of the following techniques, 
presaturation or Shaka. 4 Presaturation involves saturating the required signal (in this 
case residual water) by irradiating the frequency of the water signal in between pulse 
sequences. However, this saturation is also transferred to any functional groups like 
OH or NH protons which readily exchange with the protons of water (to see these 
signals samples would need to be run in 90% H20/10%  D20 anyway). Shaka water 
suppression or DPRGSE, Double Pulse Field Gradient Spin Echo, uses pulsed field 
gradient spin echoes, in which the refocusing pulse is the sequence sofil 80(x)-
hardl80(-x). The disadvantage of this technique is that signals close to the water 
peak are also reduced in intensity. 
2.2.3 COrrelation and TOtal Correlation Spectroscopy (COSY and TOCSY) 
COSY or Correlation Spectroscopy is a 2-dimensional homonuclear ('H, 'H)-
correlated NMR technique, in which the off-diagonal cross peaks indicate that the 
protons to which they correlate are spin-spin coupled, i.e. can be found close to one 
another in the molecule being studied. Consequently this is a powerful tool in the 
structural assignment of molecules. The through bond connectivities between protons 
separated by two or three bonds can be established using this technique. 
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TOCSY or Total Correlation Spectroscopy is a similar technique to COSY, 
but allows correlation between protons further away from one another in the same 
spin system. By extending the length of the mixing time (depending on the size of 
the molecule), all the protons in the molecule should be able to correlate to one 
another. This is often a useful technique to determine which signals belong to one 
species when analysing a mixture of compounds. 
2.2.4 Dynamic NMR 
The 'H NMR spectra of Os(II) arene complexes in either MeOD-d4 or D20 were 
recorded after equilibration at various temperatures ranging from 203 K to 343 K 
(depending on the solvent) at 10 K increments, on a Bruker DMX 360 or AVA 600 
NMR spectrometer. For slow exchange on the NMR timescale, independent peaks 
are observed for the two species. Fast exchange (on the NMR timescale) can be 
achieved by raising the temperature, and now a single sharp peak corresponding to 
both species is observed. The coalescence temperature (T a) is the temperature at 
which the peaks merge into one single broad peak, before sharpening into a single 
sharp peak. Kinetic data were obtained using the equations k = (itAv)/42, where k c is 
the rate constant at coalescence and Av is the difference in resonance frequencies of 
the two species in the absence of exchange (obtained at low temperature), and t c = 
1/k, where t e  is the lifetime of separate isomers at coalescence, and AG * = 
19.143T(l0.3 18-log k/T). 5 
2.3 pH* Measurements 
pH values (pH meter reading without correction for effects of D on glass electrode) 
of NMR samples in D20 were measured at Ca. 298 K directly in the NMR tube, 
before and after recording NMR spectra, using a Corning 240 pH meter equipped 
with a micro combination electrode calibrated with Aldrich buffer solutions at pH 4, 
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7, and 10. 
2.4 Calculation of pKa*  values 
For determinations of the pKa*  (pKa values determined for D20 solutions), the pH 
values of solutions of the complex in D20 were varied by the addition of dilute 
I-1NO3 or NaOD, and their 'H NMR spectra were recorded. Chemical shifts were 
plotted against pH*,  and the resulting pH titration curves were fitted to the 
Henderson-Hasselbalch equation. 
For the (de)protonation: 	 HA - 	H + K 
The Henderson-Hasselbaich eqn: 	pH = pKa + log i o([K]/[HA]) 
So that when half is dissociated: 	[HA] = [K] and pH = pKa  
Due to rapid protonation/deprotonation on the NMR timescale it is assumed that the 
observed chemical shifts are weighted averages according to the populations of the 
protonated and deprotonated species. The modified Henderson-Hasselbalch equation, 
where öobs  is the chemical shift at a given pH and öpj-i and öA.  are the chemical shifts 
at low and high pH respectively, is shown below. 
6,7 
sobs = 
AH +6 x 10 
(pKa* -pHt) 
1 + 10(pKat-pHt) 
The pHt  titration curves were fitted to the Henderson-Hasselbaich equation using 
ORIGIN version 5.0 (Microcal Software Ltd.) with PKat , 8AH  and  öA.  set as variables. 
The pKat  values obtained can be converted to pK a values by use of the equation 
suggested by Krezel and Bal, 8 for comparison with related values in the literature 
obtained in H20 solutions. 
pKa = 0.929pKa + 0.42 
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2.5 Electrospray lonisation Mass Spectrometry (ESI-MS) 
Electrospray ionisation mass spectra (ESI-MS) were obtained on a Micromass 
Platform II Mass Spectrometer and filtered D 20/H20 or methanol solutions were 
infused directly. The capillary voltage was 3.5 V and the cone voltage was varied 
between 10 and 45 V depending on sensitivity. The source temperature was 353 K. 
Mass spectra were recorded with a scan range m/z 200 to 1200 for positive ions. Data 
acquisition was performed on a Mass Lynx (V 2.5) Windows NT PC data system. 
2.6 X-ray Crystallography 
All diffraction data were collected by Dr. Simon Parsons and colleagues, University 
of Edinburgh, with MOKa radiation on a Bruker (Siemens) Smart Apex CCD 
diffractometer equipped with an Oxford Cryosystems low-temperature device 
operating at 150 K. Absorption corrections for all data sets were performed with the 
multi-scan procedure SADABS; 9 structures were solved with Crystals' ° using either 
Patterson or direct methods (SHELXL", S1R92 12 or DIRDIF' 3); complexes were 
refined against F or F using SHELXTL and H-atoms were placed in geometrically 
calculated positions. X-ray crystallographic data for complexes 1BPh4 , 1R, 1PF6 , 
20.25CH30H, 3, 4, 10, 12, 15, 16, 17, 18, 19, 24, 26, 24G and 24A0.5Et2O have 
been deposited in the Cambridge Crystallographic Data Centre under the accession 
numbers CCDC 291587, 291588, 630298, 291589, 291590, 291591, 603587, 
630299, 630300, 630301, 630303, 630302, 630304, 626657, 626658, 626655 and 
626656, respectively, and are available on the enclosed cd. The modelling programs 
Mercury 1.4.1, ORTEP 32, Cameron 14  and Diamond 3.0 15  were used for analysis of 
data and production of graphics. 
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2.7 CHN Elemental Analysis 
Carbon, hydrogen and nitrogen (CHN) elemental analysis were carried out at either 
The University of Edinburgh in the School of Chemistry on an Exeter Analytical 
Elemental Analyser (CE440), or at The University of St. Andrews in the School of 
Chemistry on a Carlo Erba CHNS analyser. 
2.8 Cytotoxicity Assays 16 
2.8.1 General 
Cisplatin (CDDP) was obtained from the Western General Hospital pharmacy as I 
mg/mL (3.33 mM) saline solutions, and the osmium(II) organometallic complexes 
were synthesized and characterised as described in the following Chapters. 
The A549 human lung and A2780 human ovarian cancer cell lines were 
obtained from the European Collection of Cell Cultures (ECACC).' 7 A549 and 
A2780 cells were grown as monolayers in Dulbecco's modified eagle medium 
(DMEM) with 10% foetal calf serum and RPMI 1640 medium with 5% foetal calf 
serum, respectively, with 2 mM glutamine and 1% penicillin/streptomycin, at 310 K 
in a 5% CO2 humidified atmosphere. Experiments were performed with cells within 




Figure 2.1 Images of human A549 lung cancer cells. (A) Immunofluorescent 
staining of cytokeratin in A549 cells, (B) normal culture of A549 cells at 37'C, and 
(C) cells as in (B) having been detached from the plate by treating with trypsin.' 8 
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2.8.2 Cytotoxicity Studies 19 
The A549 and A2780 cancer cells were plated at a density of 2000 and 5000 
cells/well on 96-well plates, respectively. Plated A549 and A2780 cells were grown 
for 24 h and 48 h, respectively, at 310 K in a 5% CO2 humidified atmosphere, before 
addition of the Os(II) arene complexes. The edges of the plate were excluded to 
avoid inaccuracy of the reading by the plate reader. 
A 2 mM stock solution of the osmium complex was made up in 5% DMSO 
and deionised water, by initial dissolution in DMSO followed by dilution with 
deionised water. Sonication was sometimes used to facilitate complete dissolution. 
These stock solutions were diluted with media to give final concentrations of 200 
tM and 8 pM (0.5% DMSO final concentration). Aliquots (50 p.L) of these solutions 
were added to the wells on the 96-well plate already containing 150 1.iL media, so 
that the final concentrations were 50 l.LM and 2 p.M (0.125% DMSO final 
concentration), respectively. These two concentrations were used as an initial screen 
for activity, and candidates were classified as either: 
Inactive 	<50% growth inhibition at 50 p.M 
Modest 	>50% growth inhibition at 50 p.M 
Potent activity 	>50% growth inhibition at 2 p.M 
IC5 0 values were obtained by testing at a variety of different concentrations, 
generally ranging from 0.1 to 100 p.M. One drug was tested per column and each 
concentration was tested in triplicate. Complete assays are performed a minimum of 
two times, each of which includes a column for cisplatin which acts as a positive and 
comparative control, as well as a column free of drug solution, which acts as the 
100% cell survival control. 
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After 24 h exposure (at 310 K in a 5% CO2 humidified atmosphere), the drug-
containing medium was removed, the cells washed with 50 j.tL phosphate buffered 
saline (PBS) and 200 L of fresh medium was added (200 .tL media was added to 
column I at the edge of the plate for the purpose of the subsequent SRB assay). The 
cells were left to grow for an additional 72 h, 3 doubling times (at 310 K in a 5% 
CO2 humidified atmosphere). 







0% - 100% cell survival Control 
Figure 2.2 Set up for cytotoxicity assays on a 96 well plate. The first column is a 
SRB stained control, and the last two, cisplatin and untreated cell controls (100% cell 
survival), respectively. Intensity of SRB (pink) dye is proportional to cancer cell 
survival. 
2.8.3 Sulforhodamme B (SRB) Assay 20 
Cells were attached to the 96-well plate by adding 50 j.iL 50% TCA to each well 
(final concentration 10%) and incubating at 277 K for I h before washing 5 times 
with tap water. Plates were dried with the assistance of a hairdryer or oven until no 
standing moisture was visible and the TCA-fixed cells were stained by adding 50 L 
of 0.4% sulforhodamine B (SRB) dissolved in 1% acetic acid, and left to stand for 30 
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min at ambient temperature. The excess dye was removed with 4 quick rinses of 1% 
acetic acid and again dried with the assistance of a hairdryer or oven until no 
standing moisture was visible. The cell-bound dye was solubilised by addition of 150 
tL of 10 mM Tris base (tris(hydroxymethyl)aminomethafle, pH 10.5) and plates 
were left standing at ambient temperature for I h to allow the solutions to become 
homogeneous. The optical density was then measured at 540 nm on a Bioflit BP800 
plate reader controlled with e-Lisa XL software. 1050 values (concentration of drug to 
inhibit 50% cell growth) were obtained from plots of % cell survival against Log of 
the drug concentration. 
(A) 	 (B) 	 (C) 
• 	 (D) (E) (F) 
)t 	. 
••• 	• 
Figure 2.3 Photos of a 96 well plate at each stage of the cytotoxicity testing on 
human A2780 ovarian cancer cells. (A) After addition of fresh RPMI 1640 media to 
the cells. (B) Media after 72 h doubling time, wells discoloured to yellow correspond 
to wells where cell survival is high. (C) After addition of TCA to fix the cells. (D) 
SRB dye added to stain cell matter. (E) Excess SRB dye has been removed; cell 
matter present in wells is stained purple. (F) Solubilised SRB dye, % of cell survival 
determined by the absorbance of each well at 540 mn. 
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3.1 Introduction 
The serendipitous discovery of the anticancer activity of cisplatin over 40 years ago' 
has stimulated the quest for other metal-based anticancer agents, especially 
complexes with less side-effects than cisplatin, which circumvent developed and 
intrinsic resistance, and possess a wider range of anticancer activity. Ruthenium(III) 
exhibits a similar spectrum of kinetic activity as Pt 11 , 2 and two Ru" complexes have 
entered clinical trials, trans- [RuC1 4(DMSO)(Im)JImH (NAMI-A, where Im = 
imidazole) 3 and trans- [RuC14(Ind)2]IndH (KP1019, where Ind = indazole). 4 It has 
been proposed that their mode of action involves in vivo reduction of Ru' 11 to the 
more reactive Ru". 2 ' 5 Organometallic complexes offer much scope for the design of 
therapeutic and diagnostic agents. 6 Certain Ru" arene complexes of the type [(1 6 
arene)Ru(LL)(X)][Z] (where LL is a chelating ligand such as ethylenediamine (en), 
X a leaving group such as CV, and Z a counterion) exhibit both in vitro and in vivo 
activity, in some cases with activity comparable to cisplatin and carboplatin. 7 '8 
Structure-activity relationships for these monofunctional Ru" complexes with respect 
to the arene, 8 the chelating ligand9 (LL) and the leaving group' ° (X) have been 
studied. Some related acetylacetonate (acac) complexes [(i6-arene)Ru(acac)(Cl)]  are 
also cytotoxic to cancer cells." As for cisplatin, hydrolysis (substitution of X by 
H20) may be an important step in the mechanism of action of Ru" arene complexes, 
12 and the rate-determining step in DNA binding. In this chapter the chemical and 
biological activity of arene en and acac complexes of the heavier congener Os" are 
explored. Previous reports on the aqueous chemistry of osmium arene complexes are 
limited." - " Studies of the biological activity of osmium complexes appear to have 
been largely restricted to osmium carbohydrate polymers which exhibit antiarthritic 
activity. 16  Third-row transition metal ions are commonly more inert than those of the 
first and second rows. For example, substitution reactions of Pt" complexes are 
commonly ca. five orders of magnitude slower' 7a  than those of its lighter congener 
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Pd", and similarly Os" is generally found to be much more inert than its lighter 
congener Ru".' 7 This chapter shows that the choice of the chelating ligand (LL = en 
6 or acac) in [(Ti -arene)Os(LL)Cl]
n+  complexes can have a dramatic effect on 
hydrolysis behavior and reactivity towards nucleobases,' 8 factors which are likely to 
be important in the design of Os' s arene anticancer complexes. 
3.2 Experimental Section 
3.2.1 Materials 
9-Ethylguanine, adenosine, cytidine, thymidine and ethylenediamine were purchased 
from Sigma-Aldrich, deuterated solvents, ammonium tetraphenyl-borate and 
ammonium tetrafluoro-borate from Aldrich and OsC13.nH20 from Alfa- Aesar. 
Ethylenediamine was distilled over sodium; sodium acetylacetonate monohydrate 
was dried in vacuo, and ethanol and methanol were distilled over magnesium/iodine 
prior to use. 
3.2.2 Preparation of Complexes 
Complexes 1-5 were synthesized using procedures similar to those reported 
previously, 8,9  1 ,4-dihydrobiphenyl, 1,4,5,8,9,1 0-hexahydroanthracene, [(1 6W 
bip)RuC12]2 and [( 6-p-cym)OsC12]2 were prepared by previously reported 
procedures. 1-21  [( 6-bip)Ru(en)Cl][BPh4] (1R) was kindly provided by Dr. Abraha 
Habtemariam and crystals of [(1 6-bip)Os(en)Cl][BPh4] (1BPh4) suitable for X-ray 
diffraction were obtained by Ms. Victoria Walland and Dr. Rafael Fernández, 
University of Edinburgh. 22 
[(,6-bip)OsCl2I2. 1 ,4-Dihydrobiphenyl (2.32 g, 14.9 mmol) was added to a 
solution of OsC13nH20 (1.10 g, 3.14 mmol) in ethanol (50 mL) and heated under 
reflux under Ar for 16 h. The orange-brown precipitate was collected by filtration 
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and washed with ethanol (150 mL) followed by diethyl ether (50 mL) and dried in 
vacuo. Yield: 1.23 g (94.6 %). Anal. Calcd for C24C14H20Os2 (831.95): C, 34.62; H, 
2.42%. Found: C, 34.23; H, 2.40%. 'H NMR (DMSO-d6): 6 7.70 (d, 4H, J = 7.2 Hz), 
7.46 (m, 6H), 6.66 (d, 4H, J = 5.1 Hz), 6.35 (t, 2H, J = 4.9 Hz), 6.31 (t, 4H, J = 5.1 
Hz). 
ft11 6-bz)OsC 1212. Cyclohexadiene (3 mL, 32 mmol) was added to a solution of 
OsC133H20 (0.97 g, 2.75 mmol) in ethanol (50 mL) and heated under reflux under 
Ar for 49 h. The fine yellow suspension was centrifuged to give a yellow powder. 
Yield: 0.90 g (96 %). Anal. Calcd for C 1 2C14H 1 20s2 (678.89): C, 21.18; H, 1.78%. 
Found: C, 20.85; H, 1.97%. 'H NMR (CDC1 3-a): 6 6.07 (s, 12H). 
1(11 6-THA)OsC1212. 1,4,5,8,9,1 0-Hexahydroanthracene (208 mg, 1.13 mmol) 
was added to a solution of OsC13.nH20 (250 mg, 0.71 mmol) in ethanol (25 mL) and 
heated under reflux under Ar for 72 h. The light brown precipitate was collected by 
filtration and washed with ethanol (40 mL) and diethyl ether (15 mL) and dried in 
vacuo. Yield: 260 mg (82.4%). 'H NMR (DMSO-d6): 6 = 6.10 (dd, 2H, J = 4.1 and 
2.1 Hz), 5.88 (dd, 2H, J = 4.1 and 2.2 Hz), 5.72 (s, 2H), 3.21 (m, 4H), 2.57 (m, 4H). 
L(1 1 6-bip)Ru(en)Ci][BPh4] (1R). Crystals of 1R suitable for X-ray 
diffraction were obtained at 298 K by diffusion of diethyl ether into a 
dichioromethane solution. 
ft11 6-bip)0s(en)CJILBF4I (1BF 4). A solution of [(116-bip)OsC12]2  (187 mg, 
0.22 mmol) in 12 mL methanol, was refluxed for 80 min under argon, and 
ethylenediamine (32 tL, 0.48 mmol) was added and the reaction mixture heated for a 
further 40 mm. The mixture was filtered through a 0.45 p.m pore size filter while still 
hot, NH4BF4 (390 mg, ca 8 mol eq) was added, stirred, and the solvent removed in 
the rotary evaporator. Soxlett extraction with dichioromethane for 5.5 h. The solvent 
volume was reduced to ca 5 mL and stored at 253 K overnight. The yellow 
microcrystalline product was recovered by filtration, washed with dichioromethane 
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(10 mL) and diethyl ether (10 mL) and air-dried. Yield: 129 mg (54%). ESI-MS m/z 
calcd for C14C1H18N20s: 442.1, found 441.3. Anal. Calcd for C 1 4C1H 1 8N2OsBF4 
(526.79): C, 31.92; H 3.44; N 5.32%. Found: C, 32.05; H, 3.20; N, 5.07%. 'H NMR 
(DMSO-d6): 6 = 7.69 (d, 2H, J = 7.2 Hz), 7.49 (t, 2H, J = 7.6 Hz), 7.44 (t, IH, J = 7.3 
Hz), 7.07 (b, 2H), 6.42 (d, 2H, J = 5.7 Hz), 6.13 (t, 1H, J = 5.0 Hz), 6.03 (t, 211, J = 
5.3 Hz), 4.79 (b, 2H), 2.44 (m, 2H), 2.20 (m, 2H). 
[( 6-bip)Os(acac)CIJ (2). Sodium acetylacetonate monohydrate (19.6 mg, 
0.14 mmol) was added to a suspension of [(ij  (57 mg, 0.07 mmol) in 
dry and degassed 1:1 CH2C12:MeOH (20 mL) and stirred at ambient temperature 
under Ar for 3 h. The solvent was removed in vacuo and the product extracted with 
THF (10 mL); yellow crystals formed on addition of hexane after storage at 253 K 
overnight. The product was collected by filtration, washed with diethyl ether (10 mL) 
and air-dried. Yield: 18.6 mg (56%). Anal. Calcd for C 17C1H 17020s (481.06): C, 
142.50; H, 3.57%. Found: C, 41.76; H, 3.45%. 'H NMR (CDC13-d: 6 = 7.63 (d, 2H, J 
7.8 Hz), 7.43 (m, 31-1), 6.56 (d, 2H, J = 5.6 Hz), 6.29 (t, 211, J = 5.4 Hz), 6.22 (t, 
AH, J = 5.1 Hz), 5.31 (s, 111), 1.77 (s, 6H). Crystals of 20.25CH 30H suitable for X-
ray diffraction were obtained at 253 K from THF/hexane. 
I(i6-bz)Os(acac)C 1] (3). Sodium acetylacetonate monohydrate (25.7 mg, 
0.18 mmol) was added to a suspension of [(1 6-bz)OsC1 21 2 (57.3 mg, 0.08 mmol) in 
dry and degassed 1:1 CH2C12:MeOH (8 mL) and stirred at room temperature under 
Ar for 2 d. The solvent was removed in vacuo, the product extracted with CH202 (10 
mL). A yellow precipitate formed after addition of diethyl ether and storage at 253 K 
and was collected by filtration, washed with diethyl ether (10 mL), and air-dried. 
Yield: 12.8 mg (19%). Anal. Calcd for C,,C1H,3020s (404.02): C, 32.67; H, 3.24%. 
Found: C, 32.06; H, 2.98%. 'H NMR (CDC13-d): 6 = 6.01 (s, 611), 5.39 (s, 1H), 1.57 
(s, 6H). Crystals of 3 suitable for X-ray diffraction were obtained by the slow 
diffusion of diethyl ether into a solution of 3 in chloroform at ambient temperature. 
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1(11 6-p-cym)Os(acac)C 1 1 (4). Sodium acetylacetonate monohydrate (17.6 mg, 
0.13 mmol) was added to a suspension of [( 6-p-cym)OsC12] 2 (48.2 mg, 0.06 mmol) 
in dry and degassed 1:1 CH2C12:MeOH (5 mL) and stirred at room temperature under 
Ar for 2.5 h. After filtration through a glass wool plug, the solvent was removed in 
vacuo and the product extracted with CH2C12 (10 mL). The solvent was again 
removed in vacuo and the product was re-dissolved in the minimum amount of 
acetone. Diethyl ether was added and after storage at 253 K overnight, the yellow 
product was recovered by filtration. It was washed with diethyl ether (10 mL) and 
air-dried. Yield: 28.1 mg (50%). Anal. Calcd for C15C1H21020s (460.08): C, 39.12; 
H, 4.60%. Found: C, 38.40; H, 4.44%. 'H NMR (CDC13-d): 8 = 5.92 (d, 2H, J = 5.5 
Hz), 5.70 (d, dH, J = 5.5 Hz), 5.34 (s, 1H), 2.71 (sept, 1H, J = 6.9 Hz), 2.27 (s, 3H), 
1.95 (s, 6H), 1.28 (d, 6H, J 6.9 Hz). Crystals of 4 suitable for X-ray diffraction 
were obtained by slow evaporation from an acetone/hexane solution at 253 K. 
[(
11
6-THA)Os(acac)C 1I (5). Sodium acetylacetonate monohydrate (21 mg, 
0.067 mmol) was added to a suspension of [(i6-THA)OsCl2]2  (56 mg, 0.063 mmol) 
in dry and degassed 1:1 CH2C12:MeOH (10 mL) and stirred at room temperature 
under Ar for 10 h. Unreacted dimer was removed by filtering the solution through a 
glass wool plug. The volume of the filtrate was reduced by half. A yellow precipitate 
formed after addition of diethyl ether and storage at 253 K and was collected by 
filtration, washed with diethyl ether (15 mL), and air-dried. Yield: 13 mg (20%). ESI 
MS: m/z calcd for C,9H2,020s {5-Cl}: 474. 1, found 473.2. 'H NMR (CDC13-d): ö = 
6.01 (dd, 2H, J = 3.8 and 1.8 Hz), 5.85 (dd, 2H, J = 3.8 and 1.8 Hz), 5.74 (t, 2H, J = 
1.2 Hz), 5.27 (s, 1H), 3.14 (m, 4H), 2.64 (s, 4H), 1.94 (s, 6H). 
3.2.3 Methods 
X-ray Crystallography. All diffraction data were collected by Dr. Simon 
Parsons, using a Bruker (Siemens) Smart Apex CCD diffractometer equipped with 
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an Oxford Cryosystems low-temperature device operating at 150 K. Absorption 
corrections for all data sets were performed with the multi-scan procedure 
SADABS;23 structures were solved using either Patterson or direct methods 
(SHELXL240r DIRDIF25); complexes were refined against F or F2 using SHELXTL 
and H-atoms were placed in geometrically calculated positions. X-ray 
crystallographic data for complexes 1BPh4, 111, 20.25CH30H, 3 and 4 have been 
deposited in the Cambridge Crystallographic Data Centre under the accession 
numbers CCDC 291587, 291588, 291589, 291590, and 291591, respectively, and 
can be found on the enclosed cd. 
Hydrolysis. A solution of 1 in 5% MeOD-d4 /95% DO (v/v) (ca. 1 mM and 
298 K) was prepared by dissolution of 1BF4 in MeOD-d4 followed by rapid dilution 
with D20, and 'H NMR spectra were recorded after various time intervals. The rate 
of hydrolysis was determined by fitting plots of concentrations (determined by 'H 
NMR peak integrals) versus time using the appropriate equation for pseudo first-
order kinetics using the program ORIGIN version 5.0 (Microcal Software Ltd.), with 
the amplitude, decay constant and X and Y offsets as variables. Solutions (ca. 2 mM) 
of 2-5 were made up at 298 K in D20. Sonication (ca. 10 mm) was employed to 
assist dissolution and 'H NMR spectra were recorded after various time intervals. 'H 
NMR spectra were also recorded for solutions of 1BF4-5 in D20 after addition of 1 
mol equiv of AgNO3 and removal of the AgCl precipitate by filtration through a 
glass wool plug, and after addition of excess NaCl (to give 0.15 M) to an equilibrium 
solution of 4 in D20. The 'H NMR spectrum of 4 after dissolution in a 1 M solution 
of NaCl in D20 was also recorded. 
To mimic typical biological test conditions (concentrations and solvents), 50 
j.tM stock solutions of 2, 4 and 5 in 0.125% DMSO-d6 /99.875% D20 (v/v) 
(measured pH 7.4-7.7) was prepared by dissolution of the complex in DMSO-d6 
followed by rapid dilution with D20. In addition an aliquot of the stock solution for 
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complex 4 was then diluted with D20 to give a 2 J.LM Os solution (measured pH 
8.27). 800 MHz 1 H NMR spectra were then recorded after Ca. 30 min at 298 K. 
Samples were then incubated at 310 K for 24 h (a typical cell exposure time and 
temperature) and 'H NMR spectra recorded at 310 K. 
The PH*  of a solution of 4 (ca. 2 mM) in D20 was adjusted from pH 2.1 to 
10.2, then reversed to 2.5 and retitrated to 11.8, by the addition of DO or NaOH, and 
'H NMR spectra were recorded. The pH was then readjusted to 7.12 and 100 mol 
equiv free acetylacetonate was added. The sample was stored at 310 K and the 'H 
NMR spectra recorded after various time intervals. 
Calculation of pKa*  Values. For determinations of pKa*  values (pKa values 
determined for D20 solutions), the PH*  values of solutions of 1A, 2A, 3A, 4A and 
5A in D20 (formed in situ by dissolution of the parent chloro complexes 1BF4-5) 
were varied from Ca. pH*  2.5 to Ca. 10 by the addition of dilute NaOH and 'H NMR 
spectra were recorded. 
The pKa and pKa values were determined from the pH*  titration curves as 
described in Chapter 2. 
Interactions with Nucleobases. The reaction of complexes 1 or 4 with 
nucleobases typically involved the addition of a solution containing 1 mol equiv of 
nucleobase in D20 to an equilibrium solution of 1BF4 or 4 in D20 (which contains 
largely aqua 1A and chloro 1, or largely aqua 4A and hydroxo-bridged dimer 8 
complexes, respectively), or to a solution of 1A (prepared by the addition of 1 mol 
equiv AgNO3 to a solution of 1BF4 and removal of AgCI by filtration). The pH * 
value of the sample was adjusted if necessary with dilute NaOH so as to remain 
within a physiologically-relevant range (close to 7). A sample of equimolar 4 and 9-
ethylguanine (9EtG) was also prepared by dissolution of 4 in a solution of 9EtG. 'H 
NMR spectra of these solutions were recorded at 298 K after various time intervals. 
A pH* titration of a solution containing equimolar 4 and 9EtG was carried out 
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from pH' 2 to 9 and 'H NMR spectra were recorded at 298 K. Also a solution 
containing 4 and equimolar adenosine (Ado) was titrated at 298 K from pH' 7 to 1 by 
the addition of dilute HC104. For both titrations, the purine H8 chemical shifts 
(together with that for H2 of Ado) were plotted against pH' and the data fitted to the 
Henderson-Hasselbalch equation. 
Cytotoxicity Towards Human A549 Lung Cancer Cells. Cytotoxicity 
assays on human lung A549 cancer cells was performed as described in Chapter 2 for 
complexes 2-5. 
3.3 Results 
The complexes studied in this work are shown in Figure 3.1 and their nucleobase 
adducts are shown in Figure 3.2. Osmium(II) arene complexes containing chelated en 
(1BF4) or acac (2, 3, 4 and 5) and Cl - as leaving group were synthesized in good 
yields via the Cl-bridged dimers, [(i6-arene)OsCl2]2,  where arene = biphenyl (bip), 
benzene (bz), p-cymene (p-cym) and 5,8,9,1 0-tetrahydroanthracene (THA). 
biphenyl (bip) 	 p-cymene (p-cym) 	
Arene 	>---- 	I 
Os—Cl 
5,89,10-Tetrahydroanthracene 	 Cl" \ 	\ ,..Cl 
benzene (bz) 	 (THA) 	





M X V 
IBPh4 Os BPh4 Cl 
IR 	Ru BPh4 Cl 
IBF4 Os BF4 Cl 
IA 	Os 2BF4 H20 
Arene 	1n+ 
Arene V 	n 
2 bip Cl 	0 
2A bip H20 	I 
3 bz Cl 	0 
3A bz H2O 	1 
4 p-cymCl 0 
4A p-cym H2O 	1 
5 THA Cl 	0 
5A THA H20 	I 
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Figure 3.1 The osmium arene complexes studied in this work. 
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Figure 3.2 Nucleobase adducts of osmium arene complexes studied in this work. 
3.3.1 X-ray Crystallography 
The X-ray crystal structure of [(i6-bip)Os(en)ClJ[BPh4]  (1BPh4) was previously 
obtained by Ms. Victoria Walland and Dr. Rafael Fernández, 22 in this work the X-ray 
crystal structures of [( 6-bip)Ru(en)Cl][BPli4] (1R), 26 [(16.. 
bip)Os(acac)Cl] 0.25 CH3OH (2 O.25 CH3OH), [(716-bz)Os(acac)Cl]  (3) and [(
11
6-p-
cym)Os(acac)Cl] (4)27  have been obtained. All have the familiar pseudo octahedral 
"three-leg piano-stool" geometry, with Os" (and Ru" for 1R) t-bonded to the arene 
ligand (the "seat") and a-bonded to a chloride and a chelating ligand (the three "legs" 
of the piano stool). Crystallographic data are shown in Table 3.1, and selected bond 
lengths and angles are listed in Table 3.2. No intermolecular arene ring stacking is 





Table 3.1 Crystallographic data for [( 6-bip)Os(en)C1]BPh4 1BP114, [( 6-bip)Ru(en)Cl]BPh4 1R, [( 6-bip)Os(acac)Cl] 
20.25CH30H, [(i6-bz)Os(acac)Cl]  3 and [( 6-p-cym)Os(acac)Cl] 4. 
1BPh4 1R 20.25CH30H 3 4 
Formula C38H38B 1 CIN2Os C38H38B 1 CIN2Ru C 1725H 18Cl2O225Os C 1 1 H 13C1O2Os C151-1210020s 
Molecular weight 759.20 670.07 486.97 402.88 458.97 
Colour Yellow Yellow Yellow Yellow Yellow 
Size 0.97x0.39x0.13 0.16x0.25x0.38 0.42x0.22x0.08 0.10x0.26x0.65 0.54x0.24x0.17 
2(A) 0.71073 0.71073 0.71073 0.71073 0.71073 
1/K 150 150 150 150 150 
Crystal system Monoclinic Monoclinic Orthorhombic Triclinic Triclinic 
Space group Cc Cc P2 1 2 1 2 1 P-i P-I 
a(A) 8.9165(7) 8.8984(3) 8.8029(3) 6.4848(2) 9.4688(5) 
b (A) 17.4347(14) 17.4254(6) 9.6356(3) 9.6226(4) 10.0201(6) 
c(A) 19.9254(16) 19.9718(5) 21.9080(7) 9.6765(4) 16.5231(8) 
a () 90 90 90 110.171(2) 95.496(4) 
fl ç) 93.683(1) 93.609(2) 90 97.365(2) 89.941(3) 
90 90 90 90.975(2) 92.784(4) 
Volume (A3) 3091.1(4) 3090.65(17) 1858.26(10) 560.89(5) 1558.63(15) 
Z 4 2 4 2 4 
R 0.0244 0.0419 0.0703 0.0237 0.0418 
R. 0.0573 0.0912 0.1786 0.0604 0.0827 
GOF 0.9126 0.9846 1.156 1.0641 1.030 
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Table 3.2 Selected bond lengths (A) and angles (°) for [( 6-bip)Os(en)Cl]BPh4 
1BPh4, [(11 	1R, [( 6-bip)Os(acac)ClJ 20.25CH30H, [(116 
bz)Os(acac)C1J 3 and [(TI 	4. 
Bond 	1BPh4 	1R 	20.25CH30H 	3 	 4 
length/angle' 
M-C(Arene) 2.231(4) 2.189(4) 2.03(2) 2.204(7) 2.183(4) 
2.149(4) 2.188(4) 2.08(2) 2.186(7) 2.147(5) 
2.176(4) 2.167(4) 2.17(2) 2.173(8) 2.189(5) 
2.180(4) 2.161(4) 2.22(2) 2.142(11) 2.213(4) 
2.200(4) 2.230(4) 2.18(2) 2.159(10) 2.185(5) 
2.181(4) 2.170(4) 2.09(2) 2.166(9) 2.140(5) 
M-X, 2.148(3) 2.108(3) 2.086(11) 2.078(3) 2.077(3) 
M-X2 2.131(3) 2.137(3) 2.062(11) 2.078(3) 2.078(3) 
M-C1 2.4015(9) 2.4005(10) 2.420(4) 2.4222(10) 2.4177(10) 
X,-M-X2 78.68(13) 79.26(13) 86.8(4) 87.67(13) 87.66(11) 
X1-M-CI 82.99(9) 84.76(10) 83.7(5) 83.66(9) 83.50(10) 
C1-M-X2 83.83(10) 84.01(9) 83.9(5) 83.70(10) 82.95(10) 
The structures of the Os 1 ' complex 1BPh4 and Ru" complex 111 containing 
chelated en are shown in Figure 3.3. They crystallize in the same monoclinic unit 
cell, space group Cc, with almost identical unit cell dimensions. The BPIi1 counter 
ion in both 1BPh4 and 1R sandwiches the chelated ethylenediamine, forming chains 
with short range en(NH) ... C(BPh4) interactions of 3.424(5) A (N(1) ... C(16)) for 
1BPh4 and 3.294(6) A (N(8) ... C(30)) for 111, see Figure 3.4. The metal-Cl 
(2.3963(14) A and 2.4005(10) A, for 1BPh4 and 111, respectively), metal-N 
(2.108(3)-2.148(3) A) and metal-C (2.149(4)-2.231(4) A) bond lengths are similar 
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(A) 	 C9 ClO 
C8 	Aiv 









Figure 3.3 X-ray crystal structures and atom numbering schemes for (A) [(71 
6 
bip)Os(en)Cl][BPh4] 1BPh4 and (B) [(1 6-bip)Ru(en)C1}[BPh4] 1R (50% probability 
ellipsoids). The H atoms have been omitted for clarity. 
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Figure 3.4 Diagrams showing the short range interactions between the (en)NH 
protons and aromatic 	rings of the BPh 	counter anion in (A) [( 6-bip)Os 
(en)ClI[BPh4] 1BPh4 and (B) [(1 6-bip)Ru(en)C1][BPK4] 1R giving rise to chain 
structures. 
The structures of the Os" complexes 2, 3 and 4 containing chelated acac are 
shown in Figure 3.5. 
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Figure 3.5 X-ray crystal structures and atom numbering schemes for (A) [(1i6 
bip)Os(acac)Cl] 2, (B) ft116-bz)Os(acac)C1] 3, and (C) [(71 
6_P_Cym)Os(acac)CI] 4 
(50% probability ellipsoids). The H atoms have been omitted for clarity. Two 
independent molecules of 4 crystallize in the same unit cell; only one is shown. 
The Os-Cl and Os-O bond lengths range from 2.4177(10)-2.4222(1 0) A and 
2.062(11)-2.086(l 1) A, respectively (Table 3.2). Complex 2 crystallizes with '/4 
solvent molecule of methanol and shows disorder in the coordinated biphenyl ring 
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which occupies three different positions (Figure 3.6A), resulting in a lower quality of 
determination. For all of these conformations, the propeller twist of the biphenyl 
ligand is ca. 30 0, and the pendent phenyl ring lies above the chelated acac ligand. 
Complex 3 shows disorder in the coordinated benzene ring over two different 
positions with equal occupancy (Figure 3.613). Two independent molecules of 4 




Figure 3.6 Diagrams showing the disorder in the coordinated arene ring. (A) [(16 
bip)Os(acac)Cl] 2, in which biphenyl occupies three different positions with 50, 25 
and 25% occupancy. (B) ft11 6-bz)Os(acac)Cl] 3, in which the coordinated benzene 
ring adopts two different orientations, with equal occupancy. 
An interesting feature of the crystal structures of complexes 2, 3 and 4 is the 
directional hydrogen bonding (LD-H A 150'<0<180')  between coordinated 
(arene)H and (acac)O atoms of adjacent molecules (Table 3.3), the shortest CH •O 
hydrogen bond being 2.29 A for 2. These hydrogen bonds are responsible for the 
formation of dimers, Figure 3.7. 
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Table 3.3 Selected hydrogen bonding interactions for complexes 2, 3 and 4. 
[(16-bip)Os(acac)Cl] 0.25CH30H (20.25CH30H) 
D-H"A 	 H---A (A) 	D . .. A (A) 	Z D-H A (°) 
C42-H42 014 (inter) 	2.50 	3.42(2) 163 
C51-H51054 (inter) 2.29 3.23(2) 	168 
(1 6-bz)0s(acac)C1] (3)  
D-H ... A H . .. A (A) D" A (A) L D-H A (°) 
C106-H1 051 	04 (inter) 2.34 3.332(13) 169 
C201-H204308 (inter) 2.31 3.319(9) 175 
[(1 6-p-cym)Os(acac)Cl] (4) 
D-H ... A H-- -A (A) D .. . A (A) Z D-H .. .  A (°) 
C53-H53"052 (inter) 2.56 3.412(6) 149 









(B) 	 f. 
(C) 	 IM 
Figure 3.7 Diagrams showing dimers formed by (arene)C-H 0(acac) directional 
hydrogen bonding between adjacent molecules in the X-ray crystal structure of (A) 
{(i16-bip)Os(acac)C1I1 20.25CH30H, (B) [(1 6-bz)Os(acac)C1] 3, and (C) ftr 6-p-
cym)Os(acac)Cl] 4 (50% probability ellipsoids). Additional H atoms have been 
omitted for clarity 
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3.3.2 Hydrolysis 
The 'H NMR spectrum of the en complex 1BF4, [016-bip)Os(en)Cl][BF 4], in 5% 
MeOD-d4 /95% DO at 298 K initially contained one major set of peaks. A second 
set of peaks increased in intensity with time, reaching equilibrium after ca. 30 h, 
Figure 3.8. The new peaks had similar chemical shifts to those of the aqua complex 
1A, prepared by treatment of 1BF4 with AgNO3 , under the same conditions (arene 
peaks: doublet ö 6.28, triplet 6 6.05 and triplet 6 5.96; pH*  7, Figure 3.9). Fitting the 





12h 1 lÀ 
81i 
5 min 
6.4 	6.2 	6.0 ppm 
Figure 3.8 Low field region of 'H NMR spectra recorded during the hydrolysis of 1, 
[( 6-bip)Os(en)ClJ, in 5% MeOD-d4 / 95% D20 at 298 K (Ca. 1 mM). The aqua 
adduct IA, which is the product of hydrolysis, has a low pKa*  (6.37) and readily 
deprotonates. As hydrolysis progresses, the solution becomes more acidic and the 
peaks for 1A shift to low field (relatively rapid exchange between D20 and OD 
species). x = dimer impurity in 1BF4 . 
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Figure 3.9 Low field region of the 'H NMR spectra of (A) a solution of 1BF4 , [( r16-
bip)Os(en)Cl] in D20 at 298 K and (B) after treatment of 1BF4 with I mol equiv 
AgNO3 for 24 h to remove the Cl - ligand and generate 1A, [(116-bip)Os(en)(OD)] 
(pH* 7). Peak labels: see structures; due to subsequent NH exchange with D, peak y 
for enNH protons is visible only in (A) which was recorded within 10 min of 
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Time I h 
Figure 3.10 Hydrolysis of [(TI 	(1BF4). Time dependence of the 
decay of the chloro complex 1 and formation of the aqua!hydroxo adduct lÀ in 5% 
MeOD-d4 95% D20 at 298 K. The curves represent the computer best fit for a 
pseudo first-order reaction corresponding to an hydrolysis rate constant of 0.11 h' 
(half-life of 6.4 ± 0.2 h). 
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In contrast, no peaks for the parent chioro complexes were observed in the 'H 
NMR spectra of Ca. 2 mM solutions of the acac complexes 2, 3, 4 and 5 in D20 at 
298 K. Within 10 min of dissolution, two major sets of peaks were seen in the NMR 
spectra: 2A (doublet 6 6.67, triplet 6 6.58, overlapped triplet 6 6.45) and 6 
(overlapped doublet 6 6.46, triplet 6 6.25, triplet 6 6.01), 3A (singlet 6 6.28) and 7 
(singlet 6 6.03), 4A (doublets at 6 6.28 and 6 6.07) and 8 (doublets at 6 6.04 and 6 
5.82), SA (multiplets at 6 6.33, 6.13 and 5.79) and 9 (multiplets at 6 5.98, 5.92 and 
5.86), Figure 3.11. Also peaks assignable to free acacH (6 2.26) were present in the 
spectra. 
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t A k(A)  ii  
6 







6.7 6.6 6.5 6.4 6.3 6.2 6.1 6.0 5.9 ppm 	6.7 	6.5 	6.3 	6.1 ppm 
Figure 3.11 Hydrolysis of [(i6-arene)Os(acac)Cl]  complexes. 'H NMR spectra of 
complexes (A) 2 (arene = bip), (B) 3 (bz), (C) 4 (p-cym) and (D) 5 (THA) in D20 
recorded 30 min after dissolution at concentrations of 3.5, 2.1, 3.4 and 2.2 mM, 
respectively, 298 K. Two sets of peaks appear, corresponding to the aqua species, 
[(
11
6-arene)Os(acac)( 0D2)1 (2A, 3A, 4A and 5A), and the hydroxo-bridged dimers, 
[( 6-arene)Os(j.t-OD)3Os( 6-arene)] (6, 7, 8 and 9). Assignment of the two different 
species in solutions of 2 in D20 was further confirmed by (E) a 2D COSY NMR 
spectrum (H 0 = ortho, Hm = meta and H = para coordinated arene ring protons in 
bip). 
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The ESI-MS spectra of these NMR samples contained peaks at m/z 445 (2A) 
and 741 (6), 370 (3A) and 591 (7), 426 (4A) and 701 (8), 473 (5A) and 796 (9), 
assignable to the fragment [(i 6-arene)Os(acac)] arising from 2A, 3A, 4A and 5A 
(caic mlz 445.1, 370.1, 426.1 and 474.1, respectively) and to [(11 
 for 6, 7, 8 and 9 (calc m/z 742.1, 590.0, 701.1 and 798.2, 
respectively). Further confirmation of the assignment of the 'H NMR peaks for 2A, 
3A, 4A and 5A to the aqua complexes [(i6-arene)Os(acac)(OD2)]  was obtained by 
recording the spectra of solutions of 2, 3, 4 and 5 in D20 after addition of 1 mol 
equiv AgNO3 (and removal of AgCl by filtration). 
The effect of NaCl on the hydrolysis equilibrium for 4 was investigated. 
Addition of excess NaC1 (to give 0.15 M) to an equilibrium solution of 4 (1.2 mM) in 
D20 caused the p-cymene 'H NMR peaks for species 4A to shift from 6.26 and 6.05 
ppm to 6.19 and 5.95 ppm, respectively, and broaden, whereas peaks for species 8 at 
.16.05 and 5.82 ppm, remained unchanged. The resulting spectrum was similar to that 
obtained on dissolution of 4 in a 1 M NaC1 solution in D20, see Figure 3.12. 
4/4A 	 4/4A 7 
(B) 	




6.3 	6.2 	6.1 	6.0 	5.9 	5.8 	ppm 
Figure 3.12 Effect of chloride on the hydrolysis of [(ij 	4. 'H 
NMR spectra showing the resonances for the p-cymene ring protons of (A) 4 in D20 
at equilibrium, (B) 10 min after the addition of NaC1 (final concentration 0.15 M) to 
(A), and (C) 4 after dissolution in a 1 M NaC1 solution in D20. Assignments: 4A, 
[( 6-p-cym)Os(acac)(OD2)]; 8, [(1 6-p-cym)Os(p.-OD) 30s(i 6-p-cym)]. 
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The 'H NMR spectra of solutions of 4, [(r 6-p-cym)Os(acac)Cl], at the low 
(micromolar) concentrations within the range used in the cytotoxicity tests were 
recorded. Spectra of 4 at 2 and 50 p.M (in 0.125% DMS046/99.875% D20 (v/v), 
pH* 7.7) after Ca. 30 min at 298 K and 24 h after incubation at 310 K, contained only 
one set of peaks in the arene region (ö 6.04 and ö 5.82, Figure 3.13), assignable to 
species 8. Spectra recorded in the absence of DMSO-d6 were the same. The ESI-MS 
of an equilibrium solution (Figure 3.13E) contained a peak at m/z 704, confirming 
that the major species present is the hydroxo-bridged dimer, 8, [(71 
 (calc mlz 703.9). A 'H NMR spectrum of a 50 p.M solution of 4 
in 0.15 M NaCl in D20 (mimicking the chloride concentration in cell culture media) 
at 298 K was also recorded. Again, the only peaks present in the spectrum were those 
for the hydroxo-bridged dimer 8. 
(C) 	8 8 	
(D) 	8 8 	
(E) 
100 
30 min 	 24h 	I 
(A) 	 (B) 
50 PM I 	50 p 
30 min 24 h  
6.4 	6.0 	5.6 6.4 	6.0 	5.6 200 400 
ppm ppm 
704 
600 800 m/z 
Figure 3.13 Hydrolysis 	of [(11 	(4) 	at micromolar 
concentrations. Low field region of the 800 MHz 'H NMR spectra of a 50 p.M 
solution of 4 in D20 (A) after 30 min at 298 K and (B) at 310 K after 24 h incubation 
at 310K, and of a 2 p.M solution of 4 (C) after 30 min at 298 K and (D) at 310 K 
after 24 h incubation at 310 K (biological-test concentrations and conditions). 
Assignments: 8 6.04, 5.82 p-cymene arene resonances of 8, [( 6-p-cym)Os(p.-
OD)3Os(116-p-cym)]. (E) ESI-MS of sample from (B). The major peak at m/z 704 is 
assignable to the fragment [(fl 6-p-cym)Os(p.-OD)3Os(fl 6-p-cym)]. 
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Similarly, spectra of 2 and 5 at 50 jiM (in 0.125% DMS046/99.875% D20 (v/v), 
pH* 7.8 and 8.0) after Ca. 1 h at 298 K, Contained only one set of peaks in the arene 
region assignable to species 6 and 9, Figure 3.14. 
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Figure 3.14 Low field region of the 'H NMR spectra of 50 jiM solutions of (A) 2 
and (B) 5 in D20 after ca 1 h at 298 K. Species 6 and 9 correspond to the biphenyl 
and tetrahydroanthracene hydroxo-bridged dimers, [(1 6-bip/THA)OsQ.i.-OD)3Os(r 6-
bip/THA)], respectively. 
3.3.3 p14* Dependence 
The changes in the 'H NMR chemical shifts for the protons of the coordinated 
phenyl ring of 1A present in an equilibrium solution of 1 in D20 at 298 K (see Figure 
3.8) were followed with change in pH*,  over the range 2-9. These data were fitted to 
the Henderson-Hasselbaich equation (Figure 3.15A), which yielded a pKa value of 
6.37. 
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Figure 3.15 Determination of the pKa*  values of the aqua complexes [(71 6_  
arene)Os(LL)(0D2)1 +. Dependence of the 'H NMR chemical shifts of the 
coordinated arene ring on pH*  for (A) [(TI  1A (. ortho H0, . 
meta Hm, + para Hr), (B) [(16-bip)Os(acac)(OD2)] 2A (. ortho H 0, . meta Hm, V 
para. Hr), (C) [(1 6-bz)Os(acac)(OD2)] 3A, (D) [(fl 6-p-cym)Os(acac)(OD2)} 4A and 
(E) [(1I6  -THA)Os(acac)(0D2)] +  5A. The curves represent the best fits to the 
Henderson-Hasselbalch equation and correspond to PKa values of 6.37 for 1A, 7.28 
for 2A, 7.45 for 3A, 7.84 for 4A and 7.87 for 5A. 
The PH*  dependence of the 'H NMR chemical shifts of the coordinated arenes of 
complexes 2A/6, 3A/7, 4A/8 and 5A/9 was monitored over the range 2-10 (Figure 
3.15). Those for species 6, 7, 8, 9 and free acacH 28 remained unchanged with pH* 
(over the range 2-10), but their intensities increased with increase in pH (Figure 
.3.16) 
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pH* a b C 
7.50 
7.06 
I 	I 	 U 	 I 	U 
2.3 2.2 2.1 ppm 
Figure 3.16 Displacement of acac from [(il 	(4) by hydroxo 
ligands. The methyl region of 'H NMR spectra from a solution of 4 in D20 at 298 K 
at various pH*  values. Assignments: a free acacH; b p-cymene CH3 of aqua complex 
4A; c p-cymene CH3 of hydroxo-bridged dimer, 8. At low pH*  (2.94) the major 
species is the aqua complex 4A, but the proportion of the hydroxo-bridged dimer and 
free acacH increases at higher pH. 
In contrast, the peaks for 2A, 3A, 4A and 5A shifted to high field and decreased in 
intensity with increase in pH*  (Figure 3.17), the maximum shift change being Ca. 0.3 
ppm in each case. These data yielded pKa*  values of 7.28, 7.45, 7.84 and 7.87 for the 
biphenyl complex 2A, benzene complex 3A, p-cymene complex 4A and 
tetrahydroanthracene complex 5A, respectively (Figure 3.1513, C, D and E). 
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Figure 3.17 Formation of hydroxo-bridged dimer from the aqua complex [(p 6-p-
cym)Os(acac)(OD2)]. 'H NMR spectra recorded during a pH titration of a solution 
of the chloro complex 4 in D20, containing predominantly the aqualhydroxo 
complex 4A -p-cym)Os(acac)(OD2/OD)] +lo and the dimer 8 [(ij 
 showing how the peaks for 8 increase in intensity with increase 
in pH*  but do not shift, whereas those for 4A shift to high field (deprotonation - fast 
exchange between aqua and hydroxo forms) and decrease in intensity as conversion 
into the dimer occurs at basic pH. 
Analysis of peak integrals of 'H NMR spectra showed that millimolar 
solutions of 4 in D20 at pH 2.1 contained mostly 4A, and only 4% of 8. On raising 
the pH *  to 10.2, very little of 4A remained and the proportion of 8 increased to 78%. 
However, on lowering the pH to 2.5, the amount of 4A present remained the same 
but the proportion of 8 fell to 33%, and peaks for unidentified species x1 and X2 
(which were minor components in the initial solution at pH*  2.1) increased in 
intensity. At pH 11.8, only peaks for 8 and free acacH were observed (Figure 3.18). 
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Figure 3.18 Irreversibility of acac displacement from [(ij 	(4) in 
aqueous solution. 'H NMR spectra of an equilibrium solution of 4 in D20, 298 K, at 
(A) PH*  2.13 which was then increased to (B) pH*  10. 19, and then to (C) 2.46, and 
finally raised to (D) 11.82. All 'H NMR spectra were recorded within 10 min of 
altering the pH*  of the sample. Peaks for the aqua complex 4A shift with pH due to 
(de)protonation of the coordinated water molecule. When the PH*  is lowered again 
(to pH*  2.46), the dimer 8 appears to break down to form species x 1 and X2 (not 
characterized - may include the triaqua adduct) rather than the acac adduct, 
suggesting that acac is displaced irreversibly under these conditions. 
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The pH of the solution was adjusted to 7.1 so that the solution consists entirely of 
the dimer, 8. To this solution was added 100 mol equiv of the free ligand, acacH. 
Even after incubation at 310 K for 9 days no new peaks appeared in the 'H NMR 
spectrum (Figure 3.19), suggesting the dimer stays intact under these conditions and 
acac recoordination does not occur. 
(B) 	 8+aa 	8 
88 	 d 
II 1 	 8 
(A) 
6.0 	5.0 	4.0 	3.0 	2.0 	ppm 
Figure 3.19 'H NMR spectra of (A) 100% hydroxo-bridged dimer 8, 	 -p- 
cym)Os(g-OD)30S(TI 	at pH 7.1, and (B) after addition of 100 mol equiv 
acacH and incubation at 310 K for 9 days. Peak a is free acacH and d dioxane. 
3.3.4 Interactions with Nucleobases. 
Addition of 1 mol equiv of 9-ethylguanine (9EtG), to an equilibrium solution of 
complex 1BF4, [(16-bip)Os(en)Cl}[BF4], in D20 (pH 7.28) at 298 K resulted in no 
new 'H NMR peaks after 10 mm. After 22 h 23% of 1 had reacted and a new H8 
peak appeared at 8.09 ppm (for species 1G, Figure 3.20), shifted by 0.27 ppm to low 
field relative to free (9EtG). Addition of 1 mol equiv of 9EtG to a solution of 1A 
67 
Chapter 3 Tuning the Reactivity of Os" Arene Complexes 
(pH* 7.0) (prepared by treating a solution of 1BF4 with 1 mol equiv AgNO3) also 
resulted in no new 'H NMR peaks after 10 mm, but after 22 h new peaks assignable 
to 1G had appeared, and 45% of 1A had reacted with 9EtG to form 1G (Figure 3.21). 
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Figure 3.20 Reaction of [(TI 6 -bip)Os(en)Cl] +  (1) with 9-ethylguanine. (A) H NMR 
spectrum of an equilibrium solution of 1BF4, (B) 10 min after addition of 1 mol 
equiv 9-ethylguanine in D20 at 298 K, PH*  7.28 and (C) after 22 h. Assignments: 1 
intact chioro complex; 1A the hydrolysis product [( ij  G 
unreacted 9-ethyguanine (9EtG); 1G the product, [(1 6-bip)Os(en)(9EtG)] 2 . After 22 
h, 23% of 1 had reacted. x is an unidentified species. 
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Figure 3.21 Reaction of [(TI 6 -bip)Os(en)(OD)] +  (1A) with 9-ethylguanine. (A) H 
NMR spectrum of a D20 solution containing 1A (formed by treating a solution of 
1BF4 with 1 mol equiv AgNO3 for 24 h), (B) 10 min after addition of 1 mol equiv 9-
ethylguanine (9EtG) and (C) after reaction for 22 h at 298 K, pH*  7.0. Assignments 
as in (D); 1A largely [(1 6-bip)Os(en)(OD)] at this pH; G unreacted 9-ethyguanine 
(9EtG); n H8 of unreacted 9-ethylguanine; 1G the product, [(r,6bip)Os(en)(9EtG)]2+. 
After 22 h, 45% of 1A had reacted. x is an unidentified species. 
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The addition of a solution of 1 mol equiv of adenosine (Ado), cytidine (Cyt) 
or thymidine (Thy) to an equilibrium solution of 1BF4 in D20 (containing 
predominantly 1A) at 298 K, resulted in no additional 1 11 NMR peaks over a period 
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Figure 3.22 No reaction of [(1 6-bip)Os(en)Cl] (1) with adenosine, cytidine or 
thymidine. 'H NMR spectrum of an equilibrium D20 solution of 1BF4 containing I 
mol equiv of (A) adenosine (pH* 6.04), (B) cytidine (pH*  6.07) and (C) thymidine 
(pH* 5.93) at 298 K after 24 h. Assignments: 1A ftq6-bip)Os(en)(OD2)] 2 ; A, C and 
T unreacted adenosine, cytidine and thymidine respectively; d dioxane. 
Addition of 1 mol equiv of 9EtG in D20, to an equilibrium solution of the acac 
complex 4, ft11 6-p-cym)Os(acac)Cl], in D20 (which contained 70% aqua complex 
4A, 30% hydroxo-bridged dimer 8, together with some free acacH) at 298 K, pH* 
7.50, resulted in a new set of 'H NMR peaks (for species 4G, Figure 3.23) within 10 
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mm (by which time equilibrium had been reached). Peaks for 4A diminished in 
intensity but those for 8 did not change. Based on H8 peak integrals for free (ö 7.82) 
and bound (8 7.76) 9EtG, 60% of the 9EtG reacted to form 4G. 
I 	I 	I• 	I 	I 	I 	I 	I 	I 	I 	I 	I 	I 	I 
	
7.0 6.0 5.0 4.0 3.0 	2.0 ppm 
Figure 3.23 Reaction of 9-ethylguanine with [(il 	(4). 'H NMR 
spectrum of 4 after reaction with 1 mol equiv 9EtG in D20, 298 K, at equilibrium 
(within ca. 10 min of reaction). Peak labels: G unreacted 9EtG (corresponds to 40% 
of total 9EtG), 4G [(q 6-p-cym)Os(acac)(9EtG-N7)] (60%), 8 dimer [(il 
 (33%); d dioxane; a free acacH. 
The major ESI-MS peak for the equilibrium NMR sample at a low cone voltage (10 
V) was at m/z 605, consistent with the formation of [(1 6-p-cym)Os(acac)(9EtG-
N7)f 4 , 4G (calc. m/z 605.2), see Figure 3.24A. To establish the binding site for Os" 
on 9EtG, a pH titration of the reaction mixture was monitored by 'H NMR 
spectroscopy over the range pH*  2-8, Figure 3.25. The chemical shift of H8 for 4G 
did not change with pHi, whereas that of free 9EtG moved to high field by ca. 1 ppm 
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Figure 3.24 Characterization of 9-ethylguanine and adenosine adducts by mass 
spectrometry. ESI mass spectra for solutions containing [(TJ  4 
and 1 mol equiv of (A) 9-ethylguanine, and (B) adenosine in D20. Peaks at m/z 
425/426 correspond to 4A-H20 [( 6-p-cym)Os(acac)j', m/z 701 to the hydroxo-
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Figure 3.25 Determination of {(1 6-p-cym)Os(acac)} 	binding site on 9- 
ethylguanine. Dependence of the 'H NMR chemical shift of 9EtG H8 on pH*  for a 
solution containing 4G, [(i 6-p-cym)Os(acac)(9EtG-N7)} and free 9EtG. The lack of 
pH dependence for 4G over the pH *  range 5 to 2 where N7 protonates, confirms that 
binding of 9EtG to Os" is through N7. 
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The 1 H NMR spectrum of complex 4 dissolved in a solution already containing 1 
mol equiv 9EtG, ca 15 min after sample preparation contained peaks for 4G (69%) 
and the hydroxo-bridged dimer 8 (18%), and small peaks for the aqua complex 4A 
and an unidentified species x. After incubating the sample for I h at 310 K, peaks for 
4G decreased (59%) and those for the hydroxo-bridged dimer 8 increased (36%) in 
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Figure 3.26 Formation of hydroxo-bridged dimer 8 from G adduct 4G. Low field 'H 
NMR spectra of a solution formed by dissolution of the parent chloro complex, [(71 6_  
p-cym)Os(acac)Cl] 4, in a solution already containing 1 mol equiv 9EtG (A) directly 
after sample preparation (ca. 15 mm) and (B) after incubation at 310 K for 1 h. Peak 
labels: G unreacted 9EtG; 4G [(1 6-p-cym)Os(acac)(9EtG-N7)] 4 4A unreacted aqua 
complex [(r16-p-cym)Os(acac)(OD2)1; 8 dimer 
cym)]; d dioxane; x is an unidentified impurity. 
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No new 1 H NMR peaks appeared in the spectrum of 4 on addition of 1 mol 
equiv of 9EtG under more alkaline conditions where the hydroxo-bridged dimer 8 
predominates (pH*  9.9, > 95% 8), even after 96 h, indicative of the inertness of 8. 
Addition of a solution of 1 mol equiv of Ado to an equilibrium solution of 4 
in D20 (which contains 70% aqua complex 4A, 30% hydroxo-bridged dimer 8 and 
some free acacH) at 298 K (pH*  7.31) led to the appearance of new peaks, within 10 
mm (Figure 3.27A), assignable to a major product 4A7 (accounting for 56% of Ado) 
and a minor product 4A1 (10% of Ado). In the H8/H2 region, 2 new sets of peaks 
appeared at 8.50 and 8.31 ppm for 4A7 and at 8.39 and 8.17 ppm for 4A1. ES I-MS 
studies of this NMR sample at a low cone voltage (20 V), gave a peak at m/z 694, 
consistent with [(1 6-p-cym)Os(acac)(Ado)f, 4A7/1 (caic. m/z 694.2), Figure 3.24B. 
The binding sites for J(ij  on Ado in 4A7 and 4A1 were assigned 
with the aid of a 1 1-1 NMR pH*  titration of the reaction mixture over the range 
pH*  7 
to 1,Figure 3.27B. The singlets for H8 and H2 of free Ado shifted to low field with 
an associated pKa* of 3.63, a value similar to that reported previously for Ni 
protoñation,29  whereas the H8 and H2 peaks for 4A1 did not shift over this pH 
range, consistent with the presence of NI-bound Ado in this complex, [(TI 
 Those for 4A7 shifted to low field over this pII*  range 
with an associated pKa* value of 1.92, assignable to Ni protonation of N7-bound 
Ado. This corresponds to a lowering of the pKa*  of Ni by 1.7 units for 4A7 [(r6-p-
cym)Os(acac)(Ado-N7)] compared to free Ado. Interestingly, the arene peaks for 
4A7 are greatly broadened (Figure 3.27A; no significant sharpening over the 
temperature range 298 - 323 K). 
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Figure 3.27 Reaction of [( 6-p-cym)Os(acac)C1] (4) with adenosine (Ado). (A) 'H 
NMR spectrum of a D20 solution of 4 and 1 mol equiv adenosine, pH 7.31, 298 K, 
at equilibrium (within ca. 10 min of reaction). (B) Dependence of the 'H NMR 
chemical shifts of Ado H8 and H2 resonances on pH * . Assignments: 8 hydroxo-
bridged dimer, [(1 6-pcym)Os(.t-OD)3Os(ii 6-p-cym)i 4A aqua complex [(q 6-p-
cym)Os(acac)(OD2)]; A unreacted adenosine; d dioxane; a free acacH; 4A7 major 
product, [(16-p-cym)Os(acac)(Ado-N7)]; 4A1 minor product, [(1 6-p-
cym)Os(acac)(Ado-N1). Based on peak integration, 66% Ado has reacted to give 
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The addition of 1 mol equiv Cyt or Thy to an equilibrium solution of 4 in 
D20 at 298 K, resulted in no additional 'H NMR peaks over a period of 24 h, Figure 
Figure 3.28 No reaction of thymidine or cytidine with [(TI 	(4). 
'H NMR spectrum of a D20 solution of 4 containing 1 mol equiv (A) thymidine (pH* 
6.18) and (B) cytidine (pH 6.14), at 298 K. Assignments: 8 hydroxo-bridged dimer, 
[(l6 pcym )Os( t.OD)0s0 6 pcym)1 +; 4A [(TI  C unreacted 
cytidine; T unreacted thymidine; d dioxane; a free acacH. Spectra were unchanged 
after 24 h. 
3.3.5 Cytotoxicity Towards Human A549 Lung Cancer Cells. 
Complexes 2, 3, 4 and 5 were all non-toxic towards the human lung A549 cancer cell 
line at concentrations up to 50 p.M (the highest test concentration). The IC50 values 
are therefore likely to be> 100 p.M and the complexes are deemed inactive. 
30 
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3.4 Discussion 
3.4.1 X-ray Crystallography. 
A search of the Cambridge Database revealed that only ca. 240 structures of osmium 
arene complexes have been reported compared to ca. 4000 for ruthenium arene 
complexes. The crystal structures of complexes [(1 6-bip)Os(en)Cl]BPh4 (1BPh4) and 
[( 6-bip)Os(acac)Cl] (2) are the first to be reported with q 6-biphenyl coordination to 
osmium, and 1BPh4 is the first containing an {(i 6-arene)Os(en)} fragment. 
The Os" (1BPh4) and Ru' 1 (1R) en complexes are isostructural in the solid 
state. The M-C1 bond lengths are the same (2.40 A) even though the ligand exchange 
rates are different. Similarly the Os Il  acac complex 4, and its Ru" analog ftq 6-p-
cym)Ru(acac)Cl], reported previously by Fernández et al,9 have similar M-Cl and M-
O bond lengths. 
Hydrogen bonds are observed between (arene)H and (acac)O of adjacent 
molecules in the crystal structures of osmium complexes [(i6-arene)Os(acac)C1] 2 
(arene = bip), 3 (bz) and 4 (p-cym), giving rise to dimers, Figure 3.7. Such H-bonds 
involving coordinated arenes are becoming increasingly recognized . 3 ' They were 
observed previously9 for [( 6-p-cym)Ru(acac)C1] and are also present (but not often 
noted) in the crystal structures of other reported Os II  arene acac complexes. 
32 
Hydrogen bonds can be distinguished from van der Waals interactions by their 
directional nature (ZD-H ... A 150 0<0<180')  as they consist of both van der Waals 
and electrostatic components. 33  C-H ...Q H-bonds, are typically given cut-off values 
of < 2.6 A.34  They are weaker than classical hydrogen bonds, and present only in the 
absence of stronger interactions, but can direct crystal packing. 
3 ' The weak 
polarization of arene ring C-H bonds may lead to interactions between the 
coordinated arene and H-bond acceptors in biological target sites such as DNA or 
RNA. 
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3.4.2 Hydrolysis. 
There are few previous studies of the aqueous chemistry of Os 
11  arene complexes. 13-15 
The hydrolysis of the Os" en complex 1 in water at physiological pH (Figure 3.10, 
half-life of 6.4 h, pH*  ca. 7) is ca. 40 times slower than its Ru" analog. 
12  This 
behaviour is consistent with the much slower ligand exchange rates often associated 
with osmium complexes in comparison with those of ruthenium. However, Stebler-
Rothlisberger et al. found that the Os" and Ru" complexes [(1 6-bz)M(OH2)3]2 
without a chelating ligand possess similar water exchange rates. 
14  This work shows 
that the presence of a chelating ligand can introduce significant differences between 
Os" and Ru". 
The conjugate base mechanism may play a role in the hydrolysis of complex 
1, especially in view of the HID exchange observed for the NH protons on the en 
chelating ligand. As the pH*  is changing during the hydrolysis of 1, due to 
deprotonation of the coordinated water, it is possible that the rate of hydrolysis may 
be changing with time under these conditions. The PH*  is also likely to affect the 
overall equilibrium. 
Changing the chelating ligand from en to acac in Os" arene complexes had a 
marked effect on the extent and rate of hydrolysis, as is also the case for Ru" 
analogs. 9  However, hydroxo-bridged dimers play a dominant role in the hydrolysis 
behavior of [(1 6-arene)Os(acac)Cl] complexes in water (complexes 6, 7, 8 and 9 are 
products from the hydrolysis of the bip, bz, p-cym and THA complexes 2, 3, 4 and 5, 
respectively) whereas they are reported to be only minor components, and then only 
at high pH*,  in analog Ru" systems. 9  There appear to be no previous reports of the 
formation of trihydroxo-bridged Os" arene dimers on dissolution of Os" arenes in 
water, although the dimers 36  have been synthesized by heating [1 6-arene)OsCl2]2 in 
strongly alkaline solutions.36c,36e X-ray structures of [(116 arene)Ru(tOH)3Ru(11 6 
arene)], have been reported 36 "" although the only X-ray structure of an hydroxo- 
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bridged Os" arene dimer appears to be that of [(n6-p-cym)Os(t-H)(t-HCO2)U.t-
OH)Os(1op cym)]+.36e For (sterically non-hindered) benzene as the arene ligand, 
further deprotonation of hydroxo bridges appears to be possible to give the tetramer 
[M4 (116-bz)(.t-OH)4(t 4-O)]2 (M = Ru or Os).36d  We found no (ESI-MS) evidence 
for such tetramers under the less alkaline conditions used in this work. In contrast to 
Ru", the hydroxo-bridged dimer was still detectable in highly acidic millimolar 
solutions of Os" acac complexes (pH * 2). 
Particularly relevant to the biological testing is the finding that the hydroxo-
bridged dimers (6, 8 and 9) are the only species present on dissolution of the chloro 
acac complexes, [(i 6-arene)Os(acac)Cl] (2, 4 and 5) in water at micromolar 
concentrations. The chelated acac ligand is readily protonated (e.g. by an adjacent 
coordinated aqua ligand in [(1 6-arene)Os(acac)(0D2)1) and a good leaving group at 
acidic or near neutral pH (pKa of free acacH is In strongly basic solution, 
hydroxide appears to displace acac. The high stability of the hydroxo-bridged dimer 
is further illustrated by the finding that it is still formed as a major species even in the 
presence of a large molar excess of Cl -  (3000-fold, concentrations similar to those in 
cell culture media) or free ligand (100 mol equiv acacH). In contrast, ring-opening of 
chelated en requires cleavage of the Os-N bond before protonation can occur and en 
is not readily displaced by hydroxide. 
Separate 'H NMR peaks were observed for the OH2/OH and the parent Cl 
complexes in the spectrum of the Os" en complex 1BF4 on dissolution in D20. At 
millimolar concentrations of the Os" acac complexes, the 'H NMR chemical shifts 
are consistent with the existence largely of the aqua complex (confirmed by addition 
of AgNO3) with little of the chloro complex present. Only one set of 'H NMR peaks 
was observed for solutions containing the acac aqua complex [(ri 6-p-
cym)Os(acac)(OD2)] 4A, and Cl species, [(il  4, suggesting 
rapid exchange of Cl - and coordinated 0H2/OH on the NMR timescale at 298 K, as 
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observed for ruthenium analogs. 9  Addition of a large excess of chloride shifted and 
broadened these signals (Figure 3.12), suggesting that chloride binding to 1(71 
 is indeed weak. 
3.4.3 pKa Values of Aqua Complexes. 
The pKa values of the en (q 6-arene)Os" aqua complex 1A (6.37) and acac aqua 
complexes 2A, 3A, 4A and 5A (7.28, 7.45, 7.84 and 7.87, Table 3.4) are all 
significantly lower (ca. 1.5 units) than those of analogous (11 6-arene)Ru11 aqua 
complexes. 9,39 
Table 3.4 pKa Values for [(16-arene)M(chelate)(OD2)]; [(1 6-bip)Os(en)(OD2)] 2 
1A, ftr16-bip)Os(acac)(0D2)1 + 2A, ftq6-bz)Os(acac)(OD2)} 3A, [(q 6-p-
cym)Os(acac)(0D2)f 4A, [(1 6-THA)Os(acac)(OD2)] 5A and some ruthenium arene 
aqua complexes. 
Complex Metal Arene Chelate pKa* pKa  
1A Os bip en 6.37 6.34a 
Ru bip en 7.71" 
Ru bz en 
7•9C 
Os bz en 6.3c 
2A Os bip acac 7.28 7.12" 
3A Os bz acac 7.45 7.27" 
4A Os p-cym acac 7.84 7.63" 
5A Os THA acac 7.87 7.73" 
Ru p-cym acac 9.4" 
a pKa values calculated from pKa according to Ref 38. 
b  Ref 12. C  Ref 13. d  Ref 9 
The trend in the lowering of pKa values for Os 11 versus Ru" complexes is consistent 
. 
with that reported previously for [(ii 6 -bz)M
II  (01-12)3] 2+  and [MII  (trpy)(blpy)(0H2)]
2+  
(trpy = 2,2',2"-terpyridine, bipy = 2,2'-bipyridine). 13 '39 The replacement of the neutral 
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chelated en ligand by an anionic acac raises the PKa by ca. 0.9 units. A similar 
decrease in acidity is observed for the Ru analogs (L\PKa 1.1 units),9 attributable to 
the increased electron density on the metal center. The higher acidity of Os" arene 
aqua complexes can be attributed to increased mixing of the öc (Os) -> a (OW) 
orbitals. 39 The pKa*  values of the acac complexes 2A, 3A, 4A and 5A are close to 
physiological pH (7.4), whereas that of the en complex 1A is significantly lower and 
therefore almost all of the hydrolysed en complex would be present in the hydroxo 
form, [01 
6 -bip)Os 11  (en)(OH)] + 
3.4.4 Interactions with Nucleobases. 
There is little reported work on interactions of osmium complexes and nucleobases. 
Osmium(II) polypyridyl complexes are known to bind to DNA and nucleobases, 40 '2 
and recently adducts of [(1 6-p-cym)OsCl2(PR3)] where PR3 = pta or pta-Me (pta = 
1,3 ,5-triaza-7-phosphatricyclo [3.3.1.1 ]decane) with the 1 4-mer 
ATACATGGTACATA have been detected by ESI-MS.43 
The Os" en complex [(1 6-bip)Os(en)Cl] 1 reacts only slowly with 9EtG as 
does the aqua complex [(fl 6-bip)Os(acac)(OD2)] 2  1A, and then only to a limited 
extent (45% after 22h at 298 K). No reaction was observed (after 24 h) with either 
Ado, Cyt or Thy. The Ru" analog also binds selectively to guanine when in 
competition with the other three bases, but does bind weakly to Cyt and Thy, 
highlighting the lower reactivity of Os". The aqua acac Os" adduct [(r 6-p-
cym)Os(acac)(OD2)] 4A, reacts with both 9EtG and Ado rapidly (< 10 mm), but not 
with Cyt or Thy, a similar behavior to the Ru" analog. 9 Binding to 9EtG occurs 
through N7 and to Ado 44  through N7 and Ni (with N7 binding being favored by a 
factor of ca. 6 1; cf. 4 : 1 for Ru"). Binding to Ado N7 lowers the pKa of Ni by 1.7 
pH* units, compared to 1.3 for Ru". 9  This is a similar trend to the lowering of pK a  
values of water coordinated to Os" compared to Ru". The selectivity in nucleobase 
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binding of the Os" en and acac complexes can be rationalized in terms of H-bonding 
and non-bonding repulsive interactions between the chelating ligand and nucleobase 
substituents in addition to the electronic properties of the various nucleobase 
coordination sites, 45 as has been reported previously for the Ru" analogs. 
46,9  The 
thermodynamic stability of the hydroxo-bridged dimer is again illustrated by its 
formation from the nucleobase adduct, [(ij  The inertness 
of the hydroxo-bridged dimer (8) towards nucleobases is also notable. 
3.4.5 Cytotoxicity Towards Human A549 Lung Cancer Cell Lines. 
None of the Os" arene acac complexes studied here (Figure 3.1) were cytotoxic to 
human A549 lung cancer cells at doses up to 50 p.M in contrast to their Ru" analogs, 
cf. IC50 value for [( 6-p-cym)Ru(acac)Cl} (analog of 4) of 19 p.M." At this time the 
ohly data available on the cytotoxicity of the Os" en complex 1BF4 showed it to be 
inactive . 30 This was attributable to its much slower hydrolysis (Ca. 40 times) and to 
the higher acidity of the aqua complex (Ca. 1.4 pK a units) compared the Ru 1 ' analog. 9 
This results in lower reactivity, e.g. towards nucleobases. Changing the chelating 
ligand to acac not only increases the hydrolysis rate dramatically, but also lowers the 
acidity of the aqua adduct, such that a significant amount of the aqua complex (as 
opposed to the hydroxo adduct) exists at biological pH (7.4). These aqua acac 
complexes bind to purine bases, as do the Ru" analogs. 9 However, displacement of 
the coordinated acac from Os" occurs readily, and largely irreversibly, giving rise to 
stable hydroxo-bridged dimers. These inert dimers appear to be the only species 
present in solution under biological testing conditions and may account for the 
inactivity of the Os" acac complexes towards human cancer cells. 
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3.5 Conclusions. 
This laboratory has previously shown that organometallic Ru' 1 arene complexes such 
as [(16-arene)Ru(LL)C1f where arene = e.g. biphenyl, benzene, p-cymene or THA, 
and LL = en or acac exhibit anticancer activity. 8,1  However, it is reported here that 
the 0s  acac analogs, [(i 6-arene)Os(acac)Cl], are inactive towards A549 human lung 
cancer cells despite being structurally very similar in the crystalline state. 
Differences in their solution chemistry have therefore been explored in an attempt to 
understand their contrasting biological activities. There are few previous 
investigations of the aqueous chemistry of osmium arenes.' 3 ' 5 In general, as a third-
row transition metal ion Os" might be expected to be relatively inert compared to the 
second-row ion Ru 11 . 17  However, the presence of an arene ligand can greatly increase 
the kinetic lability, 14  and, importantly, this work shows that the chelating ligand also 
plays a major role. 
With en as the chelating ligand, hydrolysis of the Os" complex 1, ftr1 6-
bip)Os(en)C1], is ca. 40 times slower than that of the Ru" analog (pH*  Ca. 7), and the 
pKa  value (6.3) of the resulting aqua adduct is 1.4 units lower. This implies that the 
less-reactive hydroxo adduct would predominate at physiological pH (7.4). Indeed 
reactions with 9EtG were slower and occurred to a lesser extent than those of the Ru" 
complexes. 
In contrast, the acac complexes [(i 6-arene)Os(acac)Cl] hydrolyze rapidly 
(<10 mm, 298 K) to give a mixture of the monoaqua complex, [(11 
6_  
arene)Os(acac)(OD2)1, and the hydroxo-bridged dimer, [(1 6 arene)Os(1.tOD)3Os(11 6 
arene)] with loss of the acac chelating ligand. The pKa values of the coordinated 
water molecules in the monoaqua acac biphenyl, benzene, p-cymene and THA 
complexes (2A, 3A, 4A and 5A, 7.1-7.7) are ca. 1.8 units lower than those of the Ru" 
analogs, for which it is reported that the hydroxo-bridged dimer is not observed as an 
hydrolysis product (except in very basic solutions, and then only as a minor 
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product). 9 
The monoaqua acac complex, [(1 6-p-cym)Os(acac)(OD2)] 4A, reacts with 
purine bases (9EtG and Ado), but not with pyrimidines (Cyt or Thy), the same base 
selectivity as was observed for the Ru' 1 analogs. 9 However the hydroxo-bridged 
dimer, [(16 arene)Os(,.tOD)3Os(r1 6 arene)i was unreactive towards both purine and 
pyrimidine bases. This may be the key to the inactivity of the Os" arene acac 
complexes, since the hydroxo-bridged dimer was the only species present in 
micromolar aqueous solutions similar to those used in the biological tests. 
This work demonstrates how the kinetics of ligand substitution reactions of 
Os" arene complexes in aqueous solution can be controlled by variation of the 
chelating ligand. Further tuning of substitution rates may be achievable by variations 
of the monodentate leaving group and the arene. Such a systematic approach should 
contribute to the rational design of Os" arene complexes as potential anticancer 
agents, and may be more widely applicable to organometallic complexes in general. 
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4.1 	Introduction 
In Chapter 3 it was shown that the anionic 0,0-chelating ligand XY = 
acetylacetonate (acac) in arene complexes [(ij  can dramatically 
increase the reactivity of the Os"-CI bond compared to, for example, complexes with 
the neutral N,N-chelating ligand XY = ethylenediamine (en). 1,2  However, loss of 
chelate resulted in the formation of inert hydroxo-bridged dimers, [(TI 
 Here the aqueous chemistry of Os" p-cymene complexes 
containing the potentially more stable 5-membered chelate rings of maltolate (3-oxy-
2-methyl-4-pyrone, ma!)' and pyridonate (3 -oxy- 1 ,2-dimethyl-4(' H)pyridone, pyrid), 
are compared to that containing the 6-membered acac chelate. The aqueous 
chemistry of the Ru" maltolate and acac analogues is also investigated. 
Maltol is a natural product, a food additive with low cytoxicity, but exhibits 
antitumour activity in some neuroblastoma cell lines. 3 Complexes of maltolate 
chelated to metals have been investigated for the treatment of some diseases. 4 The 
most extensively studied are bis(maltolato)oxovanadium(IV) and 
bis(ethylmaltolato)-oxovanadium(IV), insulin-enhancing, antidiabetic agents. 5,6 
Aluminium(III) maltolato complexes are known to enhance the toxicity of 
aluminium in neuronal cells .7  Gallium(III) tris-maltolate is on clinical trial as an 
anticancer agent, 8 and has potential as a radiopharmaceutical, 9 and ferric trimaltolate 
has been investigated for the treatment of iron-deficiency anaemia. 10 ' 11 3-Hydroxy-
1 ,2-dimethyl-4('H)pyridine is in clinical trials for the treatment of chronic iron 
overload. 12  Some reactions of Ru" arene complexes containing maltolate and similar 
ligands, e.g. ethylmaltolate, have been reported, 13-16  but not those of Os" arene 
analogues. 
The solution chemistry of complexes containing a 5-membered 0,0-chelate 
(XY), [( 6-p-cym)M(XY)C!] where M = Os" XY = ma! (10), M = Os" XY = pyrid 
(11) and M = Ru" XY = ma! (bR), is explored in this chapter, as well as the acidity 
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of the Os" aqua adducts. The reaction of the maltolato complex (10) with guanine 
and adenine derivatives, and stabilities of the resulting nucleobase adducts has been 
investigated. Particular emphasis is placed on studies under biologically-relevant 
conditions, especially at micromolar concentrations similar to those used in cell 
cytotoxicity tests. The behaviour of the 0,0-chelated Os " arene complexes under 
these conditions is surprising and is discussed in relation to their biological activity. 
4.2 Experimental Section 
4.2.1 Materials 
Sodium methoxide, 3-hydroxy-2-methyl-4-pyrone (maltol), guanosine, 9-
ethylguanine, adenosine, cytidine and thymidine were purchased from Sigma-
Aldrich, deuterated solvents and 3-hydroxy-1,2-dimethyl-4('H)pyridone from 
Aldrich and OsC13.nH20 from Alfa Aesar. 
4.2.2 Preparation of Complexes 
The preparation of [(r 6-p-cym)0sCl2]2 and [(ij 	(4) is reported in 
Chapter 3. The complexes [(ij 	(10R) and [(96-p- 
cym)Ru(acac)Cl] (4R) were kindly provided by Dr. Michael Melchart, University of 
Edinburgh. 2" 7 
[(q6-p-cym)Os(mal)Cl] (10). A solution of maltol (41.7 mg, 0.33 mmol) and 
sodium methoxide (17.7 mg, 0.33 mmol) in MeOH (5 mL) was stirred at ambient 
temperature for 45 min and added to a solution of [(fl 6-p-cym)OsCl2] 2 (99.2 mg, 
0.125 mmol) in MeOH (5 mL) under argon. The resulting mixture was stirred at 
ambient temperature under argon for 3 h, the solvent removed on a rotary evaporator, 
the residue extracted with dichloromethane followed by filtration through a glass 
wool plug. The solvent was again removed on a rotary evaporator and the product 
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was re-dissolved in the minimum amount of acetone. Diethyl ether was added and 
after storage at 253 K overnight, the yellow product was recovered by filtration. It 
was washed with diethyl ether (10 mL) and air-dried. Yield: 105.6 mg (87%). Anal. 
Calcd for C 1 611 1 90030s (485.00): C, 39.62; H 3.95%. Found: C, 39.70; H, 3.78%. 
1 H NMR (CDCI3): 6 = 7.57 (d, 1H, J = 5.0 Hz), 6.59 (d, 1H, J = 5.0 Hz), 6.04 (d, 1H, 
J = 5.3 Hz), 6.00 (d, 1H, J = 5.3 Hz), 5.81 (d, IH, J = 5.3 Hz), 5.77 (d, 1H, J = 5.5 
Hz), 2.74 (sept, 1H, J = 6.9 Hz), 2.44 (s, 3H), 2.35 (s, 3H), 1.30 (d, 3H, J = 6.9 Hz), 
1.27 (d, 3H, J = 7.1 Hz). Crystals of 10 suitable for X-ray diffraction were obtained 
by slow evaporation from a dichioromethane/diethylether solution at 253 K. 
[(1 i6-p-cym)Os(ma1)(9EtG)]PF6 (lOG). A solution of 10 (58.7 mg, 0.12 
mmol) and AgPF6 (33.9 mg, 0.13 mmol, 1.1 mol equiv) in MeOH (1.5 mL) was 
stirred at ambient temperature for 2.5 h under argon, and the resulting AgC1 
precipitate removed by filtering the solution through a glass wool plug. To this 
solution 9-ethylguanine (9EtG) (22.4 mg, 0.13 mmol, 1 mol equiv) was added and 
the resulting mixture stirred at ambient temperature under argon for 20 h. The 
solvent volume was reduced, and the orange product which precipitated out on 
addition of diethyl ether was recovered by filtration. It was washed with diethyl ether 
(10 mL) and air-dried. Yield: 70.4 mg (75%). ESI MS: m/z: calcd for C23H28N504Os: 
630.2, found 630.5. Anal. Calcd for C23H28F6N5040sP (773.69): C, 35.70; H 3.65; N 
9.05%. Found: C, 36.05; H, 3.55; N, 8.71%. 1H NMR (MeOD-d4): 6 = 7.86 (d, 1H, 
J = 5.3 Hz), 7.76 (s, 1H), 6.65 (d, 1H, J = 5.0 Hz), 6.30 (d, 1H, J = 5.5 Hz), 6.14 (d, 
1H, J = 5.5 Hz), 6.04 (d, 1H, J = 5.3 Hz), 5.95 (d, 1H, J = 5.3 Hz), 4.09 (q, 2H, J = 
7.1 Hz), 2.67 (sept, 1H, J = 7.1 Hz), 2.48 (s, 3H), 2.13 (s, 3H), 1.33 (d, 3H, J = 7.3 
Hz), 1.30 (d, 3H, J = 7.1 Hz), 1.22 (d, 3H, J = 7.1 Hz). 
[(t 6-p-cym)Os(pyrid)CI] (11). A solution of 3 -hydroxy- 1 ,2-dimethyl-
4('H)pyridone (17.6 mg, 0.126 mmol), sodium methoxide (6.8 mg, 0.126 mmol) and 
[(i 6-p-cym)OsC12]2 (47.7 mg, 0.060 mmol) in MeOH (4 mL) was stirred at ambient 
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temperature, shielded from the light for 26 h. The solvent was removed in vacuo, 
extracted with dichioromethane and filtered through a glass wool plug. The solvent 
was again removed in vacuo and the product was sonicated with acetone. The yellow 
powder recovered by filtration, washed with acetone (10 mL) and diethyl ether (10 
mL) and air-dried. Yield: 34.2 mg (57%). Anal. Calcd for C17C1H22NO20s 
(498.045): C, 41.00; H 4.45; 2.81%. Found: C, 40.70; H, 4.42; N, 2.69%. 'H NMR 
(CDC1 3-d): ö = 6.97 (d, 1H, J = 6.9 Hz), 6.50 (d, 1H, J = 6.9 Hz), 5.99 (d, 1H, J = 5.2 
Hz), 5.91 (d, 1H, J = 5.2 Hz), 5.77 (d, 1H, J = 5.2 Hz), 5.71 (d, 1H, J = 5.2 Hz), 3.65 
(s, 3H), 2.72 (sept, 1H, J = 7.0 Hz), 2.44 (s, 3H), 2.36 (s, 3H), 1.29 (d, 3H, J = 6.9 
Hz), 1.24 (d, 3H, J = 6.9 Hz). 
4.2.3 Methods 
X-ray Crystallography. The diffraction data for complex 10 was collected 
by Dr. Simon Parsons, using a Bruker (Siemens) Smart Apex CCD diffractometer 
equipped with an Oxford Cryosystems low-temperature device operating at 150 K. 
Absorption corrections were performed with the multi-scan procedure SADABS; 18 
The structure of 10 was solved using direct methods (S1R92) 19 and refined against F 
using SHELXL-97. 20 H-atoms were located in a difference map, but placed in ideal 
positions and not refined. The Cambridge Crystallographic Data Centre contains the 
supplementary crystallographic data for complex 10 under the accession numbers 
CCDC 603587, which can also be found on the enclosed cd. 
Hydrolysis. Solutions of 10 (in D20, ca. 4 mM, pH*  6.5) and 11 (in 5% 
MeOD-d4/ 95% D20, 2 mM, pH*  6.2) were prepared at 298 K and their 'H NMR 
spectra recorded at various time intervals. The 'H NMR spectrum of 10 in D20 was 
also recorded after the addition of 1 mol equiv AgNO3 and removal of AgC1 by 
filtration. 
94 
Chapter 4 Introducing Hydrolytic Stability 
Determination of pKa*  Values. For determinations of pKa*  values, the pH* 
values of solutions of 10A and hA (formed in situ by dissolution of the parent 
chloro complex 10 and 11 in 100% D20) were varied from Ca. pH* 6 to 9.5 and 3.5 to 
10, respectively, by the addition of dilute NaOH and the 'H NMR spectra were 
recorded. The pKa*  and pKa values were determined from the pH titration curves as 
described in Chapter 2. 
Nucleobase Binding. The reactions of complex 10 with nucleobases 
typically involved the addition of a solution containing 1 mol equiv nucleobase to an 
equilibrium solution of 10 in D20 (which contains largely the aqua complexes bA). 
In the case of the reaction between 10A and Guo, the aqua complex was generated 
by the addition of 1 mol equiv AgNO3 to a solution of 10 in D20 and removal of 
AgC1 by filtration, followed by the addition of a solution containing 1 mol equiv 
Guo. 'H NMR spectra of these solutions were recorded at 298 K after various time 
intervals. 
A solution containing 10 and equimolar Ado was titrated at 298 K from Ca. 
pH* 7.5 to 1 by the addition of dilute HC104. For this titration, the purine chemical 
shifts were plotted against pH*  and the data fitted to the Henderson-Hasselbalch 
equation. 
Cytotoxicity. Cytotoxicity assays on human lung A549 and ovarian A2780 
cancer cell lines was performed as described in Chapter 2 for complexes 10 and 11. 
Stability Under Biological Test Conditions. Samples were prepared so as to 
mimic typical biological test conditions (concentrations and solvents). Stock 
solutions (50 jtM) were prepared in 0.125% DMSO-d6 /99.875% D20 (v/v) by 
dissolution of complex 10/11 in DMSO-d6 followed by rapid dilution with D20 
(measured pH 6.87 and 7.08, respectively). An aliquot of the stock solution for 
complex 10 was then diluted with D20 to give a 2 jiM Os solution (measured PH* 
7.28). 'H NMR spectra were recorded after ca. 10 min at 298 K; samples were then 
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incubated at 310 K for 24 h (a typical cell exposure time and temperature) and 
spectra recorded at 310 K. Samples were also prepared in the absence of DMSO-d6. 
Solutions of 10 at 8 and 200 tM were prepared in a similar manner, but the D20 was 
replaced with 100 mM NaCl in D20. 
Stability of Os and Ru 0,0-Chelated Complexes. Stock solutions (2 mM) 
of the complexes (10, 10R, 4, 4R and 11) were prepared in D20, sonicated for ca. 10 
min and filtered through a glass wool plug. Solutions at 1 mM, 500 gM, 250 JIM, 100 
p.M, 50 pM and 20 M were prepared from these stock solutions and D20. Samples 
were incubated at 310 K (24 h) before adding dioxane as an internal standard, the 
PH* values (ca. 6 - 7.5) and their 'H NMR spectra were recorded at 298 K. ESI-MS 
spectra were obtained from 50 pM solutions of Ru complexes 411 and 10R. 
9-Ethylguanine Binding Constants. To determine the binding constant of 
the 9-ethylguanine (9EtG) adduct in [(TI  a 2 mM stock 
solution of complex lOG was prepared in D20, sonicated for ca. 10 min and filtered 
through a glass wool plug. Solutions at 1 mM, 500 jtM, 250 tM, 100 j.tM, 50 tM and 
20 pM were prepared from this stock solution and D20, dioxane added as an internal 
standard, and the 'H NMR spectra recorded at 298 K within 15 min of sample 
preparation, and after incubation at 310 K for 24 h. Complexes lOG and 1ORG were 
also prepared in situ by mixing equimolar solutions of 10 or 1OR (containing 
predominantly the aqua adducts 10A or 10RA) and 9EtG in D20 to give final 
concentrations of 1 mM, 500 jtM, 250 pM, 100 jiM, 50 jiM and 20 jiM. Dioxane was 
added as an internal reference and the 'H NMR spectra recorded (298 K) again 
within 15 min of sample preparation and after incubation at 310 K for 24 h. 
Equilibrium constants for formation of the 9EtG adducts of the aqua complexes were 
obtained from the slopes of plots of [bound complex 1OG/1ORG]/[free 9EtG] vs 
[unbound aqua complex bA/bRA], based on integration of 'H NMR peaks. These 
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data were collected before the second equilibrium, involving hydroxo-bridged dimer 
formation, contributed. 
Dynamic NMR Studies. The 'H NMR spectra of 10 and 11 in MeOD-d4 (10 
mM) were recorded after equilibration at various temperatures over the temperature 
range 203 K - 323 K (at 10 K increments) on a Bruker DMX 360 NMR spectrometer. 
Kinetic data and activation energies for the dynamic processes were determined as 
described in Chapter 2. 
4.3 	Results 
4.3.1 Preparation and Structure of Complexes 
	
The osmium arene maltolato and pyridonate complexes, [(ij 	10 
and [(TI 	11 (Figure 4.1), were prepared in good yields by 
reaction of the p-cymene chioro-bridged dimer [(ij  with the five-
membered 0,0-chelating ligand maltolate/pyridonate, a route similar to that reported 
for [(i6-mes)Ru(etmal)C1]  (mes = 1,3,5-trimethylbenzene, etmal = ethylmaltolate).' 3 











O*yL( 	oL 	 0 Ho()OH 
M 
M 	X 	n 	 X 	n 	 M 	X 	n 
10 Os CI 0 11 	CI 0 4 Os CI 0 
IOA Os 0H2/OH 1/0 	hA 0H2/OH 110 	4A Os OH2/OH 1/0 	 M 
IOR Ru 	CI 	0 4R Ru 	CI 	0 8 Os 




















IIH2 ,0s • 
Nl.AN' 
NN 	oYiT_ 
10A7 	Rnbose 	1 O 
Figure 4.1 Osmium(II) and ruthenium(II) arene complexes studied in this work. 
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Figure 4.2 X-ray crystal structure and atom numbering scheme for [(rj 6-p-
cym)Os(mal)Cl] (10) (50% probability ellipsoids). The H atoms have been omitted 
for clarity. 
Crystallographic data, bond lengths and angles are listed in Table 4.1 and Table 4.2. 
Complex 10 adopts the pseudo octahedral "three-leg piano stool" geometry, with the 
metal 7t-bonded to the p-cymene ring (the "seat") and a-bonded to a chloride and two 
oxygen atoms of the chelated maltolate ligand (the "legs"). Coordinated maltolate is 
unsymmetrical with the two osmium-oxygen bond distances being inequivalent 
(2.114(4) and 2.091(5) A), the shorter distance found on the methyl side of chelated 
maltolate. The coordinated maltolate ligand is almost planar with torsion angles (Os-
0-C-C) of 172-178°. No intermolecular arene ring stacking is observed, but several 
directional hydrogen bonds (LD-H ... A 150'<0<180')  are present between 
independent molecules in the crystal structure. Three different types of interactions 
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link together three independent molecules of [( 6-p-cym)Os(ma1)Cl] (10). One set of 
dimers is formed in the crystal structure through four short-range interactions 
between a chelated oxygen of the coordinated maltolate and p-cymene protons of a 
second molecule, O2i(mal) ... H71(p-cym) 2.57 A and O21(mal) ... H102(isopropyl p-
cym) 2.67 A. Another set of dimers is formed between the chloride (Cli) and a p-
cymene ring proton (1-141) of another molecule (2.56 A). Finally, short-range 
interactions are present between C24-1 ­1171 of the maltolate backbone and both a 
chloride (Cli 2.77 A) and maltolate oxygen (021 2.36 A) of an adjacent molecule, 
Figure 4.3 and Table 4.3. 
Table 4.1 Crystallographic data for [(il 	(10) 
10 
Formula C 1 6H 1 9C1O3Os 
Molecular weight 484.98 
Crystal description Brown tablet 
Crystal size (mm) 0.37 x 0.24 x 0.11 
1(A) 0.71073 
Temperature (K) 150 
Crystal system Monoclinic 
Space group P 1 211c 1 
a(A) 11.8586(6) 





Volume (A3) 1586.74(15) 
Z 	 4 
R 	 0.0566 
R1 	 0.0915 
GOF 0.6705 
99 
(A) 	 (B) 
Chapter 4 Introducing Hydrolytic Stability 
Table 4.2 Selected bond lengths (A) and angles (°) for [( 6-p-cym)Os(mal)C1] (10) 
Bond(s) 	 10 Bond(s) 10 
Length Length / angle 
Os-C(arene) 	2.181(7) Os-Cl 2.4326(16) 
2.172(6) Os-021 2.114(4) 
2.136(6) Os-028 2.091(5) 
2.190(7) 021-Os-028 78.67(18) 
2.178(7) 021-Os-Cl 81.88(13) 
2.162(7) Cl-Os-028 84.92(13) 
Figure 4.3 Diagram showing the dimers formed by directional hydrogen bonds 
between (A) (arene)C-H . 0(ma1), (B) (arene)C-H and (C) (mal)C-H" 0(mal)/C1 
of adjacent molecules in the X-ray crystal structure of complex 10, [(7 6-p-
cym)Os(mal)Cl] (50% probability ellipsoids). Additional H atoms have been omitted 
for clarity. 
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Table 4.3 Selected hydrogen bond lengths [A] and angles [O]  for complex 10 
D-H ... A d(HA) d(DA) ZDHA 
C13-H71"021 (inter) 2.57 3.555(8) 167 
C19-H102"021 (inter) 2.67 3.619(9) 158 
C16-1-141"01 (inter) 	2.56 	3.554(7) 	170 
C24-H171021 (inter) 2.36 3.281(8) 153 
C24-H171C11 (inter) 	2.77 	3.511(7) 	132 
4.3.2 Hydrolysis and Acidity of Aqua Adducts 
The 'H NMR spectra of complexes 10, [(il 	(D20, Ca. 4 mM, pH* 
6.5) (where pH = reading of pH meter in D20 without correction for effects of D on 
the glass electrode) and 11, [(TI  (D20, Ca. 3 mM, PH*  6.3) show 
the presence of one major species 10A (p-cymene doublets at 86.28, 6.06) and hA 
(ö 6.13 and ö 5.93), respectively. The peaks corresponding to 10A can be assigned to 
the aqua complex, [(r 6-p-cym)Os(mal)(OD 2)f, since their chemical shifts are the 
sameas those obtained when 1 mol equiv AgNO3 was used to abstract the chloride 
ligand from 10 in water. 
The changes in the 'H NMR chemical shifts of the chelate backbone proton in 
bA, [( 6-p-cym)Os(mal)(OD 2)], and coordinated p-cymene ring proton in hA, 
[( 6-p-cym)Os(pyrid)(OD 2)], which predominate in equilibrium solutions of 10 and 
11 in D20 at 298 K, were followed with changes in PH*  over the range 5.5-9.8 and 
2.9-10.6, respectively (Figure 4.4). These data were fitted to the Henderson-
Hasselbalch equation which yielded pKa values of 7.73 and 8.49 for 10A and hA, 
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Figure 4.4 Plots of the 'H NMR chemical shift versus pH*at  298 K for (A) 
maltolate ring protons of [(ij  (bA), and (B) p-cymene ring 
protons of [( 6-p-cym)Os(pyrid)(OD 2)1 (hA) in D20 at 298 K. The curves 
represent the best fits to the Henderson-Hasselbalch equation and correspond to pKa* 
values of 7.73 and 8.49 (pKa 7.60 and 8.31) for 10A and hA, respectively. (C) 
Selected 'H NMR spectra of the pH*  titration of 11 A in D20. Peaks shift to high field 
(fast exchange between aqua and hydroxo species) with increase in pH*.  No new 
peaks for the hydroxo-bridged dimer, [(ij  (8), 
appear with increase in pH*. 
A second species, 8, was detected in solutions of 10 as the pH was raised, along 
with free maltol. The 'H NMR peaks for 8 (doublets at 8 6.04 and 5.82) increased in 
intensity with increase in pH, from 6% at pH 5.9 to 45% at pH*  9.3. Species 8 has 
previously been assigned in Chapter 3 as the hydroxo-bridged dimer, [(p 6-p-
cym)Os(i-OD)3Os( 6-p-cym)].' It is notable that no new peaks for 8 were present 
during the pH titration of hA in D20 (Figure 4.4C). 
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4.3.3 NMR Studies of Chemical Exchange 
In the 'H NMR spectra of complexes 10, 1OR and 11 in CDC1 3 , there were doublets 
for each of the four p-cymene ring protons (integrating to 1 H each) and two doublets 
for the p-cymene isopropyl methyl groups (integrating to 3H each), Figure 4.5A. 
However, in the 'H NMR spectra of 10, 1OR and 11 in D20, mainly present as the 
aqua adducts 10A, 10RA and hA (vide supra), there were only two doublets for the 
coordinated ring protons (integrating to 2H each) and one doublet (integrating as 6H) 
for the two CH3 groups belonging to the isopropyl group (chemical shifts for the 
aqua complex are pH sensitive, see Figure 4.4), Figure 4.5C. The spectra of 10 in 
another non-coordinating solvent, deuterated toluene, consisted of two overlapped 
doublets and two doublets for the p-cymene ring protons, as well as two overlapped 
doublets for the p-cymene isopropyl group, Figure 4.513. However in deuterated 
methanol, the spectrum of 10 (Figure 4.5D) shows broad peaks for the aromatic 
protons, again with only two peaks for the p-cymene ring protons and a single 
doublet for the two isopropyl CH3 groups. The two broad peaks (86.16 and 5.92) for 
the p-cymene ring protons sharpened to doublets at higher temperatures (323 K) and 
split into two doublets (66.20 and 6.17) and a doublet of doublets (5.92) at lower 
temperatures (223 K), see Figure 4.6A. At the coalescence temperature (T c = 283 K), 
the rate of the dynamic process was determined to be k c = 25.9 s 1 , with lifetimes of 
the separate isomers of t = 40 ms and an activation energy, AG 62 kJ mor' at T. 
In contrast, the NMR spectrum of 11 in deuterated methanol showed two 
doublets for the four p-cymene ring protons (integrating to 2H each) and one doublet 
(integrating as 6H) for the two CH3 groups belonging to the isopropyl group. These 
broadened on lowering the temperature (T = 243 K) and one of the broad peaks 
resolved into two overlapped doublets at 203 K (Figure 4.613), with an associated k 
= 13.4 s- , with lifetimes of the separate isomers of t = 75 ms and an activation 
energy, AGI 45 kJ mol' at 243 K (T a). 
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Figure 4.5 Low field region of the 'H NMR spectrum (298 K) of 10 (containing 
resonances for the p-cymene ring protons) in the non-coordinating solvents (A) 
CDC13 (doublets at 8 6.04, 6.00, 5.81 and 5.77), (B) toluene-d8 (two overlapped 
doublets ö 5.61 and two doublets 85.26 and 5.25) (x = unidentified species 
accounting for ca. 15 % of Os), and in the coordinating proton-donor solvents (C) 
D20 (2 doublets, peak position pH sensitive and a doublet at 8 6.04 for 8), and (D) 
MeOD-d4 (2 broad peaks at 8 6.16 and 5.92). 
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Figure 4.6 Low field region of the 360 MHz 'H NMR spectrum of (A) 10, and (B) 
11 in MeOD-d4 at varying temperatures. (A) The four inequivalent p-cymene ring 
protons in 10 resolve into two doublets (ö 6.20 and 6.17), and two closely 
overlapping doublets (8 5.92) at 223 K, broaden (6 6.16 and 5.92) at 283 K 
(coalescence temperature, T) and sharpen into two doublets at 343 K (66.16 and 
5.92). (B) At 203 K the four p-cymene ring protons in 11 resolve into a sharp doublet 
(8 6.08) and two closely overlapped doublets (8 5.85 and 5.83), they broaden (8 6.11 
and 5.86) at 243 K (Ta) and sharpen into two doublets (ö 6.12 and 5.89) at 323 K. 
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4.3.4 Aqueous Stability of Complexes 10, 1OR and 11 - Speciation Under 
Biological Test Conditions 
Solutions of 10 were prepared so as to mimic those being used in the cytotoxicity 
tests. 800 MHz 'H NMR spectra of solutions of 10 at concentrations of 2 and 50 p.M 
in 0.125% DMSO-d6/ 99.875% D20, at physiological pH (ca. 7.4), were recorded 
directly after sample preparation (ca. 10 mm, 298 K) and after incubation at 310 K 
for 24 h. 'H NMR peaks (ö 6.04 and 5.82) for the hydroxo-bridged dimer, [(ri 6-p-
cym)Os(p.-OD)3Os( 6-p-cym)] (8), predominate for 10 under these conditions as 
determined by 'H NMR and ESI-MS (Figure 4.7) (100% 8 at 2 [LM after 10 min and 
after 24 h at 310 K, and at 50 p.M Ca. 28% 8 after 10 min and ca. 65% after 24 h at 
310 K). Solutions of 10 prepared in the absence of DMSO-d6 gave the similar results. 
Similar solutions of 10 (8 p.M and 200 p.M) were prepared in the presence of 100 
mM NaCl and their 'H NMR spectra were recorded as previously. Based on peak 
integrals, the hydroxo-bridged dimer (8) predominates at 8 p.M 10 both directly after 
sample preparation and after incubation at 310 K for 24 h, whereas at 200 p.M 10 Ca. 
24 % 8 was present after 10 min at 298 K and Ca. 61% 8 after 24 h at 310 K. 
In contrast, based on the peak integrals from 600 MHz 'H NMR spectra of a 
50 p.M solution of 11, there was only 10% 8 after 10 min and this increased to 52% 
after incubating for 24 hat 310 K (Figure 4.7E/F). 
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Figure 4.7 Hydrolysis of [(il 	(10) and [(il  
(11) at micromolar concentrations. Low field region of the 800 MHz 'H NMR 
spectra of (A) a 2 jiM solution, and (B) a 50 pM solution of 10 after incubation at 
310 K for 24 h (biological-test concentrations and conditions). (C) The 
corresponding ESI-MS of a sample from (A), and (D) a sample from (B). The major 
peak at mlz 684 is the first fragmentation peak of the hydroxo-bridged dimer (8). 
NMR spectra of 50 jtM solutions of 11(E) after ca. 10 min and (F) after incubation 
at 310 K for 24 h. Assignments: 8, [(il  10A [(16 
p-cym)Os(mal)(OD 2)]; hA [(rj 6-p-cym)Os(pyrid)(OD2)]; and m corresponds to 
free maltol. 
Solutions of the maltolato (10 and 10R) and acetylacetonate (acac) complexes (4 and 
4R) were prepared at varying concentrations (2 mM, 1 mM, 500 jiM, 250 jiM, 100 
jiM, 50 jiM and 20 jiM) in D20, and incubated at 310 K for 24 h before recording 
their 'H NMR spectra at 298 K. Peaks corresponding to the p-cymene ring protons of 
the aqua complex, [(i 6-p-cym)M(XY)(OD 2/OD)]'° (M = Os, XY = mal 1OA; M = 
Ru, XY = mal 10RA; M = Os, XY = acac 4A; M = Ru, XY = acac 4RA), dominated 
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the 'H NMR spectra of the more concentrated solutions. As the concentrations of 
complexes were decreased, the peaks corresponding to species 8 (6.04 and 5.82) 
and 8R (65.37 and 5.17) increased in intensity, as did those for the free maltol and 
acacH, whereas those for the aqua complexes (bA, 10RA, 4A and 4RA) decreased 
in intensity, Figure 4.8. 
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Figure 4.8 Increase in dimer concentration with decrease in metal concentration. 
Low-field region of the 'H NMR spectra (298 K) of complexes 10, 10R, 4 and 4R at 
concentrations varying from 2 mM to 20 p.M after incubation at 310 K for 24 h. 10A, 
10RA, 4A and 4RA correspond to the aqua complexes [( TI  
[( 6-p-cym)Ru(ma1)(OD2)], [( 6-p-cym)Os(acac)OD2)1 and [(116-p-
cym)Ru(acac)(OD2)], respectively, and 8 (M = Os) and 8R (M = Ru) the hydroxo-
bridged dimers, [(ij  
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Based on 'H NMR peak integrals for the p-cymene ring protons, the aqua complex 
10A accounted for 71% of the initial Os maltolato complex 10 at 2 mM, however at 
20 jiM this was much lower at 30%. A higher proportion of the Ru aqua complex 
10RA was present for 1OR (85% at 2 mM and 38% at 20 jiM), Figure 4.8A/B. Only 
61% of the Os aqua acac complex 4A was present at 2 mM 4 and this decreased to 
0% at 100 jiM 4. More of the Ru aqua acac complex 4RA (79%) was present for 2 
mM solutions of 4R, but this also decreased to 0% at 20 jiM 4R, Figure 4.8C/D. ESI-
MS of equilibrium NMR samples of 1OR and 4R at 50 jiM (containing 
predominantly peaks for hydroxo-bridged dimer 8R) gave peaks at m/z 525.1 and 
526.1 respectively, assignable to [( 6-p-cym)Ru(ji-OD) 3Ru(rj 6-p-cym)j, 8R (caic. 
m/z 526.1). 
Intriguingly, in similar solutions of the pyridinone complex, [(p 6-p-
cym)Os(pyrid)C1] 11, the aqua complex hA was the only species present after Ca. 
10 mm (though broadening of the peaks at 50 and 20 jiM was observed). After 
incubation at 310 K for 24 h peaks for the hydroxo-bridged dimer 8 were present and 
increased with decrease in osmium concentration (all the peaks for hA appeared 
broad). However, much less of 8 (based on peak integrals) was present than for the 
maltolate and acac complexes (88% hA at 2 mM and 53% hA at 20 jiM, Figure 
4.9). 
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Figure 4.9 Low-field region of the 'H NMR spectra (298 K) of complex 11 at 
concentrations varying from 2 mM to 20 j.tM after Ca. 10 min at 298 K, and after 
incubation at 310 K for 24 h. hA corresponds to the aqua complex [(i 6-p-
cym)Os(pyrid)(OD2)] and 8 the hydroxo-bridged dimer, [( ij 
Based on peak integration of the 'H NMR spectra in Figure 4.8 and Figure 4.9, the 
proportion of metal present as the hydroxo-bridged dimer 8 (Os) or 8R (Ru), after 
incubation at 310 K for 24 h, is plotted against initial complex concentration in 
Figure 4.10. Clearly the least stable complex is the osmium acac complex, [(p 6-p-
cym)Os(acac)Cl] (4), and the most stable the osmium pyridinone complex, [(r 6-p-
cym)Os(pyrid)C1J (11). 
110 











 500 	1000 	1500 	2000 
[M] / PM 
Figure 4.10 Dependence of hydroxo-bridged dimer formation (based on 'H NMR 
peak integrals) on total metal concentration for solutions of the osmium and 
ruthenium maltolato (10 and bR), acac (4 and 4R) and osmium pyridinone (11) 
complexes, [(ij  in D20 after incubation at 310 K for 24 h. --- M = 
Ru, - M = Os, • XY = mal, A XY = acac and . XY = pyrid. The most stable 
complex towards dimer formation is the osmium pyridinone complex, [( 716-p-
cym)Os(pyrid)Cl] (11), and the least stable the osmium acac complex, [(7 6-p-
cym)Os(acac)Cl] (4). 
4.3.5 Interactions of Maltolate Complexes with Nucleobases 
The reaction of 1 mol equiv guanosine (Guo) with a solution of [(ii 6-p-
cym)Os(maI)(OD 2)] (10A) was monitored at 298 K by 'H NMR spectroscopy. Two 
sets of new peaks appeared within the first 10 mm (by which time equilibrium had 
been reached), consistent with the formation of diastereoisomers of fti 6-p-
cym)Os*(mal)(Guo*)f1 (lOG'), Figure 4.11. Based on integrals of the aromatic 
protons, ca. 65% of the osmium complex reacted with Guo to form lOG' (10% 
hydroxo-bridged dimer 8 present). The H8 signals for bound Guo in [(ij 
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cym)Os(mal)(Guo)] (lOG') (ö 7.98 and 7.97), have similar chemical shifts to 
unbound Guo (ö 7.99) whereas the maltolate signals shift upfield by ca. 0.20 ppm 
compared to the aqua complex (bA). The peak integrals for the p-cymene methyl 
groups of the two diastereoisomers of lOG' (8 2.03 and 2.02) suggest that they are 
present in roughly equal amounts. 
lOG' 
G+IOG' 
i ji0 OAT 	 j& 
8.0 	7.5 	7.0 	6.5 	6.0 	5.5 ppm 
Figure 4.11 Low field region of the 'H NMR spectrum (298 K) of 10A (generated 
by the addition of 1 mol equiv AgNO3 in D20, at pH*  6.83, 4 mM, 10% of 8 is 
present) after reaction with 1 mol equiv Guo in D20. After 10 mm, 65% of the Os 
had reacted. Assignments; G correspond to free Guo, m free maltol; 10A the aqua 
complex [(ij  and lOG' the guanosine adduct [(116-p-
cym)Os(ma!)(Guo)]. 
The reaction of I mol equiv 9-ethylguanine (9EtG) with an equilibrium solution of 
10 containing predominantly 10A (in D20 at 298 K, pH*  6.68, 1 mM) was 
investigated by 1 H NMR (298 K) and ESI-MS. New peaks appeared by the time the 
first 'H NMR spectrum was recorded, and equilibrium was reached within 10 mm, 
Figure 4.12. Based on p-cymene peak integrals of bOA (8 6.27), free maltol (equal to 
[Os] present as 8) (ö 6.51) and product, [(q 6-p-cym)Os(mal)(9EtG)] (lOG) (8 6.36), 
71% of the osmium had reacted to form lOG, with ca. 10% of the osmium present as 
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the hydroxo-bridged dimer (8). The peaks are consistent with the presence of one 
new chiral complex, with inequivalent p-cymene ring protons and isopropyl methyl 
groups 
(B)
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Figure 4.12 'H NMR spectrum of (A) predominantly lOG, [(,96-p-
cym)Os(mal)(9EtG)f 4 , in D20 (298 K) from reaction of 10 (containing 
predominantly 10A) and 1 mol equiv 9EtG. G and m correspond to unbound 9-
ethylguanine and free maltol respectively. (B) 2D TOCSY NMR spectrum which 
assisted assignment. The coordinated p-cymene ring protons are inequivalent 
(doublets with integration 1H at ö 6.36, 6.15, 6.00 and 5.91), as are the isopropyl 
methyl groups (doublets with integration 3H at 8 1.21 and 1.11), due to the chiral 
centre at osmium. Assignment of h vs. i or j vs. k was not possible, but protons on 
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ESI-MS peaks for the equilibrium NMR sample at a low cone voltage (25 V) were 
detected at m/z 451.1 and 630.7, assignable to [(11 6 -p-cym)Os(mal)]+ , { 10A-OH} +  
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Figure 4.13 Characterization of 9EtG and Ado adducts of 10 by mass spectrometry. 
ES! mass spectra for solutions containing [(ij  (10) and 1 mol 
equiv of (A) 9EtG, and (B) Ado in D20. Peaks at m/z 451 correspond to {10A-
H20}, m/z 700 to the hydroxo-bridged dimer 8, 631 and 720 to lOG, [(r6-p-
cym)Os(mal)(9EtG)f, and 1 0A7/1, [( 6-p-cym)Os(ma1)(Ado)], respectively. 
A similar reaction of the ruthenium analogue 1OR with 9EtG (in D20 at 298 
K, PH*  7.11, 1 mM) was monitored, and new peaks for 1ORG, [(r 6-p-
cym)Ru(mal)(9EtG)], were present by the time the first 'H NMR spectrum was 
recorded (< 10 mm), at which time equilibrium had already been reached. Based on 
peak integrals for 10RA (8 6.76), 8R (8 5.38) and 1ORG (8 5.92), 64% of the Ru had 
reacted to form 1ORG, with ca. 10% of the Ru present as the hydroxo-bridged dimer 
(8R). The peak at 6.5 ppm corresponds to overlapped signals for both free maltol and 
1ORG, [( 6-p-cym)Ru(mal)(9EtG)], as determined by 2D NMR, Figure 4.14. 
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Figure 4.14 2D TOCSY NMR spectrum (298 K) of a solution containing 
predominantly 1ORG, [(il  in D20. G, m, 10RA and 8R 
correspond to unbound 9-ethylguanine, free maltol, the aqua complex, [(r6-p-
cym)Ru(mal)(OD2)], and the ruthenium hydroxo-bridged dimer, respectively. 
Chemical shifts for [(rj 6-p-cym)Ru(mal)(9EtG)] (10RG): 7.79 (d, 11-1), 7.69 (s, 1H), 
6.51 (d, 1H), 5.92 (d, 1H), 5.82 (d, 1H), 5.78 (d, IH), 5.61 (d, 214), 5.56 (d, 1H), 4.00 
(q, 2H), 2.71 (sep, 114), 2.38 (s, 314), 1.96 (s, 314), 1.25 (m, 61-1), 1.15 (d, 3H). 
Addition of 1 mol equiv adenosine (Ado) to equilibrium solutions of 10 (in 
D20 at 298 K, pH * 7.47) resulted in new 'H NMR peaks (Figure 4.15A) by the time 
the first spectrum was recorded, by which time equilibrium had been reached (< 10 
mm). Based on peak integrals, 63% of 10 (13% hydroxo-bridged dimer, 8) reacted 
with Ado to give a mixture of a major, 10A7 (44%) and a minor 1OA1 (19%) 
product. To confirm the binding site for the metal fragment on Ado for both adducts, 
a pH* titration of the reaction mixture was monitored by 'H NMR spectroscopy over 
the range pH * 7.5-1, Figure 4.15B. The H8 and H2 singlets assigned to free Ado 
shifted to low field with an associated PKa° value of ca. 3.6, similar to that reported 
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for N  protonation,2 ' whereas the H8 and H2 singlets for the minor species 1OA1 did 
not shift over this range, consistent with the presence of NI-bound Ado in this 
complex, [(il  (bA!). The corresponding singlets for the 
major product 10A7 shifted to low field over this PH*  range with an associated pKa  
of 1.85 (PKa 2.14), consistent with N7 bound Ado. The N7 : Ni binding ratio for 
coordinated Ado was Ca. 2.4 : 1. ESI-MS peaks for the equilibrium NMR sample of 
10 and Ado, at a low cone voltage (20 V), were detected at m/z 450.9, 700.4 and 
7 i 9.6, assignable to [( 6-p-cym)Os(mal)], { 1OA-H20 } + (caic. m/z 451.1), [( 6-p-
cym)Os(t-OH)30s(rj 6-p-cym)], 8 (caic. m/z 701.1) and [( 6-p-cym)Os(mal)(Ado)], 
10A7/1 (caic. m/z 719.2), Figure 4.13B. 
(A) 	 Ado 	 (B) 
J:JL 8 i 
8.6 	8.4 	8.2 	8.0 ppm 
Ado 
I 0A7 
•. jilt . 	• 	lOAf 
2 	4 6 8 
pH 
Figure 4.15 Reaction of adenosine with complex 10. (A) Low field region of the 'H 
NMR spectrum of 10 (in D20, pH * 7.47 at 298 K, containing predominantly bOA 
with 13% of 8 present) after reaction with 1 mol equiv Ado. (B) Dependence of the 
'H NMR chemical shifts of Ado H8 and H2 resonances on pH, which allow 
determination of the metal binding sites on Ado in the major products 10A7 (44%) 
and minor products 1OA1 (19%), as N7 and Ni, respectively. 
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The addition of a solution containing 1 mol equiv 9EtG and 1 mol equiv Ado 
to an equilibrium solution of the Os maltolato complex 10 (in D20 at 298 K, pH 
7.71) resulted in new peaks in the first 'H NMR spectrum recorded (< 10 mm). 
Based on peak integrals of the p-cymene aromatic region, 75% of the Os had reacted 
to give 36% [(ij  (lOG) and 39% [(116-p-
cym)Os(mal)(Ado)] (10A7 and 1OA1) with 14% of the Os present as the inert 
hydroxo-bridged dimer 8, [(ij  The ratio of 9EtG-
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Figure 4.16 Low field region of the 'H NMR spectrum showing the 1 : 1 : 1 
competition reaction of 10 with 9EtG (G) and Ado (in D20 at 298 K and pH*  7.71). 
The ratio of binding to G and A is 1 1.1. Assignments; 10A7 [(i 6-p-
cym)Os(mal)(Ado-N7)], 1OA1 [( 6-p-cym)Os(ma1)(Ado-N1)], lOG [(1 6-p-
cym)Os(mal)(9EtG)], 10A [( 6-p-cym)Os(ma1)(OD 2)} and m corresponds to free 
maltol 
The addition of 1 mol equiv cytidine (Cyt) or thymidine (Thy) to an 
equilibrium solution of 10 (in D20 at 298 K, pH*  7.01 and 6.67) resulted in no 
additional peaks in the 'H NMR spectrum even after incubation at 310 K for 20 h, 
Figure 4.17. 
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Figure 4.17 'H NMR spectra for reaction mixtures of 10 and 1 mol equiv of cytidine 
(in D20 at 298 k and pH * 7.01) at (A) time = 5 mm, (B) after incubation at 310 K for 
20 h, and 1 mol equiv of thymidine (in D20 at 298 K and pH * 6.67) at (C) time = 5 
mm, (D) after incubation at 310 K for 20 h. No new peaks appear in the spectra. 
Assignments: 1OA [(ij  C and T unreacted cytidine and 
thymidine, respectively; 8 hydroxo-bridged dimer, [(ij 
 m free maltol; d dioxane. 
4.3.6 Stability of 9-Ethylguanine Adducts 
Solutions of the 9EtG adduct lOG, [(716-p-cym)Os(mal)(9EtG)], in D20 at varying 
concentrations (20 p.M - 2 mM) were prepared and their 'H NMR spectra recorded 
within 10 min of sample preparation at 298 K (Figure 4.18A), as well as after 
incubation at 310 K for 24 h (Figure 4.18B). At high concentrations, peaks for 1 O 
dominated (77% lOG at 2 mM), but as the complex concentration decreased, peaks 
for the aqua complex (10A) and free maltol (and a small amount of hydroxo-bridged 
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dimer 8) increased in intensity (29% lOG at 20 1iM). At Ca. 200 .tM lOG, 50% of the 
9EtG remained bound. The apparent formation constant for lOG was determined as 
log K = 4.32±0.02 from the species distribution plot in Figure 4.19. After incubation 
at 310 K for 24 h, complex lOG still dominated at high concentration (69% lOG at 2 
mM), but free maltol and the hydroxo-bridged dimer (8) dominated at lower 
concentrations (0% lOG at 20 .tM), Figure 4.18B. 
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Figure 4.18 Low-field region of the 'H NMR spectrum of the 9-ethylguanine (9EtG) 
complex lOG, [(ij 	at concentrations varying from 2 mM to 
20 p.M. (A) Directly after sample preparation at 298 K, and (B) after incubation at 
310 	K 	for 24 	h. Assignments: 8 hydroxo-bridged dimer, [(TI 
 m 	free maltol; 	10A 	monoaqua complex 	[( 6-p- 
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Figure 4.19 Plot showing the distribution of {(i6-p-cym)Os}2  groups amongst the 
species lOG, [(TI  (.), the aqua complex 10A (.), and the 
hydroxo-bridged dimer 8 (•). The inset shows a plot of [10G]/[free 9EtG] vs [bA], 
based on integration of 'H NMR peaks (Figure 4.18A). From the slope, an 
equilibrium constant of log K = 4.32±0.02 was calculated. 
The 9EtG complex lOG and the Ru analogue bORG were also prepared in 
situ at varying concentrations by mixing equimolar solutions of 10 or 1OR and 9EtG 
so that the final concentrations were 20 tM - 1 mM. 'H NMR spectra were recorded 
after ca. 10 min at 298 K, as well as after incubation at 310 K for 24 h (Figure 4.20). 
For reactions (after ca. 10 mm) of the Os maltolato complex 10 with 9EtG, 73% of 
9EtG-bound adduct lOG was formed at 1 mM and only 31% at 20 tM; for the Ru 
analogue, 64% of the 9EtG-bound adduct bORG formed at 1 mM but none at 20 tM. 
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Figure 4.20 Low-field region of the 'H NMR spectra (298 K) of 10 or 1OR in the 
presence of 1 mol equiv 9-ethylguanine (9EtG) to give complexes lOG [(1 6-p-
cym)Os(ma1)(9EtG)] and 1ORG [(TI  respectively, at 
concentrations varying from 1 mM to 20 .tM. (A) 10 and 9EtG directly after sample 
preparation, and (B) after incubation at 310 K for 24 h, (C) 1OR and 9EtG directly 
after sample preparation, and (D) after incubation at 310 K for 24 h. Assignments: 8 
(M = Os) and 8R (M = Ru) hydroxo-bridged dimers, -p-cyrn)M( ~t-ODW(TI 
 m free maltol; 10A (M = Os) and 10RA (M = Ru) the monoaqua complex 
[(116  -p-cym)M(mal)(0D2)] +  ; G unbound 9EtG. 
Based on integration of 'H NMR peaks in Figure 4.20A and Figure 4.20C, values for 
the formation constants were determined as log K = 4.41±0.04 for the Os complex 
lOG, and 3.87±0.09 for the ruthenium complex 1ORG, Figure 4.21. 
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Figure 4.21 Plot of [(ij 6 -p-cym)M(mal)(9EtG)] +  /[free 9EtG] vs [(116_p_ 
cym)M(mal)(OD2)1 +, for determination of the apparent stability constants of [(7 6-p-
cym)Os(mal)(9EtG)] (10G) and [( 6-p-cym)Ru(mal)(9EtG)] (1 ORG). 
Concentrations are based on peak integration of the 'H NMR spectra in Figure 
4.20A/C at the initial mixing time before dimer formation plays a significant role. 
From the slopes, the constants log K were determined as 4.41±0.04 and 3.87±0.09 
for Os (lOG) and Ru (10RG), respectively. 
4.3.7 Cytotoxicity 
Complex 10 is non-toxic towards the human lung A549 and ovarian A2780 cancer 
cell lines, at concentrations up to 50 tM (the highest test concentration). The IC 5 0 
values are therefore likely to be> 100 .tM and the complexes are deemed inactive. 22 
Human lung A549 cancer cells exposed to 50 tM of the osmium pyridonate complex 
11, show ca. 80% cell survival (10 50 values are still likely to be> 100 jiM). Complex 
11 also shows activity towards human ovarian A2780 cancer cells with an IC 50 value 
of ca. 30 jiM (Figure 4.22). 
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Figure 4.22 Plot of % cell survival vs log drug conc (Os) for [(1 6-p-
cym)Os(pyrid)Cl] (11) when tested against human A2780 ovarian cancer cells. An 
IC 50 value of 30 tM (concentration that inhibits cell growth by 50%) is obtained 
from this curve. 
4.4 Discussion 
4.4.1 Structure of Osmium Maltolato Complex 
There appear to be no previous reports of the structures of maltolato complexes of 
Os" arenes, although those of Ru" complexes have been reported, [(1 6.. 
mes)Ru(mal)C1] and [( 6-p-cym)Ru(mal)Cl] 2H20 (101121-120). 14" 7 The structures 
of the Os (10) and Ru (1011-21-120) 17  maltolato complexes are very similar. In the 
context of hydrolysis it is interesting to note that the osmium-chloride bond length 
(2.4326(16) A) is significantly longer than for the N,N-chelated complexes [(1 6W 
2 bip)Os(en)Cl] +  (2.3963(14) A). 1  The osmium-oxygen bond lengths in 10 (2.091(5) - 
2.114(4) A) are longer than those of its respective acac analogue 4 (2.0700(16) - 
2.078(3) A),' with the longer Os-O bond lengths being on the carbonyl side of the 
maltolate ligand. 
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4.4.2 Dynamic 0,0-Chelate Ring-Opening 
The presence of chiral Os centres in complexes 10 and 11 due to the unsymmetrical 
nature of maltolate and pyridonate, is evident in 'H NMR spectra in non-coordinating 
solvents (e.g. CDC13 and toluene-d8), the four p-cymene ring protons and two 
isopropyl methyl groups being inequivalent. In coordinating proton-donor solvents 
such as D20 and MeOD44, a dynamic process appears to take place at the metal 
centre with AG values of 62 and 45 kJ moV' for 10 and 11 in MeOD44 , 
respectively. This probably involves either ring-opening of the chelate aided by the 
coordinating proton donor solvent, flipping and rebinding, or inversion at the Os 
centre by a mechanism similar to that proposed by Davies et al. 23 This dynamic 
process is faster for 10 in D20 than in MeOD-d4 and such a dynamic process may 
contribute to the mechanism of 0,0-chelate displacement in water. If the dynamic 
process does involve chelate protonation, then this would explain the fact that it 
occurs more rapidly for 11 in MeOD-d4 compared to that of 10 (at 298 K), because 
pyridonate is more basic than maltolate (pKa pyridH 9.7 and malH 8.62, 
respectively). 24" 2 
4.4.3 Hydrolysis 
The hydrolysis of complexes 10 and 11 is rapid in water, with one major set of 'H 
NMR peaks present (corresponding predominantly to the aqua complex) as soon as 
the first 'H NMR spectrum is recorded, with rapid exchange between the aqua and 
chioro species on the NMR timescale. Such rapid exchange in comparison to the 
N,N-chelated en complexes probably results from the increased electron density at 
the metal centre due to the anionic maltolate and pyridonate ligands, as well as 
possible stabilizing interactions between hydrogens of coordinated water and the 
oxygen atoms of the chelated ligand. The rapid hydrolysis of complexes 10/11 and 
the proposed stabilising H-bonds between the maltolate oxygens and the hydrogen 
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atoms of incoming water molecules, are in accordance with reported DFT 
calculations for the hydrolysis of the similar complex 4, [(ij  
containing the anionic 0,0-chelating acac ligand) 7 
4.4.4 Acidity of Aqua Complexes 
The pKa value for the Os maltolato aqua complex 10A (7.73) is ca. I pKa unit 
higher in comparison to complexes containing the neutral en ligand," 25 but in a 
similar range to those of the corresponding acac complexes, Table 4•4•I2  The pKa* 
value for the Os pyridonate aqua complex hA (8.49) is much higher than that for its 
very similar maltolate analogue, and currently appears to be the highest value 
reported for coordinated water in an osmium arene complex. This may be due to the 
increased negative charge that can be present on the osmium centre, and the possible 
resonance structures involving the aromatic back-bone which stabilise positively 
charged complexes obtained by substituting Cl - with a neutral ligand like 0112 
(Figure 4.23). 
>-9- > - Q- -CI- 
CK 0 	+ Cl-D 	
Os.,,10 





Figure 4.23 Stabilising effect of delocalisation of charge on pyridonate backbone in 
complex 11. Possible origin of increased stability of complex 11 in aqueous solutions 
and low acidity of coordinated water. 
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Table 4.4 pKa and pKa*  values for [(i 6-arene)M(XY)(OH2)] complexes, 
M = Os or Ru, XY = maltolate (mal), pyridonate (pyrid), acetylacetonate 
(acac) or ethylenediamine (en), arene = p-cymene (p-cym) or biphenyl (bip) 
Complex Metal Arene XY pKa' pKa  
10A Os p-cym mal 7.73 7 . 60a 
10RA Ru p-cym mal 9.24" 
4A Os p-cym acac 7.84 7.63 
4RA Ru p-cym acac 9.4P' 
hA Os p-cym pyrid 8.49 8 . 31a 
Os bip en 6.37 6 . 34a,c 
Ru bip en 7 . 71e 
a The pKa values are calculated from pKa*  according to Ref 26. b  Ref 17 
C  Ref 1 and Chapter 3. d  Ref 2. 'Ref 25. 
As described in Chapter 3, water is significantly more acidic (by Ca. 1.6 pKa  
units) when coordinated to Os" compared to Ru". 1,27 The implications of these pKa  
values are that at physiological pH (7.4) a significant portion (ca. 40%) of complex 
10A would be present as the less reactive hydroxo species, [(71 
 whereas almost all (>95%) of complex 11A would be present as 
the reactive aqua complex, [(r 6-p-cym)Os(pyrid)(OH 2)]. 
The lower pKa value (ie. higher affinity for hydroxide) of the Os aqua 
maltolate complex 10A could contribute to the finding that the Os maltolato complex 
10 forms the hydroxo-bridged dimer more readily and at lower pH values than its Ru 
maltolate analogue 1OR or osmium pyridonate complex 11. It seems likely that one 
of the maltolate oxygens (probably the deprotonated oxygen adjacent to the methyl 
group) accepts a proton from the suitably positioned coordinated water, and does so 
more readily from the more acidic water coordinated to Os in [(p6-p-
cym)Os(maI)(OH2)] 10A compared to Ru in [( 6-p-cym)Ru(mal)(OH 2)] 1OR or Os 
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in [(TI 	hA, leading to chelate ring opening, eventual loss 
of maltol and formation of the stable hydroxo-bridged dimer 8. 
4.4.5 Stability of Complexes Under Biological Test Conditions 
This work shows that introduction of the 5-membered maltolate chelate ring provides 
stabilization towards hydroxo-bridged dimer formation in comparison to the 6-
membered acac complexes,' but the dominant species present in aqueous solution 
under conditions relevant to the biological tests (micromolar concentrations, ca. pH 
7, 24 h exposure at 310 K) for both the Os 11  maltolato complex 10 and Ru" analogue 
10R, are the hydroxo-bridged dimers 8 and 811, respectively (Figure 4.10). 
Remarkably, even in solutions of 10 (8 and 200 pM) containing 0.1 M NaCl, the 
hydroxo-bridged dimer was the major species present, implying that the high levels 
of chloride in blood plasma would not prevent hydroxo-bridged dimer formation and 
deactivation of the complex. 
Though the formation of a dimer with decrease in concentration is initially 
counterintuitive, it does result in an increase in entropy, as illustrated in Equation 1. 
2[(q6-p-cym)Os(maI)(OD2)] 	 [(q6-p-cym)Os(OD) 30s(q6-p-cym)] + 2mal 	(1) 
The hydroxo-bridged dimer forms most readily from the osmium acac 
complex 4, ft116-p-cym)Os(acac)Clj,  and less readily from complex 10, [(11 
 (Figure 4.10). The ruthenium complexes (411 and 10R) are more 
stable than their osmium analogues. Both maltolate and acetylacetonate are readily 
protonated at physiological pH values, the conjugate acids of the free ligands having 
pKa values of 8.62 and 8.88, respectively. 24  A possible mechanism for the formation 
of the hydroxo-bridged dimers 8 and 811 involves protonation of one of the maltolate 
oxygens followed by ring-opening and eventual loss of the maltolate, although the 
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intermediates, if they are formed, must be short-lived since they were not detected in 
these experiments. The higher acidity of water coordinated to Os" compared to Ru" 
(ca. 1.6 pKa units) probably contributes to the easier protonation of 0,0-chelated 
ligands in Os complexes. It is interesting to note that coordinated water in the triaqua 
benzene complex, [(i6-benzene)0s(OH2)3]2  is thought to be highly acidic. (pKa Ca. 
2.33.4).27 Thus on loss of coordinated chelate, deprotonation of other coordinated 
aqua ligands is likely to occur readily. 
Intriguingly the osmium pyridonate complex 11 shows highest stability 
overall. This is surprising as structurally 11 appears to be very similar to its maltolate 
analogue, 10. The differences between the two lie in the backbone of the chelate. For 
maltolate no delocalisation of charge can occur in the aromatic ring containing an 
oxygen atom, in contrast resonance structures can be drawn when this is replaced 
with a nitrogen atom with an available lone pair, Figure 4.23. 
4.4.6 . Interactions with Nucleobases 
DNA is an important potential biological target for many metal-based anticancer 
agents. 28 Distortions of DNA structure often correlate with anticancer activity. 29 
Little work has been reported on the reactivity of Os arene complexes towards DNA 
nucleobases. 
The Os" maltolato complex 10 reacts with both G (Guo and 9EtG) and A 
(Ado) nucleobases rapidly (< 10 mm, by the time the first 'H NMR spectrum was 
recorded), yet no reaction was observed with the pyrimidines Cyt or Thy. The extent 
of the reaction with 9EtG was similar for both the Os complex 10 (71%) and Ru 
complex 1OR (64%). 
Complex 10 reacted with Ado with a ratio of N7 : N  coordination of Ado of 
2.4: 1 (10), and can be compared with 3: 1 for {('q 6-p-cym)Ru(mal)} (bR), and Ca. 
6 : 1 for J(ij  The pKa* for the NiH deprotonation of [(116_p_ 
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cym)Os(mal)(Ado-N7)] +  (10A7) of 1.85 is similar to the analogous pKa for [0 6-p-
cym)Os(acac)(Ado-N7)] (1.92).' In competition reactions of complex 10 with G and 
A, the ratio of G-N7 : A-(N7+N1) binding was 1.1 1 for the osmium complex 10, 
which was similar to that reported for the Ru analog 1OR (1 : 1.1).' {(16 
arene)Ru(en)} 2  preferentially forms adducts with G nucleobases when in 
competition with A, C and T. 3° Replacement of en by the anionic 0,0-chelating 
ligand acac" 2  changes the selectivity so that the affinity for N7 and NI of A bases as 
well as N7 of G are comparable. Similar base selectivity is found on replacing acac 
with maltolate, i.e. binding to purine bases (Guo, 9EtG and Ado), but not to 
pyrimidines (Cyt or Thy). The observation of similar reactivity of both Os" and Ru" 
maltolate complexes 10 and 1OR towards nucleobases is notable in view of the 
inertness often associated with third row transition metals (Os) compared to their 
lighter congeners (Ru). The high reactivity associated with acac complexes, [( 116-p-
cym)Os(acac)Cl], with nucleobases (reported in Chapter 3), has been retained on 
replacing acac with maltolate. 
{( 6-p-cymene)0s(mal)} appears to bind more strongly to 9EtG (log K Ca. 
4.4) compared to the Ru analogue (log K ca. 3.9). These appear to be the first 
determinations of stability constants for metal arene - nucleobase adducts, although 
binding constants for DNA-intercalating Ru" arene complexes have been reported. 3 ' 
However, since the binding is relatively weak, high concentrations of the complex 
might need to reach DNA in the nucleus for effective lesions (and cytotoxicity) to 
occur. Unlike DNA platination,32 binding of complexes 10 and 1OR to DNA 
nucleobases is likely to be reversible and the lesions more readily repaired by 
enzymes. The formation of hydroxo-bridged dimers (8 and 8R) provides a driving 
force for the dissociation of nucleobase adducts. These dimers appear to be the 
thermodynamically stable products from the dissociation of nucleobase adducts in 
aqueous solution (Figure 4.18, Figure 4.20 and Scheme 4.1). 
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Scheme 4.1 General scheme for hydrolysis and nucleobase binding to complexes 10 
and 10R. Hydrolysis is rapid, as is binding to the G nucleobase. However, with time 
the hydroxo-bridged dimer predominates (forming irreversibly) as the 
thermodynamically more stable product. 
4.4.7 Cytotoxicity 
Despite the reactivity of the Os maltolato complex, [(ij 	10, 
towards DNA nucleobases, it was found to be non-toxic towards both the human 
lung A549 and ovarian A2780 cancer cell lines at concentrations up to 50 j.tM (the 
highest test concentration). The Ru analogue, [(ij  bR, has also 
been found to be inactive, 33 although the ruthenium acac complex, [(r 6-p-
cym)Ru(acac)Cl] 4R, is cytotoxic (1050 19 p.M towards A2780 cells). 
17,33,14 The 
inactivity of 10 and 1OR is presumably due to the instability of their nucleobase 
adducts which readily dissociate into their corresponding hydroxo-bridged dimers. 
The trend in cancer cell cytotoxicity of osmium arene complexes containing 
0,0-chelating ligands correlates with increase in aqueous stability with respect to 
dimer formation. The only stable candidate out of the complexes studied here was 
complex 11, [(16-p-cym)Os(pyrid)Cl], in which positive charge could be delocalised 
onto the pyridonate backbone, stabilising charged structures (aqua or nucleobase 
adducts). Presumably the ruthenium analogue of 11, [(16-p-cym)Ru(pyrid)Cl], would 
show even greater stability than the osmium complex and exhibit even greater 
activity towards cancer cells. 
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4.5 Conclusions 
Chioro Os" arene complexes containing the anionic 0,0-chelating maltolate or 
pyridonate ligands are highly reactive in aqueous solution. They hydrolyse and bind 
to purine nucleobases rapidly, properties shared by Ru 1 ' acac analogues which are 
cytotoxic to cancer cells. 34 
The presence of a 5-membered maltolate chelate ring increases the hydrolytic 
stability of these metal arene complexes compared to their acac analogues. However, 
they are still deactivated to a significant extent at biologically-relevant (micromolar) 
concentrations by formation of inert hydroxo-bridged dimers, even in the presence of 
100 mM NaCl. However, the presence of a 5-membered pyridonate chelate ring 
increases the hydrolytic stability of the osmium arene complex, [(716-p-
cym)Os(pyrid)Cl], significantly, and subsequently displays activity against human 
ovarian A2780 cancer cells (1050 ca. 30 .tM). These findings highlight the 
importance of probing the aqueous chemistry at low micromolar concentrations 
when complexes are designed for biological applications. 
The evidence for facile maltolate and pyridonate ring-opening in proton 
donating solvents (Figure 4.6), and the lower pKa  of water coordinated to {(1 6-p-
cym)0s(mal)} (7.60) compared to Ru (9.24), suggests that the mechanism of dimer 
formation involves protonation of 0,0-chelate by coordinated water, ring-opening 
and loss of chelate. The higher acidity of coordinated water may favour protonation 
of chelate on Os" compared to Ru", and the higher affinity for hydroxide may lead to 
direct substitution in basic solutions. 
The binding of purine nucleobases to {(r 6-p-cym)0s/Ru(mal)} is rapid and 
reversible, the dissociation of adducts being driven by the high thermodynamic 
stability of the hydroxo-bridged dimers, especially for Os. Intriguingly, binding of 
{( 6-p-cym)Os(mal)} to 9EtG appears to be stronger than for the Ru" analogue. 
However, the binding of both these Os and Ru complexes to G nucleobases is 
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relatively weak and labile which may not only allow efficient removal and repair of 
DNA adducts in cells, but give rise to the formation of stable hydroxo-bridged 
dimers. 
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5.1 Introduction 
The design and development of organometallic drugs is a relatively new but rapidly 
developing field. 1,2  Organometallic complexes of the group 8 elements ruthenium 
and iron are receiving increasing attention as potential anticancer agents, 3-6  yet the 
pharmacological potential of organometallic osmium complexes has been little 
explored. In general, relatively little is known about the chemistry of osmium arene 
complexes compared to those of iron and ruthenium. A SciFinder search revealed Ca. 
8 times fewer publications for osmium arene complexes. 
Ruthenium and platinum complexes containing chelating N,N-heterocyclic 
ligands, e.g. phenanthroline (phen), bipyridine (bipy) and phenylazo-pyridine (azpy), 
have been extensively studied and a number have been reported to show anticancer 
activity. 7-9 Romeo et al. have investigated the ligand exchange kinetics of platinum 
complexes containing different bidentate nitrogen chelating ligands,' ° and the DNA 
intercalation ability of this class of ligands on platinum and ruthenium has also 
received attention. 11-14  Osmium complexes containing such heterocyclic bidentate 
nitrogen chelates have been investigated as DNA photoreagents,' 5 ' 7 but these 
complexes were coordinately saturated, containing no exchangeable ligand, and so 
providing no information on ligand exchange rates on osmium containing different 
nitrogen chelators. However, it is clear that bidentate nitrogen chelators such as bipy 
form characteristically stable osmium complexes. 18  This is potentially important for 
possible anticancer candidates, since the dissociation of oxygen chelating ligands 
from osmium at micromolar concentrations can deactivate complexes under 
biological testing conditions, as shown in Chapters 3 and 4•I920 
In this chapter the kinetics and solution behaviour of Os" arene complexes 
containing a series of different bidentate nitrogen chelators, including diamines and 
azopyridines are explored, and attempts are made to relate this to their activity 
towards cancer cell lines. 
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5.2 Experimental Section 
5.2.1 Materials 
OsC13.nH20 was purchased from Alfa Aesaer, ethylenediamine and 4-(2-
pyridylazo)-N,N-dimethylaniline (azpy-NMe 2) from Sigma-Aldrich, 9-ethylguanine 
and guanosine 5 '-monophosphate from Sigma, ammonium tetrafluoroborate, 
ammonium hexafluorophosphate, 2-picolylamine (ampy), 2,2'-dipyridine (bipy), 
1,1 0-phenanthroline (phen) and deuterated solvents from Aldrich. 
5.2.2 Preparation of complexes 
Complexes 1PF6, 12-19 were synthesized from the dimers [(rj 6-bip)OsCl2} 2 , [(16.. 
THA)OsC12]2 and [(q 6-p-cym)OsCl2]2, which were prepared as described in Chapter 
3. The synthesis of [(16-bip)Os(en)Cl]BF4  (1BF4) is also reported in Chapter 3. The 
ligand [3,2-a: 2',3'-c]phenazine (dppz) and the ruthenium complex, [(TI 6_  
bip)Ru(en)Cl]PF6, were kindly provided by Drs. Michael Melchart and Abraha 
Habtemariam, University of Edinburgh. 
[(i 6-bip)Os(en)C1]PF 6 (1PF6). Synthesis as for [(i 6-bip)Os(en)CI]BF4 
(1BF4) in Chapter 3, using NH 4PF6 instead of NH4BF4 . Yield: 139 mg (67%). ESI 
MS: m/z calcd for C,4C1H18N2Os: 442. 1, found 441.4. 'H NMR (DMSO-d6): 8 = 7.69 
(d, 2H, J = 7.2 Hz), 7.49 (t, 2H, J = 7.4 Hz), 7.44 (t, 1H, J = 7.3 Hz), 7.07 (b, 2H), 
6.42 (d, 211, J = 5.5 Hz), 6.13 (t, 1H, J = 5.1 Hz), 6.03 (t, 2H, J = 5.4 Hz), 4.80 (b, 
2H) 3 2.45 (m, 2H), 2.20 (m, 2H). Crystals of 1PF 6 suitable for X-ray diffraction were 
obtained by slow evaporation of a dichloromethane solution at ambient temperature. 
I(vi6-THA)Os(en)CIIBF4 (12). A solution of [(i6-THA)OsCl2]2  (27.1 mg, 
0.03 mmol) in methanol (5 mL), was refluxed for 1.5 h under argon, ethylenediamine 
(5 p.L, 0.075 mmol) was added, and the reaction mixture heated for a further 40 mm. 
The mixture was filtered through a glass wool plug while still hot and a filtered 
solution of NI-LBF4 (29 mg, ca. 9 mol eq) in methanol (2 mL) was added, stirred, and 
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the solvent removed in vacuo. Soxlett extraction using dichloromethane was carried 
out for 6.5 h. The solvent was allowed to slowly evaporate overnight (ca. 0.5 mL). 
The crystalline product was recovered by filtration, washed with diethyl ether (10 
mL) and air-dried. Yield: 6.4 mg (19%). Anal. Calcd for C16C1H22N20sBF 4 (554.85): 
C, 34.63; H 4.00; N 5.05%. Found: C, 34.33; H, 3.44; N, 4.87%. 'H NMR (DMSO-
do): 8 = 6.84 (b, 2H), 5.85 (dd, 2H, J = 4.0 and 1.8 Hz), 5.78 (s, 2H), 5.73 (dd, 2H, J 
3.9 and 1.9 Hz), 4.72 (b, 2H), 3.34 (m, 4H, J = 175.1 and 16.4 Hz), 2.65 (s, 4H), 
2.45 (m, 2H), 2.19 (m, 2H). Crystals suitable for X-ray diffraction were obtained by 
slow evaporation of a dichloromethane solution of 12 at ambient temperature. 
L(q6-p-cym)Os(ampy)C1JPF6 (13). To a solution of [(ij  (49.7 
mg, 0.06 mmol) in 4 mL methanol, was added 2-picolylamine (14 iL, 0.13 mmol). 
The reaction mixture was stirred at ambient temperature and shielded from the light 
for 20 h. A filtered solution of NH 4PF6 (100 mg, ca. 5 mol eq) in 2 mL MeOH was 
added, the solvent volume was reduced on a rotovap until a yellow precipitate began 
to form (ca. 2 mL). The reaction vessel was stored at 253 K for 2 h. The product was 
recovered by filtration, washed with methanol (4 mL) and diethyl ether (10 mL) and 
air-dried. Yield: 60.6 mg (79%). Anal. Calcd for C16C1H22N2OsPF 6 (614.07): C, 
31.35; H 3.62; N 4.57%. Found: C, 30.91; H, 3.33; N, 4.60%. 'H NMR (MeOD-d 4): 
= 9.06 (d, 1H, J = 5.7 Hz), 7.97 (dd, 1H, J = 8.5 and 7.6 Hz), 7.65 (d, 1H, J = 7.9 
Hz), 7.48 (dd, 1H, J = 7.6 and 6.6 Hz), 6.09 (d, 1H, J = 5.5 Hz), 6.06 (d, 1H, J = 5.5 
Hz), 5.91 (d, 1H, J = 5.5 Hz), 5.88 (d, 1H, J = 5.5 Hz), 4.41 (m, 2H), 2.71 (sep, 1H, J 
= 6.9 Hz), 2.17 (s, 3H), 1.25 (d, 3H, J = 6.8 Hz), 1.19 (d, 3H, J = 6.6 Hz). 
[(ti6-p-cym)Os(bipy)C 1]PF6 (14). A solution of 2,2'-dipyridine (21.1 mg, 
0.14 mmol) and [(ij  (51.1 mg, 0.07 mmol) in 4 ml, methanol was 
stirred for 19 h at ambient temperature. It was then filtered through a glass wool plug 
and a filtered solution of NH4PF6 (100 mg, ca. 5 mol eq) in 2 mL MeOH was added. 
The solvent volume was reduced on a rotovap to ca. 3 mL. A yellow precipitate 
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formed as the solution cooled to ambient temperature. The product was recovered by 
filtration, washed with methanol (4 mL) and diethyl ether (10 mL) and air-dried. 
Yield: 63.2 mg (74%). Anal. Calcd for C20C1H22N 20sPF6 (661.05): C, 36.34; H 3.35; 
N 4.24%. Found: C, 36.19; H, 3.36; N, 4.08%. 'H NMR (CDC13): 6 = 9.24 (d, 2H, J 
= 5.6 Hz), 8.26 (d, 2H, J = 8.0 Hz), 8.09 (dd, 2H, J = 8.7 and 7.8 Hz), 7.67 (dd, 2H, J 
7.8 and 6.6 Hz), 6.11 (d, 2H, J = 5.8 Hz), 5.86 (d, 2H, J = 5.7 Hz), 2.57 (sep, 1H, J 
= 6.9 Hz), 2.32 (s, 3H), 1 .05(d, 6H, J = 6.9 Hz). 
I(t16-p-cym)0s(phen)CIJPF6 (15). A solution of 1,10-phenanthroline (23.6 
mg, 0.13 mmol) in 1 mL methanol was added to a solution of [( 6-p-cym)OsC1 2] 2 
(49.1 mg, 0.06 mmol) in 3 mL methanol, and stirred at 323 K for 1 h under argon. 
The solution was filtered through a glass wool plug and the solvent volume reduced 
to Ca. 2 mL. A filtered solution of NH 4PF6 (100 mg, ca. 5 mol eq) in 2 mL MeOH 
was added, and the solvent was removed in vacuo. The residue was sonicated in 
ethanol to give a bright yellow suspension. The yellow powder was recovered by 
filtration, washed with ethanol (10 mL) and diethyl ether (10 mL), and air-dried. 
Yield: 67.4 mg (79%). Anal. Calcd for C22C1H22N 20sPF6 (685.07): C, 38.57; H 3.24; 
N 4.09%. Found: C, 38.61; H, 3.15; N, 3.96%. 'H NMR (CDC1 3): 6 = 9.59 (d, 2H, J 
= 5.3 Hz), 8.57 (d, 2H, J = 8.2 Hz), 8.07 (s, 2H), 8.03 (dd, 2H, J = 8.2 and 5.3 Hz), 
6.27 (d, 2H, J = 5.9 Hz), 6.03 (d, 2H, J = 5.8 Hz), 2.57 (sep, 1H, J = 6.9 Hz), 2.29 (s, 
3H), 1.00 (d, 6H, J = 6.9 Hz). Crystals suitable for X-ray diffraction were obtained 
by diffusion of hexane into a solution of 15 in chloroform at ambient temperature. 
[(t 6-bip)0s(dppz)CI]PF 6 (16). A solution of [( 6-bip)OsC12} 2 (22.3 mg, 0.03 
mmol) was refluxed in 5 mL MeOH : 2.5 mL H20 for 2 h under argon and then 
filtered through a cotton wool plug to remove a dark black precipitate. To the 
resulting pale yellow solution was added a solution of dppz (dipyrido[3,2-a:2',3'-
c]phenazine) (15.8 mg, 0.06 mmol) in 5 mL MeOH. The reaction mixture was stirred 
at 323 K for 80 min under argon. The mixture was filtered through a glass wool plug 
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and the solvent volume reduced (Ca. 5 mL). Addition of a filtered solution of NH 4PF6 
(90 mg, Ca. 10 mol eq) in 1 mL MeOH gave rise to a yellow precipitate which was 
recovered by filtration, washed with methanol (5 mL) and diethyl ether (10 mL), and 
air-dried. Yield: 32.5 mg (75%). Anal. Calcd for (16+CH30H) C31C1H24N400sPF6 
(839.20): C, 44.37; H 2.88; N 6.68%. Found: C, 43.61; H, 2.43; N, 7.15%. 'H NMR 
(DMSO-d6): ö = 9.80 (d, 2H, J = 5.6 Hz), 9.73 (d, 2H, J = 8.4 Hz), 8.56 (dd, 2H, J 
6.6 and 3.5 Hz), 8.24 (dd, 2H, J = 6.7 and 3.4 Hz), 8.21 (dd, 2H, J = 8.3 and 5.6 Hz), 
7.60 (d, 2H, J = 7.9 Hz), 7.56 (t, 1H, J = 7.1 Hz), 7.40 (t, 2H, J = 7.7 Hz), 7.02 (d, 
2H, J = 6.0 Hz), 6.86 (t, 2H, J = 5.8 Hz), 6.49 (t, 1H, J = 5.6 Hz). Crystals suitable 
for X-ray diffraction were obtained by diffusion of diethyl ether into a solution of 16 
in methanol at ambient temperature. 
[( 6-bip)Os(azpy-NMe 2)CI1PF6 (17). A solution of [(ij 	(50.7 
mg, 0.06 mmol) in 10 mL MeOH was refluxed for 3 h under argon and hot-filtered to 
remove a dark black precipitate. To the resulting pale yellow solution was added 
dropwise a solution of azpy-NMe2 (4-(2-pyridylazo)-N,-N-dimethylaniline) (35.3 
mg, 0.16 mmol) in 5 mL MeOH, which resulted in an instant colour change to blue. 
The resulting mixture was stirred at ambient temperature for 1 h under argon. The 
solvent volume was reduced to Ca. 10 mL, NH 4PF6 (114 mg,> 10 mol eq) added and 
left at 253 K overnight. The blue precipitate was recovered by filtration, washed with 
ethanol (20 mL) and diethyl ether (10 mL), and air-dried. The product was 
recrystallised from dichloromethane. Yield: 66.4 mg (73%). ESI MS: m/z calcd for 
C25C1H24N40s: 607.1, found 607.4. 'H NMR (CDC1 3): 8 = 8.57 (d, 1H, J = 5.7 Hz), 
8.31 (d, 1H, J = 7.6 Hz), 8.00 (d, 2H, J = 8.7 Hz), 7.94 (t, 1H, J = 7.9 Hz), 7.50 (m, 
5H), 7.32 (t, 1H, J = 7.9 Hz), 6.64 (d, 2H, J = 8.7 Hz), 6.50 (t, 214, J = 6.8 Hz), 6.23 
(t, 2H, J = 5.7 Hz), 6.15 (t, 1H, J = 5.7 Hz), 3.30 (s, 6H). Crystals suitable for X-ray 
diffraction were obtained by diffusion of diethyl ether into a solution of 17 in 
methanol at ambient temperature. 
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ft 116-p-cym)Os(azpy-NMe2)CJJPF6 (18). Dropwise addition of a solution of 
azpy-NMe2  (31.6 mg, 0.14 mmol) in 4 mL MeOH to a solution of [(716-p-
cym)OsC12] 2 (55.5 mg, 0.07 mmol) in 15 mL MeOH, resulted in an instant colour 
change to blue. The resulting mixture was stirred at ambient temperature for 6.5 h 
under argon and the solvent volume was then reduced to ca. 5 mL. Blue crystals 
formed on adding NH4PF6 (100 mg, Ca. 5 mol eq) to the solution after standing 
overnight at 253 K. The product was recovered by filtration, washed with ethanol (20 
mL) and diethyl ether (10 mL), air-dried, and recrystalised from dichloromethane. 
Yield: 92.1 mg (90%). Anal. Calcd for C23C1H28N 40sPF6  (731.14): C, 37.78; H 3.86; 
N 7.66%. Found: C, 37.81; H, 3.74; N, 7.67%. 'H NMR (CDC13): 6 = 9.18 (d, 1H, J 
= 5.8 Hz), 8.32 (d, 1H, J = 7.9 Hz), 8.06 (d, 2H, J = 9.0 Hz), 8.00 (t, 1H, J = 7.7 Hz), 
7.62 (t, 1H, J = 6.6 Hz), 6.77 (d, 2H, J = 9.2 Hz), 6. 25 (d, IH, J = 5.7 Hz), 6.03 (d, 
1H,J = 5.8 Hz), 5.93 (d, 1H, J = 5.8 Hz), 5.82 (d, 1H, J = 5.6 Hz), 3.32 (s, 6H), 2.34 
(s, 3H), 2.33 (sept, 1H, J = 7.0 Hz), 0.96 (d, 3H, J = 7.0 Hz), 0.87 (d, 3H, J = 6.9 Hz). 
Crystals suitable for X-ray diffraction were obtained by slow evaporation of a 
methanol solution of 18 at ambient temperature. 
F(i6-bip)Os(NCCH3 -IV)C121 (19). To a suspension of [( 6-bip)OsC1 2 ] 2 (98 
mg, 0.12 mmol) in dichloromethane (6 mL) was added acetonitrile (0.5 mL) and the 
reaction mixture heated (320 K) with stirring under argon, shielded from the light, 
for 3 h. The reaction mixture was filtered and the volume of the filtrate reduced on a 
rotovap (4 mL) and diethyl ether added until yellow crystals began to form. After 
standing at 253 K overnight, the yellow crystals were recovered by filtration, washed 
with diethylether (5 mL) and hexane (5 mL), and air dried. Yield: 80.7 mg (76%). 
Anal. Calcd for C14C12H,3NOs (456.40): C, 36.84; H 2.87; N 3.07%. Found: C, 
36.24; H, 2.69; N, 2.80%. 'H NMR (DMSO-d6): 6 = 7.70 (d, 2H, J = 7.9 Hz), 7.45 
(m, 3H), 6.66 (d, 2H, J = 5.5 Hz), 6.36 (t, 1H, J = 5.1 Hz), 6.32 (t, 2H, J = 5.1 Hz), 
2.07 (s, 3H). Crystals of 19 suitable for X-ray diffraction were obtained by diffusion 
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of diethyl ether into an aliquot of the first reaction mixture, at ambient temperature in 
the dark. 
5.2.3 Methods 
X-ray Crystallography. All diffraction data were collected by Dr. Simon 
Parsons, using a Bruker (Siemens) Smart Apex CCD diffractometer equipped with 
an Oxford Cryosystems low-temperature device operating at 150 K. Absorption 
corrections for all data sets were performed with the multi-scan procedure 
SADABS;2 ' structures were solved using direct methods (SHELXL 22, S1R9223 or 
DIRDIF24); complexes were refined against F using SHELXTL and H-atoms were 
placed in geometrically calculated positions. X-ray crystallographic data for 
complexes 1PF6, 12, 15-19 have been deposited in the Cambridge Crystallographic 
Data Centre under the accession numbers CCDC 630298, 630299, 630300, 630301, 
630303, 630302 and 630304, respectively, and can be found on the enclosed cd. 
Kinetics of hydrolysis. The kinetics of hydrolysis of complexes 1BF4, 12-15 
were monitored at various temperatures by preparation of 0.8 mM solutions, 
prepared in methanol-d4 (5%) followed by subsequent dilution with D20 (pH*  ca. 2, 
so that deprotonation of the aqua ligand is prevented) at the required temperature. 
Samples were filtered, placed in the NMR spectrometer preset at the desired 
temperature and spectra recorded at various time intervals. Data, based on peak 
integrals, were fitted to first-order kinetics to give the rate constant (k). The 
Arrhenius activation energies (E a), activation enthalpies (L\H) and activation 
entropies (AS) were determined from the slopes of the Arrhenius and (intercepts of) 
Eyring plots. 
The kinetics of hydrolysis and pKa*  values of coordinated water of complexes 
16, 17 and 18 were not determined due to the poor aqueous solubility of these 
complexes. 
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To study the aqueous stability of complex 19, a 2 mM solution was prepared 
in D20 and its 'H NMR spectrum recorded directly after sample preparation (Ca. 15 
mm). 
Determination of pKa*  Values. For determination of PKa values (pKa values 
for D20 solutions), the pH values of solutions of the aqua complexes 12A-15A in 
D20 (formed in situ by hydrolysis of the parent chloro complexes 12-15) were varied 
from ca. PH*  2 to 10 by the addition of dilute NaOD and HNO3 and the 'H NMR 
spectra were recorded. The PKa and pKa values were determined from the pH 
titration curves as described in Chapter 2. 
Interactions with Nucleobases. The reaction of complex 13 with 9-
ethylguanine (9EtG) at pH 7.4 and 310 K was monitored over time using 'H NMR 
spectroscopy by mixing equal amounts of equilibrium D20 solutions (1 mM) of 13 
and 9EtG. The pH values of these solutions were adjusted with dilute NaOH, so as 
to remain close to physiological pH 7.4, and solutions were allowed to equilibrate at 
310 K before mixing. Their 'H NMR spectra were recorded at 310 K after various 
time intervals. 
Similarly, equal volumes of equilibrium solutions of 1BF4 and 5'-GMP in 
D20 were mixed at 298 K (final concentration 1.6 mM, pH*  6.9) and 'H NMR 
spectra recorded at various time intervals. To determine the Os" binding sites on 5'-
GMP, a pH*  titration over the range 2-12 was monitored by 'H NMR spectroscopy 
and the chemical shifts of the H8 signals plotted against pH * . 
Solutions containing 1BF4 or the ruthenium analogue, [(1 6-bip)Ru(en)Cl]PF6 
1R, and 1 mol equiv 9EtG were prepared in D20 at varying concentrations (1 mM, 
500 pM, 250 riM, 100 tM and 50 p.M) and after incubation at 310 K for 24 h (so as 
to reach equilibrium) their 'H NMR spectra were recorded at 298 K. Binding 
constants (log K) for 9EtG were obtained from the slopes of plots of [bound 
9EtG]/[Free 9EtG] vs [Free metal complex], based on peak integrals. 
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In addition, a stock solution (1 mM) of 1BF4 and 9EtG which had already 
been allowed to reach equilibrium (24 h at 310 K), was diluted to give subsequent 
solutions of 500 1.tM, 250 jtM, 100 iM and 50 riM. These were incubated at 310 K 
for a further 24 h before recording their 'H NMR spectra at 298 K. 
Cancer Cell Cytotoxicity. Cytotoxicity assays on human lung A549 and 
ovarian A2780 cancer cell lines was performed as described in Chapter 2. 
Stability Studies. The stabilities of complexes 1PF6, 1BF4 and 12 were 
investigated by preparing 1 mM solutions in 5% MeOD-d4 /95% isotonic saline 
solution (150 mM NaC1) (v/v) by dissolution of the complex in MeOD-d4 followed 
by rapid dilution with the isotonic saline solution. 'H NMR spectra were recorded 
after various time intervals (10 mm, 1 week, 2 weeks and 2 months) during which 
time the sample was stored at ambient temperature in the dark. 
The stability of 1BF4 in DMSO under various conditions was also 
investigated. Two solutions (ca. 4 mM) of 1BF4 were prepared in DMSO-d6 and their 
'H NMR spectra recorded directly after sample preparation (< 10 mm). One sample 
was stored at ambient temperature, stoppered in the dark for 24 h, and one was 
exposed to heat, sonication, direct sunlight and the air for 24 h, before recording its 
'H NMR spectrum. 
5.3 Results 
Monofunctional (chloride) osmium(II) arene complexes containing neutral diamine 
or azopyridine N,N-chelating ligands, as well as the bifunctional complex [(11 6_  
bip)Os(NCCH3-JV)C12] (19), Figure 5.1, were synthesised in good yields via the Cl-
bridged dimers, [(i6-arene)O5C12]2  where arene = biphenyl (bip), 
tetrahydroanthracene (THA) or p-cymene (p-cym). Seven complexes were further 
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Figure 5.1 Osmium(II) arene complexes studied here containing N-donor ligands. 
5.3.1 X-ray Crystal Structures 
The X-ray crystal structures of [( ij 	1PF6, [016-THA)Os(en)Cl}BF4 
12, [( 6-p-cym)Os(phen)Cl]PF6 15, [( ij 	16, [(16 
bip)Os(azpy-NMe2)Cl]PF6 17, ft71 6-p-cym)Os(azpy-NMe2)Cl]PF6 18 and [(ij  
bip)Os(NCCH3-N)C12] 19, were determined. The structures and atom numbering 
schemes are shown in Figure 5.2. 
The complexes adopt the expected pseudo octahedral "three-leg piano-stool" 
geometry with the osmium it-bonded to the arene ligand (1.65-1.71 A to centroid of 
ring), cy-bonded to a chloride (2.41-2.37 A) and the two nitrogen atoms of the chelate 
(2.02-2.15 A), these constitute the three legs of the piano stool. Crystallographic data 
and selected bond lengths and angles are shown in Table 5.1 and Table 5.2. 
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Figure 5.2 X-ray structures and atom numbering schemes of complexes (A) [(116 .. 
bip)0s(en)Cl]PF6 1PF6, (B) [(1 6-THA)Os(en)Cl]BF4 12, (C) [(q6-p-
cym)Os(phen)Cl]PF6 15, (D) [(r1 6-bip)Os(dppz)Cl]PF6 16, (E) [(71 
 17, (F) [(116-p-cym)Os(azpy-NMe2)Cl]PF6 18 and (G) [(TI 
6_  
bip)0s(NCCH3-N)C121 19 (50% probability ellipsoids). The H atoms and counterions 
have been omitted for clarity. 
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Table 5.1 Crystallographic Data for [(ij 	1PF6, [(716-THA)Os(en)C1]BF 4 12, [( 6-p-cym)Os(phen)C1]PF6 15, [(r 6-p- 
il- 00 
cym)Os(dppz)Cl]PF6 16, [(ij 	17, [(i 6-p-cym)Os(azpy-NMe2)C1]PF6 18 and [(ij 	19 
1PF6 	 12 	 15 	 16 	 17 	 18 	 19 
Formula C14H8ClF6N20sP C 16H22BC1F4N2Os C22H22CIF6N20sP C30H21 CIF6N40sP C50H48C12F 12N8Os2P2 C46H5602F 12N8Os2P2 C 14H 13 C12NOs 
Molecular 
584.92 554.82 685.04 807.13 751.11 731.12 456.37 
weight 
Crystal 
Colourless block Yellow plate Yellow block Yellow lath Dark green prism Black block Yellow plate 
description 
Crystal size 
0.08 xO.08 x 0.34 0.09x0.15 xO.44 0.14 xO.16 xO.36 0.13 x 0.16 xO.61 0.17 xO.22 xO.26 0.33 xO.52 xO.55 0.17x0.42 xO.81 
(mm) 
2(A) 0.71073 0.71073 0.71073 0.71073 0.71073 0.71073 0.71073 
Temperature 
150 150 150 150 150 150 150 
(K) 
Crystal . 	. . 	. Monoclinic . 	. 	. . 	. 
Monoclinic Monoclinic Orthorhombic . Triclinic Triclinic Monoclinic 
system twinned 
Space group P121/cl P121/ni Pbca P121/cl P-1 P-I P121/cl 
a (A) 19.5853(8) 12.722(3) 12.7769(3) 11.8153(12) 8.1226(3) 8.2549(3) 10.0020(15) 
b (A) 9.0300(4) 7.9298(16) 13.3958(2) 8.7125(9) 10.0165(4) 12.2787(4) 7.009(1) 
C (A) 23.2542(8) 18.142(4) 26.6395(6) 26.175(3) 17.3516(6) 12.8556(5) 19.717(3) 
a(° ) 90 90 90 90 101.105(2) 84.792(2) 90 
fl  112.608(2) 105.28(3) 90 102.952(4) 96.365(2) 82.980(2) 102.447(2) 
y () 90 90 90 90 109.27 1(2) 80.680(2) 90 
Volume 
(A) 
3796.6(3) 1765.6(7) 4559.53(16) 2626.0(5) 1284.28(9) 1272.84(8) 1349.8(3) 
Z 8 4 8 4 1 1 4 
R(F02) 0.0913 0.0307 0.048 0.043 0.039 0.031 0.0285 
R,(F02) 0.0972 0.0907 0.066 0.045 0.077 0.065 0.0802 
GOF 0.6814 0.9498 0.599 1.056 0.941, 0.665 1.0434 I 
Table 5.2 Selected Bond Lengths (A) and Angles (°) for [(ij 	1PF6, [( 6-THA)Os(en)C1]BF4 12, [(r 6-p- 
cym)Oshen)Cl]PF6 15, [(ij 	16, [( 6-bip)Os(azpy-NMe2)C1]PF6 17, [( 6-p-cym)Os(azpy-NMe2)Cl]PF6 
18 and [(16-bip)Os(NCCH3-]V)Cl21 19 
Bond 
1PF6 12 15 16 17 18 19 
length/angle' 
Os-C(Arene) 2.232(7) 2.156(5) 2.196(3) 2.215(8) 2.220(4) 2.278(4) 2.178(4) 
2.208(7) 2.180(5) 2.208(3) 2.192(7) 2.207(5) 2.209(4) 2.193(5) 
2.195(7) 2.224(4) 2.187(3) 2.195(5) 2.189(5) 2.214(3) 2.181(4) 
2.176(8) 2.171(5) 2.224(3) 2.139(7) 2.219(5) 2.220(3) 2.170(4) 
2.169(7) 2.218(5) 2.194(4) 2.173(8) 2.211(5) 2.175(3) 2.183(5) 
2.194(7) 2.200(5) 2.178(3) 2.257(5) 2.201(5) 2.231(4) 2.186(4) 
Os-Ni 2.136(6) 2.127(4) 2.091(3) 2.117(5) 2.055(3) 2.055(3) 2.057(4) 
Os-X2 2.152(6) 2.140(4) 2.094(3) 2.073(5) 2.071(4) 2.021(3) 2.4139(12) 
Os-Cl 2.3918(19) 2.4107(12) 2.4062(9) 2.3958(14) 2.3962(11) 2.3711(8) 2.3976(11) 
N1-Os-X2 78.7(2) 78.48(16) 77.22(11) 76.98(17) 74.89(14) 74.99(12) 85.01(11) 
N I -Os-Cl 83.47(17) 82.88(12) 83.17(8) 85.14(17) 85.10(10) 83.26(8) 84.00(11) 
C1-Os-X2 83.65(18) 81.87(11) 83.06(8) 84.69(17) 83.94(10) 87.17(8) 86.14(4) 
= 2nd nitrogen donor group and N1 = pyridine (and X2 = azo) in 17 and 18. For complex 19, X2 C12. 
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Complex 1PF6 crystallises with 2 independent molecules in the unit cell. The 
biphenyl unit is twisted (by 27 or 43°) and intermolecular arene ring-stacking is 
observed between the coordinated arene in two independent molecules (4.34 A at a 
dihedral angle of 32.4 0). In contrast the coordinated THA ligand in complex 12 is 
almost planar, being slightly bent upwards (away from the legs) by 6.5°. Two 
molecules crystallize so that their arenes are parallel, see Figure 5.3, the distance 
between the TI-IA ligands is 3.3 A and the rings are separated by 4.13, 4.10 and 4.13 
A, at dihedral angles of 32, 27 and 32°, respectively. 
Figure 5.3 Diagram showing 2t-stacking between the (A) planar THA arenes of 
neighbouring molecules in the X-ray crystal structure of [(716-THA)Os(en)CflBF4 12. 
(B) The centroids of three fused rings on independent molecules are separated by 
4.13, 4.10 and 4.13 A, at dihedral angles of 32, 27 and 32°, respectively. 50% 
ellipsoids. H atoms and the BF4 counterion have been omitted for clarity. 
Further intermolecular arene ring stacking is observed in the crystal structures of 
complex 15 and the twinned complex 16, between one of the bound pyridine rings 
and the related pyridine of a second molecule (3.72 A and 4.75 A at dihedral angles 
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of 37.0 and 40.0° for 15 and 16, respectively), Figure 5.4. The biphenyl ligand in the 
crystal structures of 16 and 17 is twisted by 33° and 32°, respectively. Arene ring 
stacking was also observed in the crystal structure of 17, between the coordinated 
pyridine and the phenyl ring attached to the azo group of an adjacent molecule (4.7 A 
at a dihedral angle of 50°), but not in that of complex 18. 
(A) 	 (B) 
Figure 5.4 Diagram showing for the cation of complex 16 [(16-bip)Os(dppz)Clj (A) 
the planarity of the extended dppz chelating ligand, and (B) 7t-stacking between a 
coordinated pyridine ring of one molecule and the related pyridine ring of a second 
molecule. 50% ellipsoids. H atoms and the PF 6 counterion have been omitted for 
clarity. 
Complex 19 in which biphenyl is twisted by 42°, crystallises so that dimers link 4 
independent molecules through CII of one molecule and the C81-181 and C51­151 of 
two others (C8 ... Cll 3.513(5) and C5C11 3.680(6) A, respectively), Figure 5.5. 
The PF6 (and BF4) counter ions in these crystal structures are extensively 
involved in H-bonding to the chelated ligand or arene protons. 
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Figure 5.5 Diagram showing four independent molecules in the X-ray crystal 
structure of 19, [(16-bip)Os(NCCH 3-IV)C12]. Dimers are formed by interactions 
between Cli of one molecule and C8H81 (C8 ... Cll 3.513(5) A) and C51­151 (C5 ... Cll 
3.680(6) A) of another. 
5.3.2 Kinetics of Hydrolysis 
The rate of hydrolysis of complex 13 at 298 K in aqueous solution (13 20) was 
monitored at various pH' values of 8, 6 and 2. The rate of hydrolysis, based on peak 
integrals for p-cymene peaks of the intact chioro complex 13 (5.93 and 5.91 ppm) 
and the aqua complex 13A (5.76 and 5.74 ppm), was rapid at pH' 8, with a half life 
of Ca. 0.11 h. At pH' Ca. 6 the rate of hydrolysis was slower (ti,. 0.66 h), with less 
hydrolysis of the complex and at pH' Ca. 2, even slower. A fit to pseudo-first-order 
kinetics yielded a rate constant of k 0.13 h - 1 (ti. 5.3 h, Figure 5.6A) at pH' 2. 
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Figure 5.6 Time dependence for formation of the aqua complex 13A (based on 'H 
NMR peak integrals) during hydrolysis of 13 [(il  (A) at 298 
K in D20 at various pH * values; 8 (.), 6 (.) and 2 (A), giving half-lifes of ca. 0. 11, 
0.66 and 5.3 h, respectively. (B) Hydrolysis of 13 in acidic D20 (pH Ca. 2) at 298 K 
(m), 304 K (.), 310 K (A) and 316 K (Y) 
A comparison of the rates of hydrolysis of complexes 1BF 4 and 12-15 under 
acidic aqueous conditions (D20, pH * Ca. 2), so as to prevent deprotonation of the 
coordinated water (Figure 5.613 and Table 5.3), showed that the rates decrease in the 
order 13 > 12 > 1BF4>> 14 15. From the data obtained at various temperatures, 
the Arrhenius activation energies (E a), activation enthalpies (AH) and activation 
entropies (AS T) were determined, Table 5.3 and Figure 57. The large negative LS 
values for complexes 1BF4, 12 and 13 are notable. 
The 'H NMR spectrum of a solution (2 mM) of complex 19, [(-q 6_  
bip)Os(NCCH3)C12], in D20 resulted in peaks for a number of minor unidentified 
species and major peaks (ca. 60% of species) at 6.46, 6.25 and 6.01 ppm assignable 
to the trihydroxo-bridged dimer, [(il  6, Figure 5.8.' 
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Table 5.3 Rate data for the aquation of complexes 1BF4 and 12-15 at varying 
temperatures 
Ea AH 
U mol' kJ mo)' J K' mo) 1 
298 0.046±0.007 15.11±0.22 
310 0.250±0.001 2.80±0.08 
1BF4 101.2 ± 2.0 98.6 ± 2.0 -60.6 ± 6.3 
318 0.615±0.014 1.13±0.03 
333 3.439±0.151 0.20±0.01 
298 0.082 ± 0.001 8.47 ± 0.13 
310 0.423 ± 0.009 1.64 ± 0.03 
12 97.8 ± 4.1 95.1 ± 4.2 -54.2 ± 13.3 
318 1.205 ± 0.052 0.58 ± 0.03 
333 5.105±0.232 0.14±0.01 
298 0.131 ± 0.002 5.29 ± 0.08 
304 0.308 ± 0.007 2.25 ± 0.05 
13 94.3 ± 4.6 91.7 ± 4.6 -46.2 ± 15.2 
310 0.545 ± 0.009 1.27 ± 0.02 
316 1.203 ± 0.037 0.58 ± 0.02 
323 0.150 ± 0.003 4.63 ± 0.10 
328 0.266 ± 0.007 2.61 ± 0.07 
14 98.3 ± 14.1 95.5 ± 14.1 -35.1 ± 42.5 
333 0.643±0.016 1.08±0.03 
343 1.217±0.039 0.57±0.02 
318 0.073±0.001 9.45 ±0.14 
328 0.343 ± 0.006 2.02 ± 0.04 
15 105.4 ± 9.8 102.6 ± 9.8 -56.9 ± 29.6 
333 0.609±0.012 1.14±0.02 
347 2.105 ± 0.125 0.33 ± 0.02 
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Figure 5.7 (A) Arrhenius and (B) Eyring plots for the hydrolysis of complexes 
1BF4, 12-15 at various temperatures. Labels: [(ij  (1BF4, .), [(i-. 
THA)Os(en)C1]PF6 (12, •), [( 6-p-cym)Os(ampy)C1]PF 6 (13, A), [(r 6-p-
cym)Os(bipy)Cl]PF6 (14, Y) and [(ij  (15, •). Activation 
energies, Ea, were obtained from the slope of the Arrhenius plot in (A) and activation 
enthalpies, and entropies, L\S, from the slope and intercept of the plot in (B), 
see Table 5.3. 
6 6 
7.0 	6.6 	6.2 	ppm 
Figure 5.8 Formation of the hydroxo-bridged dimer [(ij  
6 from [(ij  19 in aqueous solution, within 15 min of sample 
preparation. Low field region of the 'H NMR spectrum, showing the coordinated 
biphenyl arene ring protons. The hydroxo-bridged dimer 6, accounts for Ca. 60% of 
{( 6-bip)Os} 2 species present in solution. Other peaks have not been assigned. 
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5.3.3 pKa determination 
Peaks for coordinated arene ring protons of the aqua complexes, [(11 6_ 
arene)Os(NN)(OD2)} 2 12A-15A, shifted to high field with increase in PH*.  The 
chemical shifts were plotted against PH*  (Figure 5.9) and the data fitted to the 
Henderson-Hasselbaich equation, from which the pKat values of the coordinated 
water were determined. This yielded a value of 5.8 for complexes containing two it-
acceptor pyridine groups as N-donors (14A/15A), and 6.3 for complexes containing a 







1 5.8 	 4A 
12A 
2 	4 	6 	8 	10 
PH* 
Figure 5.9 Determination of pKa*  values for the aqua complexes [(,q 6_  
arene)Os(NN)(OD2)] 2 . Dependence of 'H NMR chemical shifts of coordinated 
arene ring protons on pH*  for [(ij 	(12A), [( 6-p- 
cym)Os(ampy)(0D2)] 2+  (13A), [(i 6 -p-cym)Os(bipy)(0D2)]2+ 
6_p_ (14A) and [(ii 
cym)Os(Then)(OD2)] 2 (15A). The curves represent best fits to the Henderson-
Hasselbaich equation and correspond to pKa*  values of 6.36, 6.32, 5.81 and 5.80, 
respectively. 
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Table 5.4 PKa and PKa values for the deprotonation of the 
coordinated water molecule in hydrolysed complexes 1A, 12A-15A 
* 
[( 6-bip)Os(en)(OD2)} 2 1A 6.37 b 6.34a 
[(116-THA)Os(en)(OD2)]2 12A 6.36 6.33 a 
[( 6-p-cym)Os(ampy)(OD2)] 2 13A 6.32 6.29a 
[( 6-p-cym)Os(bipy)(OD2)] 2 14A 5.81 5. 82 a 
[( 6-p-cym)Os(,hen)(OD2)} 2 15A 5.80 5.81 a 
a pKa values calculated from PKa according to Ref 25. 
b Value reported previously in Chapter 3. 
5.3.4 Guanine Adducts 
New peaks, assignable to the adduct [(ij 	13G, appeared 
in the 'H NMR spectrum of 13 and 9EtG (1:1, 0.5 mM) over time and under 
biologically-relevant conditions (pH*  7.4, 310 K), Figure 5.10A. Based on peak 
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Figure 5.10 (A) Low field region of the 'H NMR spectrum of an aqueous solution 
of 13 (0.5 mM) after reacting with 1 mol equiv 9EtG for 15 h (pH * 7.4 and 310 K). 
Peak assignments: [(ij 	13A, H8 of free 9EtG G and the 
9EtG bound product [(TI 	13G. (B) Time dependence, 
based on 'H NMR peak integrals, for formation of [(ij  
13G in the above reaction. 
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Similarly, new peaks appeared over time in the H8 region in 'H NMR spectra 
of 1:1 solutions of 1BF4 and 5'-GMP (1.6 mM, D20, PH*  6.9, 298 K). After 30 h Ca. 
40% of the 5'-GMP had reacted, Figure 5.1 1A. The H8 peak for free 5'-GMP (8.15 
ppm, b), decreased in intensity with an approximate half-life of Ca. 8.5 h, and peaks 
for new species a (8.45 ppm) and c (8.03 ppm) appeared with half-lives of ca. 8.5 
and 9.0 h, respectively, with c forming before a (Figure 5.11B). Peaks were assigned 
and binding sites on 5'-GMP established, by monitoring a pH*  titration of the mixture 
by 'H NMR spectroscopy (Figure 5.11C). Peak b for free 5'-GMP, was assigned by 
addition of excess 5'-GMP to the mixture, and shifted with pH to give three pKa* 
values of 2.55, 6.57 and 9.86, corresponding to N711, phosphate backbone and NiH 
deprotonation respectively. Peak a shifted with two associated pKa*  values of 5.94 
and 8.09 (phosphate and NiH deprotonation), consistent with N7-bound 5'-GMP, 
[(71  Peak c shifted with two associated different 
pKa* 
values of 0.95 and 8.09 assignable to N711 and Ni H deprotonation, and consistent 
with phosphate bound 5'-GMP, [(ij 	Peak x may be due to 
the dinuclear complex, where two {(ij 	fragments bind to the N7 and 
the phosphate backbone of the same 5'-GMP unit. 26 
Solutions of 1BF4 or the Ru" analogue [(ij 	1R (1 mM - 50 
p.M) containing 1 mol equiv 9EtG, were incubated at 310 K and their 'H NMR 
spectra recorded. Peaks for free 9EtG (118, 8.10 ppm), increased in intensity with 
decrease in metal concentration, Figure 5. 12AIB. Species distribution plots based on 
peak integrals, Figure 5.12C, yielded apparent binding constants of log K = 
3.13±0.03 and 4.78±0.09 for formation of [(ij  1G and [(6 
bip)Ru(en)(9EtG)] 2+  1RG, respectively. 
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Figure 5.11 (A) Low field region of the 'H NMR spectrum of an aqueous solution 
of 1BF4 (1.6 mM) and 1 mol equiv 5'-GMP after 30 h at 298 K. (B) Time 
dependence, based on 'H NMR peak integrals, of decay/formation of peaks a, b and 
c from the above reaction. (C) Plots of H8 chemical shift vs pH*,  solid curves are 
computer fits giving pKa*  values for a (5.94 and 8.09), b (2.55, 6.57 and 9.86) and c 
(0.95, and 9.66). Peak assignments (see structures): a, Os-N7GMP; b, free 5'-GMP; 
C, Os-O(P03)GMP; and x possible dinuclear structure Os-O(P03)GMPN7-0s. 
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Figure 5.12 Low field region of the 'H NMR spectra of (A) [( 6-bip)Os(en)Cl]BF4 
1BF4 and (B) [(1 6-bip)Ru(en)Cl]PF6 1R in the presence of 1 mol equiv 9-
ethylguanine (9EtG) showing the formation of [(ij 	1G and 
[( 6-bip)Ru(en)(9EtG)] 21 1RG, respectively, at concentrations varying from 1 mM to 
50 pM, after incubation at 310 K for 24 h. (C) Determination of the apparent 
formation constants for the osmium and ruthenium analogues, [(16.. 
bip)Os(en)(9EtG)] 2 (1G) and [( 6-bip)Ru(en)(9EtG)] 2 (1RG). The extent of 
binding was determined by peak integration of the 'H NMR spectra in (A) and (B). 
From the slopes of the plots of [(Tj 	9EtG] vs 
bip)M(en)(OD2)] 2 (M = Os 1A, M = Ru iRA), the binding constants log K = 
3.13±0.03 and 4.78±0.09 were determined for Os" (1G) and Ru" (MG), 
respectively. 
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Similar solutions were prepared by diluting an equilibrium stock solution of 
1BF4 and 9EtG (1 mM) to give 500 - 50 j.M solutions, which were incubated at 310 
K for a further 24 h before recording their 'H NMR spectra. Based on 'H NMR peak 
integration of H8 peaks for bound 9EtG (8.21 ppm) and free 9EtG (8.10 ppm), no 
significant change in ratio occurred with decrease in concentration (Figure 5.13). 
.1A 










8.0 	7.5 ppm 
Figure 5.13 Low field region of the 'H NMR spectrum of 1 mM solution of [(1 6 
bip)Os(en)C1]BF4 (1BF4) and 1 mol equiv 9EtG (G) after incubation at 310 K for 24 
h. This solution was then diluted to the concentrations shown and incubated at 310 K 
for a further 24 h before the 'H NMR spectrum was again recorded. Based on peak 
integrals, significant dissociation of bound 9EtG from [(i6-bip)Os(en)(9EtG)]2  1G 
does not occur readily. 
Binding of 1 to 9EtG was further confirmed by ESI-MS. An equilibrium 
NMR sample (containing equal amounts of 1BF4 and 9EtG), gave peaks at m/z 294.1 
and 585.7 consistent with [(ii 6 -bip)Os(en)(9EtG)] 2+  (calc. m/z 292.6) and [(11 6  - 
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5.3.5 Anticancer Activity 
The cytotoxicity of complexes 1BF4 and 12-19 towards the human lung A549 cancer 
cell line was investigated. In addition complexes 1BF4, 1PF6, 12 and 16 were tested 
towards the human ovarian A2780 cancer cell line. Complexes 13-15 and 17-19 were 
non-toxic up to the highest test concentration (50 .tM). The IC 5 0 (concentration 
inhibiting cell growth by 50%) values are therefore likely to be> 100 p.M and the 
complexes are deemed inactive. However, complexes 1BF4, 1PF6, 12 and 16 were 
active (Figure 5.14 and Table 5.5). Complexes 1BF4/PF6 and 12 displayed IC 5 0 
values of 6-10 p.M. The IC 50 values for complex 16 were estimated to be <40 p.M for 
A549 cells and <2 p.M for A2780 cells. Tests on 16 were complicated by its poor 
solubility in water. It was initially dissolved in DMSO and then rapidly diluted with 
water, but could only be administered to the cells as a suspension 27  to maintain a low 
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Figure 5.14 Cytotoxicity of 	[( 6-bip)Os(en)Cl]PF6 (1PF6, 	), [- 
bip)Os(en)Cl]BF4 (1BF4, ---) and  {(i6-THA)Os(en)Cl]BF4  (12, -----) towards (A) 
human A549 lung cancer cells, and (B) human A2780 ovarian cancer cells. The IC 50 
values (concentration that inhibits cell growth by 50%) obtained from these curves 
are given in Table 5.5. 
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Table 5.5 In vitro growth inhibition of human 




1PF6 10 7.0 
1BF4 10 7.6 
12 6.4 9.4 
13 >100 - 
14 >100 - 
15 >100 - 
16 a b 
17 >100 - 
18 >100 - 
19 >100 - 
a <40 .tM, see text b <2 tM, see text 
5.16 Stability Studies 
Since complex 1BF4 had previously been found to have a low cytotoxicity, 19 its 
stability during the sample preparation process was investigated. This initially 
involves dissolution in DMSO and subsequent dilution with water. Solutions of 1BF4 
in DMSO were prepared; sample one was stored stoppered at ambient temperature in 
the dark, and sample two was exposed to the air, heat, sonication and direct sunlight, 
all of which may have been encountered during the earlier sample preparation. 
Directly after sample preparation the solution was clear and pale yellow colour, and 
after 24 h sample one appeared unchanged and no additional peaks were present in 
the 'H NMR spectrum. However, sample two (exposed to extreme conditions) was 
now dark red and new peaks were seen in the 'H NMR spectrum (Figure 5.15). 
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Figure 5.15 Decomposition of [(r1 6-bip)Os(en)C1]BF4 (1BF4) in DMSO. (A) 
Sample directly after preparation and (B) after exposure to the air, heat, sonication 
and direct sunlight, for 24 h. Low field region of the 'H NMR spectra of (C) sample 
(A), and (D) sample (B), showing the biphenyl arene ring protons of the non-
coordinated ring. There were no changes to solutions of 1BF4 in DMSO stored 
stoppered in the dark at ambient temperature. Peaks assigned a correspond to the 
intact complex, [( TI  and b is the unidentified decomposition product. 
'H NIMR spectra of 1 mM solutions of the active complexes, 1PF6, 1BF4 and 
12 in isotonic saline solution (150 mM NaCI) were recorded directly after sample 
preparation and after storage at ambient temperature in the dark for I week, 2 weeks 
and 2 months. Small peaks for the aqua complexes (<10%) were present. The only 
changes in the 'H NMR spectra were loss of peaks assigned as the NH protons of en, 
due to exchange with deuterium (Figure 5.16). 
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Figure 5.16 Stability of 1 mM solutions of complexes 1PF6, 1BF4 and 12 for 
aqueous drug formulation in isotonic saline (0.154 M NaCl), (A) [(1 6. 
bip)Os(en)Cl]PF6 (1PF6), (B) [( 6-bip)Os(en)ClBF4 (1BF4) and (C) [(1 6_ 
THA)Os(en)Cl]BF4 (12) after 10 min at 298 K and after storage at ambient 
temperature in the dark for 2 months. Peaks are due to predominantly the chloro 
species with a small amount of aqua adduct in solution (<10%). No new peaks 
appeared with time, however peaks for the NH protons (assigned *) disappeared over 
time due to exchanged with deuterium. Assignments: in methanol and d dioxane. 
This data suggests that these complexes could readily be formulated for drug use. 
The 'H NMR spectrum of a 50 jM solution of 13 in D20, Ca. 10 min after 
sample preparation, gave rise to p-cymene arene peaks predominantly for the aqua 
complex 13A (78 %) with minor peaks present for the intact chloro species 13 (12 
%). No new peaks appeared after incubation of the sample at 310 K for 24 h (Figure 
5.17). 
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Figure 5.17 Low field region of the 'H NMR spectrum of a 50 jiM aqueous solution 
of [( 6-p-cym)Os(ampy)Cl]PF 6 13 in D20 (A) after 10 min at 298 K, and (B) after 
incubation at 310 K for 24 h. Major peaks are assignable to the aqua adduct, [(Ti6-p-
cym)Os(ampy)(OD2)] 2 13A, and minor peaks (12%) to the intact chloro complex 
13. 
5.4 Discussion 
Eight new osmium arene complexes with the general formula [( -Q 6_arene)Os(NN)Cl] 
containing NN = bidentate nitrogen chelating ligands 1PF6, 12-18 and [(,q 6_  
bip)Os(NCCH3)C12] 19, have been synthesized via the Cl-bridged dimers, [(11 6 
arene)OsC1 2]2 . 
5.4.1 X-ray Crystal Structures 
The X-ray crystal structure of the PF6 salt of complex 1 was determined for 
comparison with that of the BPh salt reported in Chapter 3•19  They are structurally 
very similar. The X-ray structure of complex 12 appears to be the first of an osmium 
complex bound to tetrahydroanthracene (THA). In 12, the arene, THA, is planar, as it 
is in the ruthenium analogue of 12, and it has been proposed that the increase in 
cytotoxicity of [(116-arene)Ru(en)C1],  on replacing arene = bip by THA is due to the 
possibility that the coordinated THA can intercalate into DNA . 28 The ability of the 
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THA ligand to n-n stack is evident in the crystal structure of the osmium complex 12, 
Figure 5.3. it-n stacking is also evident in the crystal structures of complexes 15 and 
16, especially for 16 involving the dppz ligand, which has been extensively studied 
as a DNA intercalator.' 5 ' 29 This feature in combination with the flexible extended 
arene ring system (bip) may mean intercalation via both dppz and/or bip contributes 
to the cytotoxicity of 16. Finally, crystal structures of the highly coloured complexes 
containing azopyridine type ligands in 17 and 18, also show n-n stacking. The crystal 
structure of the ruthenium analogue of 18 has previously been determined and again 
appears to be structurally similar. 30 These appear to be the first reported X-ray crystal 
structures of osmium arene complexes containing coordinated dppz or azopyridine 
ligands. 
5.42 Rates of Hydrolysis and Acidity of Coordinated Water 
The incorporation of a chelating ligand into these Os" arene complexes is crucial for 
maintaining their aqueous stability. Complex 19, which contains only monodentate 
non-arene ligands and a single donor nitrogen ligand, is deactivated in water to form 
predominantly the inert hydroxo-bridged dimer, [(ij  6. 
The rate of hydrolysis of complex 13, [(ij  was found 
to be markedly pH*dependent,  increasing with increase in pH*.  Two equilibria are 
involved (Equation 1), the first of which is hydrolysis and the second deprotonation 
of coordinated water. Due to the relatively low pKa*  values of water coordinated to 
osmium in these complexes, the hydroxo species is formed even at neutral PH*.  This 
shifts the equilibrium to the right, effectively increasing the rate of hydrolysis. To 
measure the rate of the hydrolysis step, alone, the pH*  was lowered. 
+1-120 	 -H 
{Os-CI} 	. 	- {Os-OH2}2 	- 	{Os-OH} 	 (1) 
+cr 
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The high pH*dependence  for 13 and the presence of exchangeable NH protons on the 
chelate suggest that the conjugate base mechanism may be involved. 
The rate of hydrolysis of complexes 1BF4 and 12 containing a chelating 
ligand with two primary amine donors (en) is faster (Ca. 5.5 and 8 times, 
respectively) than for complexes containing two it-acceptor pyridine groups (bipy 
and phen). This is attributable to the reduced electron density on Os". Intriguingly, 
complex 13, containing the unsymmetrical chelate, 2-picolylamine, hydrolyses most 
rapidly despite replacement of one of the amine groups with a pyridine. This is 
contrary to the expected trend and that observed for square-planar platinum 
complexes.' ° The rate of hydrolysis of complex 13 was also the most sensitive to 
changes in PH*.  A direct comparison between complexes 1BF4, 12 and 13-15 cannot 
be made due to the nature of the different arenes, with p-cymene being more electron 
rich than either biphenyl (bip) or tetrahydroanthracene (THA). Complex 12 
containing THA as the arene hydrolyses almost twice as fast as complex 1BF4 in 
which the arene is bip, in agreement with observations made for the ruthenium 
analogues. 31 
Osmium complexes are generally more inert than those of its lighter congener 
ruthenium, and the data reported here show that complexes 1BF4 and 12 hydrolyse 
ca. 100 times more slowly than their ruthenium analogue, [(1 6 
bip/THA)Ru(en)Cl]. 3 ' Hydrolysis of the osmium complex [(116-bz)Os(en)Cl], and 
anation of the aqua adduct, [(TI  also occur Ca. 100 times more 
slowly (khy dro 1.2xl0 s 1 and ki 0 . 13 x 10.2  M' s 1 , 298 K)32 than for the related 
ruthenium complex, [(i1 6-bip)Ru(en)(Cl/OH2)] (kh ydro 1.3 x 0 and ka 0.15 M' 
S_', 298 K).3 ' The activation parameters for hydrolysis of the complexes, [(11 
6_ 
bip)M(en)Cl] where M = Os or Ru can now be compared . 3 ' As expected the 
Arrhenius activation energy, E a, for hydrolysis of the osmium complex is higher than 
that for its ruthenium analogue (SE a Ca. 26 kJ mol') as is the enthalpy of activation, 
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AH, (LAH ca. 26 kJ mol') with similar entropies of activation, ASS. The AE" of 26 
U mor' is in good agreement with reported theoretical calculations, which give a 
AE,, of 20 kJ mold for the hydrolysis of these Os 1 ' and Ru' 1 complexes.20 '33 The large 
negative AST values for the hydrolysis of osmium complexes 1BF4, 12-13 are 
indicative of an associative process (Table 5.3). The errors associated with the AS 
values for the hydrolysis of complexes 14 and 15 are too large to allow comparisons. 
Another indication of the electron density on osmium and of the Os-O bond 
strength, is the acidity of the coordinated water. On comparing the pKa*  values of the 
aqua complexes 1A, 12A, 13A, 14A and iSA (Table 5.4), it is evident that water 
coordinated to osmium bound to two it-acceptor groups such as pyridines is more 
acidic (pKa 5.8) than when one of the nitrogen donors is a primary amine (pKa*  6.3). 
Water bound to ruthenium analogues is less acidic, but shows the same trend, pKa  
values of 7.71 and 7.2 for [(il  and [(1 6-p-
cym)Ru(bipy)(OH2)] 2 , respectively. 31 '34 
543 Binding to Guanine 
The kinetics for the reactions of 13 and 1BF4 with 9EtG and 5'-GMP, respectively, 
were investigated. In addition the stability constants of [(i6-bip)Os(en)(9EtG)]2  1G 
and its ruthenium analogue [(1 6-bip)Ru(en)(9EtG)] 2 1RG were determined. 
An equilibrium solution of the p-cymlampy complex 13 containing 
predominantly the hydroxo/aqua complex 13A, reacted with 9EtG under 
biologically-relevant conditions (3 10 K, pH*  7.4) with an associated half life of ca. 
3.2h. 
The reaction of the bip/en complex 1BF4 with 5'-GMP at 298 K resulted in 
the formation of 3 Os"-GMP adducts (2 major and 1 very minor) as judged by the H8 
'H NMR signals. From reported work on the binding of the ruthenium analogue [(1 6 
bip)Ru(en)C1]PF6 1R to 5'-GMP, 26 and from pH*  titrations of the products, the major 
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species can be assigned as N7-bound 5'-GMP, [(1 6-bip)Os(en)(5'-GMP-N7)], with 
the phosphate bound 5'-GMP, [(1 6-bip)Os(en)(5'-GMP-OP)], also being formed in 
significant amounts (ratio of 2 : 1 for N7 and phosphate-bound adducts, after 30 h at 
298K). The minor product (labelled x in Figure 5.11 A) may be a dinuclear adduct, 
with two osmium units bound to the nucleotide, one to the N7 and the other to the 
phosphate group, [(TI  '-GMP-N7)0s(en)( 6-bip)] 2 , however its 
concentration was to low to follow by 'H NMR in the pH*  titration of the reaction 
mixture. The time dependence of the species distribution (Figure 5.11B) within the 
first 5 h suggests that phosphate binding occurs first, followed by N7 binding. This 
would be consistent with the migration mechanism proposed by Chen et al. for the 
ruthenium analogue 1R. The migration of Os" from the phosphate to N7 of 5'-GMP, 
appears to be slower than for the ruthenium analog. After 22 h at 298 K all of the 
Ru" was bound to the N7 of 5'-GMP, 26 compared to 66% of the bound 5'-GMP for 
Os" (Figure 5.1 113). 
The 9EtG binding constants for formation of the Os" adduct [(TI 6_ 
bip)Os(en)(9EtG)] 1G of log K = 3.13±0.03 is an order of magnitude lower than for 
the Ru" analog (log K = 4.78±0.09), Figure 5.12C. Intriguingly, the stronger binding 
to Ru(II) is opposite to that determined in Chapter 4 for the maltolate (mal) 
6 	 + 	 20 complexes [(i -p-cym)M(mal)(9EtG)] , for which log K = 4.41 (Os) and 3.87 (Ru). 
Despite the lower formation constant the kinetic stability of the Os" complex 1G is 
high: 9EtG did not readily dissociate, even in 50 M solutions incubated at 310 K for 
24 h. This suggests that once formed on DNA (or RNA), {(ij bip)Os(en)} adducts 
with G bases may persist long enough to interfere with downstream DNA processing 
(including protein recognition and excision/repair). 
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5.4.4 Cancer Cell Cytotoxicity 
It was reported previously that complex 1BF4, [(Tj 	was inactive 
against the human ovarian A2780 cancer cell line (10 50 >100 jiM). 19 Because the 
chemical properties of the complex appeared to be compatible with activity, its 
cytotoxicity was reinvestigated. Apart from the potential variability of cell culture 
media (especially foetal calf serum) and the cell population, a possible explanation of 
the previous data can be related to partial decomposition of the complex in stock 
solutions prepared in DMSO. It has been shown that solutions of 1BF4 in DMSO can 
decompose after sonication, heating and longer term standing in air and direct 
sunlight, as is evident from colour change from yellow to dark red (Figure 5.1 5AIB). 
However, such solutions are stable when stoppered and stored at ambient 
temperature in the dark, and then exhibit good activity as does the PF 6 salt (1PF6), 
giving IC50 values of 7-10 jiM against the human ovarian A2780 and lung A549 
cancer cell lines (Table 5.5). Changing the arene from biphenyl in 1BF4 to the 
extended tetrahydroanthracene (complex 12, IC50 values of 6-9 jiM, Table 5.5) had 
little effect, whereas for the ruthenium analogues this increases the activity by 10 
fold. 35 Further work will be required to investigate whether Os-bound extended 
arenes can intercalate into DNA in a manner similar to Ru-bound arenes. 36 
The p-cym/ampy complex 13 was non-cytotoxic towards A549 cells despite 
its similar rate of hydrolysis to the bip/en and THA/en complexes 1BF4 and 12, 
similar stability at micromolar concentrations (50 jiM) and the ability to bind to G 
nucleobases. The reasons for the inactivity are therefore not clear. However, the 
other complexes tested which have pyridyl ligands (14 and 15) were also inactive, as 
are some Ru" arenes with unsubstituted pyridyl ligands. 37 
The inactivity of complexes 14, 15, 17 and 18 can be correlated with their 
slow kinetics of hydrolysis and higher acidity of coordinated water. Complex 19, 
which contains only monodentate non-arene ligands, is deactivated in water by 
171 
Chapter 5 Investigating Different NN-Chelates 
formation of the inert hydroxo-bridged dimer. The dppz complex 16 is probably too 
substitution-inert to bind effectively to G bases on DNA, but both the arene (bip) and 
chelating ligand (dppz) have the ability to intercalate into DNA 15,29  (vide supra), 
which may contribute to the mechanism for the cytotoxicity of 16 against both the 
A549 and A2780 cancer cell lines. 
Despite the instability of complex 1BF4 in DMSO, solutions of the active 
complexes 1PF6, 1BF4 and 12 were found to be stable in isotonic saline solutions 
(150 mM NaCl) stored at ambient temperature in the dark over a period of two 
months. This suggests that drug formulation in aqueous solution would be feasible 
for these complexes. 
5.5 Conclusions 
While organometallic complexes offer a versatile platform for the design of new 
medicines, and anticancer agents in particular, their aqueous solution chemistry has 
been relatively little explored. An understanding of how ligand design can be used to 
control their redox and ligand substitution reactions under conditions of biological 
relevance, is vital for the establishment of structure-activity relationships and the 
understanding of their mechanisms of action. 
Although osmium complexes are often considered to be kinetically inert, this 
work shows that for half-sandwich Os" arene complexes, reactivity depends strongly 
on the other ligands in the complex, which can play both steric and electronic roles. 
Although [(116-arene)Os(N,N)Cl]  complexes containing en as the N,N-chelator 
hydrolyse relatively rapidly (ti,, 1.6 h at 310 K), the introduction of it-acceptor 
pyridines as the N-donors, considerably slows down hydrolysis, and therefore a large 
window of reactivity is accessible. This also increases the acidity of the aqua adduct, 
the formation of which can act as an activation mechanism. The en complexes [(11 6 
bip)Os(en)Cl]PFBF4 and [(i6-THA)Os(en)Cl]BF4  are as cytotoxic to human A549 
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lung and A2780 ovarian cancer cells as the drug carboplatin, whereas those 
complexes containing a pyridine N-donor were inactive. An exception was the dppz 
complex with biphenyl as the arene [(ij  which could also act as 
a DNA intercalator. 
Although the binding constant of {(TI 	adducts with G 
nucleobases are lower by an order of magnitude than those of Ru", once formed they 
appear to be relatively kinetically stable with respect to dissociation. It is unclear 
why the complex [(ij  which hydrolyses at a similar rate, has 
a similar pKa for its aqua adduct, and rate of binding to G nucleobases, exhibits low 
cytotoxicity. 
Thus this chapter shows that half-sandwich Os 1 ' arene complexes containing 
N,N-chelating ligands can be designed to display cancer cell cytotoxicity comparable 
to their Ru" analogs, even though reactivities are 100 times less. Such a range of 
kinetic effects can be useful for balancing cytotoxicity and unwanted side-effects of 
anticancer drugs, as illustrated by the clinical profiles of cisplatin and its less labile 
second generation drug carboplatin. Some of the Os" complexes prepared here 
appear to be stable under conditions relevant to drug formulation (e.g. isotonic 
saline) and make interesting candidates for further investigation. 
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6.1 Introduction 
Transition metal complexes offer enormous scope for the design of therapeutic 
agents with novel mechanisms of action.' Advances in this field depend upon 
demonstrations that the concept of rational design can be applied to metal complexes. 
For this, knowledge of how to control the thermodynamics and kinetics of ligand 
substitution and redox reactions under biologically-relevant conditions is essential, in 
particular the hydrolytic chemistry. This is well illustrated for the platinum 
anticancer field. It was apparent early on  that an understanding of the aqueous 
chemistry of cisplatin and related complexes, including aquation rates, hydrolysis 
equilibria, acidity of aqua adducts, formation of hydroxo-bridged oligomers, aids not 
only the design of new generations of platinum agents, but also an understanding of 
the mechanism of cytotoxicity. The early use of cisplatin, which hydrolyses readily, 
has been supplemented by more stable complexes such as carboplatin and oxaliplatin 
which have fewer side-effects. 3 Recently the design of active trans diam(m)o Pt" 
complexes has been aided by the discovery that trans carboxylato ligands can 
decrease kinetic activity by about an order of magnitude compared to their chloro 
analogues. 4 The choice of the types of coordinated ligands and coordination 
geometry provides an ability to "fine-tune" the chemical reactivity of complexes, 
potentially allowing control of pharmacological properties, including cell uptake, 
distribution, DNA binding, metabolism and toxic side-effects. 
Organometallic chemistry offers a potentially rich field for biological and 
medical applications, 5 but, as pointed out recently, 6 a lack of understanding of the 
aqueous chemistry of organometallic complexes is currently a major obstacle for 
further developments. This is particularly true for osmium(II) arene complexes. 7-9 
Here I attempt to design active osmium half-sandwich complexes by controlling their 
aqueous chemistry. Osmium complexes are usually considered to be relatively inert 
in keeping with the normal behaviour of a third row transition metal. However, 
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recent work in this laboratory on ruthenium arene complexes has shown that aqueous 
reactivity of [(i 6-arene)Ru(XY)Z] complexes is highly dependent on the nature of 
the chelating ligand XY and monodentate ligand Z (the leaving group), as well as the 
arene.' °" A similar pattern of reactivity may therefore apply to osmium, the heavier 
congener of ruthenium. A theoretical analogy between cisplatin and Ru" arene 
anticancer complexes has recently been proposed by Deubel et al. 12 
In this chapter the tuning of the reactivity of osmium(II) arene complexes 
[(
11
6-arene)Os(XY)CI] containing XY = an anionic N,O-chelating ligand with a 
primary amine or pyridine as the N-donor, and carboxylate or aryloxide as the 0-
donor is investigated. The rate of hydrolysis, acidity of the aqua adducts, dynamic 
chelate ring-opening, interactions with nucleobases, and relationship to cancer cell 
cytotoxicity is studied. These data suggest that the aqueous solution chemistry of 
organometallic osmium arene complexes can be controlled for the rational design of 
biologically active agents. 
6.2 Experimental Section 
6.2.1 Materials 
OsC13.n1120 was purchased from Alfa Aesar, sodium methoxide, a-aminoisobutyric 
acid, 2-picolinic acid, silver hexafluorophosphate, 9-ethylguanine, 9-ethyladenine, 
adenosine, cytidine and thymidine from Sigma, and sodium glycinate, L-alanine, f3-
alanine, 8-hydroxyquinoline and deuterated solvents from Aldrich. 
6.2.2 Preparation of Complexes 
The preparation of the dimers [( 6-p-cym)0sC12] 2 and [(TI 	is reported in 
Chapter 3. Complexes 20-26 were synthesized from the dimeric precursor [(,q 6 
arene)OsC12] 2, using procedures similar to those reported previously for other half-
sandwich Ru" arene complexes. 13,14 
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I(1 6-p-cym)Os(g1y)C1] (20). A solution of sodium glycinate (12.3 mg, 0.13 
mmol) and [(ij  (47.3 mg, 0.06 mmol) in MeOH (5 mL) was stirred at 
ambient temperature for 5.5 h, the solvent removed on a rotary evaporator, and the 
residue extracted with dichioromethane and filtered through a cotton wool plug. The 
solvent volume was reduced to Ca. 3 mL, and the solution stored at 253 K overnight. 
A pale yellow powder which formed was recovered by filtration, washed with diethyl 
ether (10 mL) and air-dried. Yield: 33.1 mg (59%). Anal. Calcd for 20+H20 
C12C1H20NO 30s (451.98): C, 31.89; H 4.46; N 3.10%. Found: C, 31.98; H, 3.92; N, 
3.05%. 'H NMR (MeOD-d4): 8 = 6.02 (d, 1H, J = 5.3 Hz), 5.98 (d, 1H, J = 5.3 Hz), 
5.80 (d, 1H, J = 5.3 Hz), 5.76 (d, 1H, J = 5.3 Hz), 3.20 (m, 2H), 2.73 (sept, 1H, J = 
6.8 Hz), 2.25 (s, 3H), 1.32 (d, 6H, J = 7.0 Hz). 
[(116-p-cym)Os(L-aIa)c1] (21). A solution of L-alanine (11.6 mg, 0.13 
mmol), sodium methoxide (7.7 mg, 0.14 mmol) and [(ij  (47.2 mg, 
0.06 mmol) in MeOH (5 mL) was stirred at ambient temperature for 22 h. The 
solvent was removed on a rotary evaporator, and the residue extracted with 
dichioromethane and filtered through a cotton wool plug. The solvent was again 
removed and the product recovered by titrating with diethyl ether. Yield: 46 mg 
(86%). Anal. Calcd for C13C1H20NO20s (447.99): C, 33.85; H 4.50; N 3.13%. 
Found: C, 34.38; H, 4.01; N, 3.00%. 'H NMR (MeOD-d4): 6 = 7.51 (br, NH), 6.40 
(br, NH), 6.02 (d, 2H), 5.99 (d, 1H), 5.95 (d, 1H), 5.81 (m, 3H), 5.74 (d, 1H), 5.29 
(br, NH), 3.98 (br, NH), 3.40 (q, 1H), 3.25 (q, 1H), 2.73 (sept, H), 2.72 (sept, H), 
2.23 (s, 3H), 2.22 (s, 3H), 1.42 (d, 3H), 1.34 (d, 3H), 1.32 (d, 6H), 1.31 (d, 6H). 
Diastereoisomers were present in a 1.5:1 ratio. 
I(t16-p-cym)Os(aiba)C11 (22). A solution of u-aminoisobutyric acid (13.9 mg, 
0.13 mmol), sodium methoxide (7.3 mg, 0.14 mmol) and [(ij  (50.8 
mg, 0.06 mmol) in MeOH (5 mL) was stirred at ambient temperature for 22 h and 
filtered through a glass wool plug. The solvent was removed on a rotary evaporator, 
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and the residue extracted with dichloromethane (15 mL) and filtered through a cotton 
wool plug. The solvent volume was reduced to ca. 3 mL, and the product precipitated 
after addition of diethyl ether and storage at 253 K for 1 h. The mustard yellow 
powder was recovered by filtration, washed with diethyl ether (10 mL) and air-dried. 
Yield: 24.8 mg (42%). Anal. Calcd for C14C1H22NO 20s (447.99): C, 36.40; H 4.80; 
N 3.03%. Found: C, 36.44; H, 4.68; N, 2.88%. 'H NMR (MeOD-d 4): 6 = 6.04 (d, 
1H, J = 5.3 Hz), 5.99 (d, 1H, J = 5.0 Hz), 5.87 (d, 1H, J = 5.3 Hz), 5.84 (d, 1H, J = 
5.3 Hz), 2.72 (sept, IH, J = 7.0 Hz), 2.21 (s, 3H), 1.43 (s, 3H), 1.34 (s, 3H), 1.33 (d, 
3H, J = 6.9 Hz), 1.30 (d, 31-1 9 J = 6.8 Hz). 
[(vj6-p-cym)Os(-ala)CJ] (23). A solution of 3-alanine (12.0 mg, 0.13 mmol), 
sodium methoxide (7.3 mg, 0.14 mmol) and [( 6-p-cym)OsC1 2]2 (50.7 mg, 0.06 
mmol) in MeOH (4 mL) was stirred at ambient temperature for 19 h. The solvent 
volume was reduced to ca. 3 mL, and the product precipitated after addition of 
diethyl ether and storage at 253 K overnight. The yellow powder was recovered by 
filtration, washed with diethyl ether (10 mL) and air-dried. Yield: 15.1 mg (26.3%). 
Anal. Calcd for (231-120) C13C1H20NO20s (466.00): C, 33.51; H 4.76; N 3.01%. 
Found: C, 33.86; H, 4.33: N, 3.06%. 'H NMR (MeOD-d4): 6 = 7.13 (b, 1H), 6.04 (d, 
1H, J = 5.3 Hz), 5.96 (d, 1H, J = 5.3 Hz), 5.86 (d, 1H, J = 5.3 Hz), 5.72 (d, 1H, J = 
5.3 Hz), 4.14 (b, 1H), 3.04 (m, 1H), 2.75 (sept, 1H, J = 6.8 Hz), 2.64 (m, 1H,), 2.46 
(ddd, 1H, J= 17.1, 11.1 and 2.7 Hz), 2.29 (dd, IH, J = 17.0 and 6.3 Hz), 2.19(s, 311), 
1.31 (d, 3H, J = 6.9 Hz), 1.30 (d, 3H, J = 7.2 Hz). 
[(t 6-p-cym)Os(pico)CtJ (24). A solution of picolinic acid (18.6 mg, 0.15 
mmol) and sodium methoxide (8.3 mg, 0.15 mmol) in MeOH (3 mL) was stirred at 
ambient temperature for 45 min and added to a solution of [(ii6-p-cym)OsCl2] 2 (50.8 
mg, 0.06 mmol) in MeOH (5 mL) under argon. The resulting mixture was stirred at 
ambient temperature under argon for 20 h, the solvent was removed on a rotary 
evaporator, and the residue extracted with dichioromethane and filtered through a 
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cotton wool plug. The solvent volume was reduced to ca. 3 ml, and the product 
precipitated after addition of diethyl ether. The yellow powder was recovered by 
filtration, washed with diethyl ether (10 mL) and air-dried. Yield: 55.8 mg (90%). 
Anal. Calcd for C16C1H18NO20s (482.00): C, 39.87; H 3.76; N 2.91%. Found C, 
39.87; H, 3.67; N, 2.80%. 'H NMR (CDC13): 6 = 8.78 (d, lH, J = 5.7 Hz), 8.12 (d, 
1H, J = 7.6 Hz), 7.93 (td, lH, J = 7.6 Hz), 7.50 (td, 1H, J = 6.4 Hz), 5.94 (d, 1H, J = 
5.7 Hz), 5.89 (d, 1H, J = 5.7 Hz), 5.72 (d, 1H, J = 5.7 Hz), 5.67 (d, 1H, J = 5.7 Hz), 
2.74 (sept, 1H, J = 6.8 Hz), 2.35 (s, 3H), 1.22 (d, 3H, J = 5.3 Hz), 1.21 (d, 3H, J = 5.3 
Hz). Crystals of 24 suitable for X-ray diffraction were obtained by evaporation of a 
chloroform/diethyl ether solution at ambient temperature in the dark. 
L(1i6-bip)Os(pico)C 1 1 (25). A solution of [(TI  (51.3 mg, 0.06 
mmol) in MeOH (5 ml) was refluxed under argon for 1 h before adding a solution of 
picolinic acid (16.8 mg, 0.14 mmol) and sodium methoxide (7.3 mg, 0.14 mmol) in 
MeOH (2 mL), which had been stirred at ambient temperature for 30 mm. The 
resulting mixture was stirred at ambient temperature for 20 h, filtered through a 
cotton wool plug, and the solvent removed on a rotary evaporator. The residue was 
extracted with dichioromethane, filtered and the solvent removed again. The 
resulting solid was re-dissolved in methanol and the solvent volume reduced until a 
precipitate began to form. The vessel was stored at 278 K and the yellow powder 
recovered by filtration, washed with diethyl ether (10 mL), and air-dried. Yield: 23.9 
mg (39%). Anal. Calcd for 25+H20 C18C1H16NO30s (520.01): C, 41.57; H 3.10; N 
2.69%. Found: C, 41.85; H, 2.50; N, 3.17%. 'H NMR (CDC13): 6 = 8.30 (d, 1H, J = 
5.4 Hz), 8.12 (d, 1H, J = 7.9 Hz), 7.86 (t, 1H, J = 7.7 Hz), 7.51 (m, 2H), 7.40 (m, 
211), 7.28 (7, 1H, J = 6.6 Hz), 6.40 (d, 1H, J = 5.3 Hz), 6.36 (d, IH, J = 4.9 Hz), 6.23 
(t, 1H, J = 5.0 Hz), 6.21 (t, 1H, J = 5.0 Hz) ,6.15 (t, lH, J = 5.0 Hz). 
L(11 6-p-cym)Os(oxine)CIJ (26). A solution of 8-hydroxyquinoline (18.6 mg, 
0.13 mmol) and sodium methoxide (6.9 mg, 0.13 mmol) in MeOH (2 mL) was added 
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to a solution of [(ij 	(48.3 mg, 0.06 mmol) in MeOH (4 mL) and the 
resulting mixture stirred at ambient temperature for 5 h. The solvent was removed on 
a rotary evaporator, the residue extracted with acetone (ca. 10 mL), the solvent 
volume reduced until a yellow precipitate started to form, and stored at 253 K 
overnight. The yellow microcrystal line solid was recovered by filtration, washed 
with diethyl ether (5 mL) and air-dried. Yield: 43.5 mg (71%). Anal. Calcd for 
C19C1H20NOOs (504.05): C, 45.27; H 4.00; N 2.78%. Found: C, 45.35; H, 4.03; N, 
2.68%. 'H NMR (CDC1 3 ): ö = 8.77 (d, IH, J = 4.9 Hz), 8.05 (d, IH, J = 8.3 Hz), 
7.37 (t, 1H, J = 7.9 Hz), 7.28 (dd, 1H, J = 8.3 and 5.0 Hz), 7.03 (d, 1H, J = 7.9 Hz), 
6.84 (d, 1H, J = 7.9 Hz), 5.93 (d, 1H, J = 5.3 Hz), 5.82 (d, 1H, J = 5.3 Hz), 5.70 (d, 
1H, J = 5.3 Hz), 5.63 (d, 1H, J = 5.3 Hz), 2.62 (sept, IH, J = 6.8 Hz), 2.36 (s, 3H), 
1.12 (dd, 6H, J = 8.9 and 7.6 Hz). Crystals of 26 suitable for X-ray diffraction were 
obtained by evaporation of an acetone/diethyl ether solution at ambient temperature 
in the dark. 
[(q6-p-cym)Os(pico)(9EtG)JPF 6 (24GPF6). A solution of [(i 6-p-
cym)Os(pico)Cl] (32.6 mg, 0.07 mmol) and AgPF 6 (18.5 mg, 1.1 mol equiv) in 
MeOH (3 mL) was stirred at ambient temperature for 5.5 h. The AgC1 precipitate 
was removed by filtration through a glass wool plug and 9-ethylguanine (12.2 mg, 
1.1 mol equiv) was added to the resulting solution. The reaction mixture was stirred 
at ambient temperature under argon for ca. 42 h. The resulting pale yellow precipitate 
was recovered by filtration, washed with methanol (3 mL) and diethyl ether (10 mL), 
and air-dried. Yield: 28.0 mg (54%). Anal. Calcd for C23H27N6O 3 OsPF6 (770.69): C, 
35.84; H 3.53; N 10.90%. Found: C, 35.74; H, 3.21; N, 11.23%. 'H NMR (MeOD-
d4): 6 = 9.64 (d, IH, J = 5.3 Hz), 8.12 (td, 1H, J = 7.8 and 1.3 Hz), 7.95 (d, 1H, J = 
7.9 Hz), 7.85 (s, lH), 7.74 (td, IH, J = 6.8 and 1.5 Hz), 6.50 (d, 1H, J = 5.7 Hz), 6.24 
(d, 1H, J = 5.7 Hz), 6.12 (d, 1H, J = 5.7 Hz), 6.04 (d, 1H, J = 5.7 Hz), 4.13 (dq, 2H, J 
7.3 and 2.6 Hz), 2.53 (sept, IH, J = 6.8 Hz), 2.04 (s, 3H), 1.39 (t, 3H, J = 7.2 Hz), 
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1.17 (d, 3H, J = 6.8 Hz), 1.03 (d, 3H, J = 6.8 Hz). Crystals of 24GPF6 suitable for 
X-ray diffraction were obtained by diffusion of diethyl ether into a methanol solution 
at 278 K. 
L(16-p-cym)
0
s(pico)(9EtA)]PF6 (24A7PF6). A solution of [(1 6-p-
cym)Os(pico)ClJ (24.9 mg, 0.05 mmol) and AgPF 6  (13.3 mg, 1.0 mol equiv) in 
MeOH (3 mL) was stirred at ambient temperature for 2 h. The AgCl precipitate was 
removed by filtration through a glass wool plug and 9-ethyladenine (8.6 mg, 1.0 mol 
equiv) was added. The reaction mixture was stirred at ambient temperature under 
argon for Ca. 78 h. A yellow product precipitated out after addition of diethyl ether, 
was recovered by filtration, washed with methanol (2 mL) and diethyl ether (10 mL), 
and air-dried. Yield: 13.3 mg (34%). Anal. Calcd for C23H27N6O 2 OsPF6 (754.69): C, 
36.60; H 3.61; N 11.14%. Found: C, 37.04; H, 3.57; N, 10.95%. 'H NMR (MeOD-
d4): 6 =9.59 (d, 1H, J = 5.3 Hz), 8.34 (s, 1H), 8.30 (s, 1H), 8.30 (overlapped t, IH, ca 
7 Hz), 8.06 (d, 1H, J = 7.5 Hz), 8.01 (t, IH, J = 6.3Hz), 6.64 (d, 1H, J = 5.6 Hz), 6.52 
(d,1 H, J = 5.4 Hz), 6.16 (d, 1H, J = 5.3 Hz), 6.11 (d, 1H, J = 5.6 Hz), 4.63 (br s, 2H), 
4.31 (sept, 2H, J = 7.0 Hz), 4.25 (sept, 2H, J = 7.0 Hz), 2.64 (sept, 1H, J = 6.8 Hz), 
1.85 (s, 3H), .1.41 (t, 3H, J = 7.3 Hz), 1.17 (d, 3H, J = 6.8 Hz), 1.01 (d, 3H, J 7.0 
Hz). Crystals of 24A7PF 6 0.5Et2O suitable for X-ray diffraction were obtained by 
diffusion of diethyl ether into a methanol solution at 278 K. 
6.2.3 Methods 
X-ray Crystallography. All diffraction data were collected by Dr. Simon 
Parsons and colleagues, using a Bruker (Siemens) Smart Apex CCD diffractometer 
equipped with an Oxford Cryosystems low-temperature device operating at 150 K. 
Absorption corrections for all data sets were performed with the multi-scan 
procedure SADABS; 15  structures were solved using either Patterson or direct 
methods (SHELXL' 6or DIRDIF' 7); complexes were refined against F using 
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SHELXTL and H-atoms were placed in geometrically calculated positions. X-ray 
crystallographic data for complex 24, 26, 24GPF6 and 24A7PF6 0.5Et2O have been 
deposited in the Cambridge Crystallographic Data Centre under the accession 
numbers CCDC 626657, 626658, 626655 and 626656, respectively, and can be 
found on the enclosed cd. 
Hydrolysis. Solutions of 20-26 (2 mM) in 5% MeOD-d4 /95% D20 (v/v) 
were prepared by dissolution of the complex in MeOD-d4 followed by rapid dilution 
with D20. Solutions of 50 tM were prepared by subsequent dilution of these 2 mM 
stock solutions with D20 (final ratio 0.125% MeOD-d 4 /99.875% D20 (v/v)). The 'H 
NMR spectra for the 2 mM and 50 p.M solutions were recorded within the first 10 
min of sample preparation and after incubation at 310 K for 24 h. The speciation of 
20-26 in 100 mM NaCl was investigated by adding 2.5 M NaCl (25 j.tL) to the 2 mM 
NMR sample in D20. The effects of varying concentrations of chloride were 
investigated by preparing aqueous solutions of 24 (1 mM and 50 p.M) in 100 mM, 
22.7 mM and 4 mM NaCl in D20, recording 'H NMR spectra within the first 10 mm 
of sample preparation, and after incubation at 310 K for 24 h. 
The longer term stability of complex 24 was investigated by preparing 1 mM 
solutions in 5% MeOD-d4 /95% isotonic saline solution (150 mM NaC1) (v/v) by 
dissolution of 24 in MeOD-d4 followed by rapid dilution with the isotonic saline 
solution. 'H NMR spectra were recorded after various time intervals (10 mm, 1 
week, 2 weeks and 2 months) during which time the sample was stored at ambient 
temperature in the dark. 
Determination of pKa*  values. For determinations of pKa*  values (pKa values 
for solutions in D 20), the pH' values of the aqua complexes of 20-26 in D20 (formed 
in situ by dissolution of the parent chloro complexes) were varied from ca. pH' 3 to 
10 by the addition of dilute NaOD and I-fNO 3 , and 'H NMR spectra were recorded. 
pH' titrations of complexes 24G and 24A7 were carried out from pH' 3 to 12 and 1 
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to 8, respectively. The chemical shifts of the arene ring (20-26), purine 1-18 (24G and 
24A7) and H2 (24A7) protons were plotted against pH*. The pKa*  values were 
determined from the pH*  titration curves as described in Chapter 2. 
Kinetics for hydrolysis. Although complexes 20-23 and 26 hydrolysed too 
rapidly to monitor by 'H NMR, the kinetics for 24 and 25 could be followed at 
various temperatures (278 - 298 K). For this, the complex was dissolved in methanol-
d4 and aliquots were added to D20 (equilibrated at the required temperature) to give 
a final concentration of Ca. 0.8 mM complex in 95% D20/5% methanol-d4 (pH* Ca. 2, 
so that the aqua ligand is not deprotonated). Samples were filtered and spectra 
recorded at various time intervals. Data, based on peak integrals, were fitted to the 
appropriate equation for first-order kinetics. The Arrhenius activation energies (E a), 
activation enthalpies (AH) and activation entropies (AS) were determined from 
Arrhenius and Eyring plots.' 8 
Variable Temperature NMR. The 'H NMR spectra of complexes 23, 24 
and 26 in D20 (1 mM, 5% MeOD-d4 to assist dissolution) were recorded after 
equilibration at various temperatures (at 10 K increments). Kinetic data and 
activation energies for the dynamic prQcesses were determined as described in 
Chapter 2. Similarly, 10 mM solutions of 24 and 26 in methanol-d 4 were recorded 
after equilibration at various temperatures. 
Cancer Cell Cytotoxicity. Cytotoxicity assays on human lung A549 and 
ovarian A2780 cancer cell lines were performed as described in Chapter 2 for 
complexes 20-26. 
Interactions with Nucleobases. The reaction of 24 with nucleobases 
typically involved addition of a solution Containing 1 mol equiv of nucleobase in 
D20 (or 1 mol equiv of 9-ethylguanine and 1 mol equiv 9-ethyladenine in a 
competition reaction), to an equilibrium solution of 24 in D20 (>90% aqua). The pH* 
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(physiological). 'H NMR spectra of these solutions were recorded at 298 K after 
various time intervals. 
NMR spectra of aqueous solutions (D20) of the 9EtG and 9EtA complexes 
24G and 24A7, respectively, were recorded at various concentrations (20 PM 
- 2 
mM) at 298 K and after incubation at 310 K for various time intervals. The 
equilibrium constant for dissociation of 9EtA from 24A7 was obtained from the 
slope of the plot of [bound complex]/[free 9EtA] vs [24A], using concentrations 
based on 'H NMR peak integrals. 
6.3 Results 
6.3.1 Synthesis and Characterization of Complexes 
Seven new Os" arene chloro complexes containing amino acidates, picolinate or 8-
hydroxyquinolinate as anionic N,O-chelating ligands (Figure 6.1) have been 
synthesized in good yields via the Cl-bridged dimer, {(i 6-arene)OsCl2]2, arene = 




23 	 24 
































Figure 6.1 Osmium arene complexes studied in this work. 
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The X-ray crystal structures of [(r 6-p-cym)Os(pico)Cl} 24 and fti 6-p-
cym)Os(oxine)C1] 26 (Figure 6.2) have been determined. The complexes adopt the 
familiar pseudo octahedral "three-leg piano-stool" geometry with the osmium m-
bonded to the arene ligand (Os-ring centroid distances of 1.652(2) A for 24 and 
1.6557(12) A for 26), a-bonded to a chloride (2.4048(13) and 2.4235(7) A), a 
pyridine nitrogen (2.090(4) and 2.098(2) A) and a deprotonated oxygen atom 
(2.080(3) and 2.081(2) A) of the chelating ligand, which constitute the three legs of 
the piano stool. Crystallographic data, selected bond lengths and angles are given in 
Tables 6.1 and 6.2. 
(B) 	C91 
C21 C31 	 C51 	C61 
C1 1 	 C41 	 C41 
C61 	 C31 















Figure 6.2 X-ray crystal structures and atom numbering schemes for (A) [(i 6-p-
cym)Os(pico)C1] (24) and (B) ftr 6-p-cym)Os(oxine)Cl] (26) (50% probability 
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Table 6.1 	Crystallographic data for [(ij 	24, [(716-p- 
cym)Os(oxine)C1] 26, [(ij 	PP6 26GPF6 and [(116-p- 
cym)Os(pico)(9EtA)] PF 6 24A7PF6 0.5 Et20 
24 	 26 	 24GPF6 	24A7PF6 0.5Et2O 
Formula C 16H 18C lNO 2Os C 9 H 20C1NO2Os C23 H27F6N6O3 OsP C25 H23 F6N60250sp 
Molecular weight 481.98 504.03 770.67 791.74 
Crystal description Yellow block Red-brown block Yellow block Yellow block 
Crystal size (mm) 0.14 x 0.15 x 0.55 0.21 x 0.33 x 0.42 0.21 x 0.21 x 0.33 0.20 x 0.28 x 0.50 
A(A) 0.71073 0.71073 0.71073 0.71073 
Temperature (K) 150 150 150 150 
Monoclinic, 
Crystal system Monoclinic Monoclinic Orthorhombic 
twinned via 2(l 00) 
Space group P121/n I P1 21/n I Pna2l P211  
a(A) 10.1041(7) 10.5949(3) 19.0626(3) 12.2879(4) 
b (A) 15.0060(9) 13.2740(3) 8.49080(10) 15.9787(5) 
c(A) 10.2928(6) 12.2343(3) 16.3786(3) 15.1512(5) 
a(°) 90 90 90 90 
P  99.521(3) 102.0310(10) 90 98.317(2) 
y( °) 90 90 90 90 
Volume (A3) 1539.12(17) 1682.80(7) 2650.99(7) 2943.57(16) 
Z 4 4 4 4 
R 0.042 0.024 0.043 0.0444 
R 0.087 0.051 0.081 0.1118 
GOF 0.760 0.877 0.757 1.114 
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Table 6.2 	Selected bond lengths (A) and angles (°) for {( 6-p-cym)Os(pico)Cl] 
24, [( 6-p-cym)Os(oxine)C1J 26, [(1 6-p-cym)Os(pico)(9EtG)]pF 6 24GPF6 and [(ij 
p-cym)Os(pico)(9EtA)] PF 6 24A7PF6 P0.5 Et20 
Bond 
length/anglea 
24 26 24GPF6 24A7PF60.5Et2O 
Os-C(Arene) 2.202(5) 2.174(3) 2.195(6) 2.176(9) 
2.170(5) 2.191(3) 2.195(6) 2.176(9) 
2.163(5) 2.196(3) 2.164(10) 2.182(8) 
2.180(5) 2.198(3) 2.229(6) 2.184(8) 
2.172(5) 2.173(3) 2.188(6) 2.205(7) 
2.174(5) 2.169(3) 2.180(6) 2.206(8) 
Os-X1 2.090(4) 2.098(2) 2.101(5) 2.094(7) 
Os-X2 2.080(3) 2.081(2) 2.097(7) 2.081(7) 
Os-X3 2.4048(13) 2.4235(7) 2.117(5) 2.119(7) 
X1-Os-X2 77.33(15) 78.22(9) 76.0(2) 76.9(2) 
XI-OS-X3 83.18(11) 83.07(7) 84.1(2) 81.8(3) 
X3-Os-X2  83.85(11) 85.05(6) 80.6(2) 85.2(2) 
Dimers are present in the crystal structures of 24 and 26, linked by short-
range interactions between the coordinated chloride and an aromatic ring proton of 
the chelating ligand (Cl(l) ... H(321) 2.81 A) orp-cymene arene (Cl(l) ... H(21 1) 2.69 
A), respectively. Further short-range interactions are present between aromatic ring 
protons and oxygen atoms of the chelate, Figure 6.3 and Table 6.3A/B. 
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Figure 6.3 (A) Dimer in the X-ray crystal structure of 24 formed through directional 
hydrogen bonds between coordinated Cli and chelate ring proton (1-1321), chelate 
oxygen atoms (082 and 092) and aromatic ring protons (H221 and H311) of an 
independent molecule of 24. (B) The dimer formed in the X-ray crystal structure of 
26 through directional hydrogen bonds between the coordinated CI  and 0112 of one 
molecule and the p-cymene H21 I and H31 I arene ring protons of a second molecule. 
(50% probability ellipsoids). The remaining H atoms have been omitted for clarity. 
Table 6.3 Selected hydrogen bond lengths [A] and angles ri for complexes 
24, 26, 24GPF6 and 24A7PF60.5Et20 
(A) [( 6-p-cym)0s(pico)Cl] (24) 
D-H ... A 	 d(H ... A) 	d(DA) 	ZDHA 
C32-F1321 ... Cl1 (inter) 2.81 3.652(5) 152 
C22-11221092 (inter) 2.49 3.371(6) 156 
C31-H311092 (inter) 2.52 3.476(6) 166 
C31-1-1311 ... 082 (inter) 2.44 3.25 1(7) 140 
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Table 6.3 (continued) 	- 
(B) [(i 6-p-cym)Os(oxine)Cl] (26) 
D-H ... A d(HA) d(DA) ZDHA 
C21-H211C11 (inter) 2.69 3.666(3) 164 
(C) [( 6-p-cym)0s(ico)(9EtG)]PF 6 (24GPF6) 
D-H.. A d(H .. . A) d(D A) ZDHA 








(D) [(116-p-cym)Os(pico)(9EtA)JPF 6 (24A7?F6 0. 5Et20) 









6.3.2 Aqueous Solution Chemistry and pKa* Determination. 
Aqueous solutions of the chioro complexes 20-25, directly after sample preparation 
(<10 mm), gave rise to 1 major and I minor set of 'H NMR peaks, with.resolved 
peaks for each of the four p-cymene ring protons, consistent with the presence of 
stereogenic osmium centres (the L-alanine complex 21 was present as a Ca. 1:1 
mixture of diastereoisomers). When the pH* values of the solutions were increased 
from Ca. 3 to 10, the major set of NMR peaks gradually shifted to high field (Figure 
6.4A), consistent with assignment to aqua adducts. Plots of the chemical shifts 
against pH (Figure 6.4A and Figure 6.5) were fitted to the Henderson- Hasselbalch 
equation, and gave rise to pKa values between 7.27 and 7.55 for complexes 
containing both primary amines and carboxylate groups as donors, but lower values 
of 6.33 and 6.67 for the picolinate complexes (24 and 25) which contain pyridine as a 
tertiary amine donor instead of a primary amine donor (Table 6.4). 
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Figure 6.4 The dependence of the arene region of 'H NMR spectra of (A) [(rj 6-p-
cym)Os(pico)Cl] (24) and (B) [( ij  (26) in D20, containing 
predominantly the aqua adducts, on pH*.  The plots show fits giving pKa* values of 
6.67 and 7.71 for the aqua complexes 24A and 26A, respectively. The four 
magnetically inequivalent arene ring protons give rise to separate peaks in the spectra 
of 24A, and exhibit the same PH* dependence. However, the four peaks for 26A are 
resolved only at basic pH*  and broaden and sharpen into two doublets at acidic pH*, 
indicative of involvement in a dynamic chemical exchange process. 
193 

















4 6 8 10 12 
pH* 
! 
4 6 8 10 
pH* 
Figure 6.5 Plots of the 'H NMR chemical shifts of coordinated arene ring protons 
versus pH* for (A) [( 11 6-p-cym)Os(gly)Cl] (20), (B) [(1 6-p-cym)Os(L-ala)Cl] (21), 
(C) [(r1 6-p-cym)Os(aiba)Cl] (22), (D) ft1 6-p-cym)Os(3ala)C1] (23) and (E) [(p6.. 
bip)Os(pico)Cl] (25) in D20 (containing predominantly the aqua adducts). The 
curves represent the best fits to the Henderson-Hasselbalch equation, corresponding 
to pKa* values of 7.27, 7.14, 7.17, 7.55 and 6.33 for (A)—(E), respectively. 
Table 6.4 pKa* values for the deprotonation of the coordinated D20 in complexes 
20A-26A and the Ni-H of N7-coordinated nucleobase in 24G and 24A7 
Complex PKa* 
[(11 6-p-cym)Os(gly)(OD 2)] 20A 7.27 
{(fl 6-p-cym)Os(L-ala)(OD 2)] 21A 7.14 
ft11 6-p-cym)Os(aiba)(OD 2)] 22A 7.17 
[('i6-p-cym)Os(P -a1 a)(OD2)] 23A 7.55 
[(11 6-p-cym)Os(pico)(OD 2)] 24A 6.67 
[(
71
6-bip)Os(pico)(OD2)1 25A 6.33 
[(11





6-p-cym)Os(pico)(9-EtG-N7)] 24G 8.97 
[(11 6-p-cym)Os(pico)(9-EtAiv7)} 24A7 2.06 
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The minor sets of peaks for coordinated p-cymene increased in intensity on 
addition of NaC1 and are assigned to the intact chloro complex (Table 6.5). 
Table 6.5 'H NMR chemical shifts of the coordinated arene ring protons of the 
intact chioro complexes (20-26) in D 20 
Compound c / ppm 
20 	6.14 (d, 1H), 6.09 (d, 1H), 5.89 (m, 2H) 
21 6.14 (m, 2H), 6.09 (d, IH), 6.07 (d, IH), 5.90 (m, 2H), 5.89 (m, 
2H), 5.87 (m, 2H) 
22 	6.15 (d, 1H), 6.09 (d, IH), 5.95 (d, 2H) 
23 6.15 (d, 1H), 6.08 (d, 1H), 5.96 (d, 1H), 5.84(d, 1H) 
24 	627 (m, 2H), 6.00 (d, 1H), 5.98 (d, 1H) 
25 6.73 (d, 1H), 6.70 (d, 1H), 6.49 (t, 1H), 6.46 (t, 1H), 6.34 (t, 1H) 
26 	6.26 (d, 1H), 6.13 (d, 1H), 5.97 (d, 1H), 5.86 (d, 1H) 
During the pH* titration of the 13-alaninate complex 23, new p-cym doublets 
appeared at 8 6.04 and 8 5.82, with increase in PH*. These peaks have previously 
been assigned 19,20 in Chapter 3, to the hydroxo-bridged dimer, ft716-p-cymOs(t-
OD)3Os(17 6-p-cym)] (8). After incubation of aqueous solutions of 20-23 (2 mM) at 
310 K for 24 h (pH*  ca. 6.2-6.7), the only changes to the spectra were new peaks for 
8 (accounting for 10% of 20, 6% of 21, 3% of 22 and 37% of 23). NMR spectra of 
aqueous solutions of the hydroxyquinolate complex 26, contained two doublets 
assignable to the p-cym ring protons of the aqua adduct 26A, which shifted to high 
field with increase in pH*  (Figure 6.413) with an associated pKa* of 7.71. When the 
pH* was increased to 8.55 these doublets broadened and at pH*  10.15 resolved into 
four sharp doublets (6 6.07, 6 6.01, 6 5.73 and 6 5.68), Figure 6.413. The NMR 
spectrum of a solution of 26 in 100 mM NaCl contained four doublets for p-cymene 
ring protons (Table 6.5) assignable to the intact chioro complex 26. 
Fresh aqueous solutions (5% MeOD-d4 /95% D20) containing complexes 20- 
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23 at low concentration (50 p.M) at 298 K, all gave rise to peaks for aqua adducts, 
and for 21 and 23 peaks for hydroxo-bridged dimer 8 as well. After incubation at 310 
K for 24 h, dimer 8 was present in all the solutions, and for 23 was the only species 
present, Figure 6.6. Similar solutions of complexes 24 and 25 (50 j.tM) initially 
contained a mixture of the intact chloro and aqua complexes, but after incubation, 
only peaks for the aqua complex were present. Complex 26 was present as the aqua 
complex both initially and after incubation. It was notable therefore that neither 
complexes 24, 25 nor 26 formed the hydroxo-bridged dimer 8 when incubated at 
biologically-relevant concentrations (50 p.M). 
O
R 	p-cym 	p-cym 	p-cym 	p-cym 	p-cym 	bip 	p-cym 
	
0 Oc 	 0 	 0 	 0 
0 H2N 	H2N 0 H2N 0 H2NJ (N 0 (N Q (N 
CH, 	H3C CH, 
24 h 
(A) 	(B) 	(C) 	(D) 	(E) 	(F) 	(G) 
310 	 J J _ji W J L 
10 mm 	
8 
298KJ . 	 8 .__ 
6.4 6.0 	6.4 6.0 	6.4 6.0 	6.4 	6.0 	6.4 6.0 	7.0 	6.5 	6.5 6.0 ppm 
Figure 6.6 Low field region of the 'H NMR spectra of 50 .tM aqueous solutions of 
(A) [( 6-p-cym)Os(gly)C1] (20), (B) [(i6-p-cym)Os(L-ala)ClJ (21), (C) [0i6-p-
cym)Os(aiba)ClJ (22), (D) [(il  (23), (E) [( 6-p-cym)Os(pico)Cl] 
(24), (F) [( 6-bip)Os(pico)ClJ (25) and (G) ft11 6-p-cym)Os(oxine)Cl] (26) after 10 
min at 298 K in D 20 and after incubation at 310 K for 24 h. Major peaks are 
assignable to the aqua adducts (20A-26A) of the dissolved complex. Minor peaks + 
in (E) and (F) are due to the parent chloro compounds 24 and 25, respectively. Peaks 
assigned as 8 are due to the hydroxo-bridged dimer, 
cym)] . 
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'H NMR spectra of 24 in isotonic saline solution (150 mM NaCl), Ca. 10 mm 
after sample preparation, contained peaks predominantly for the intact chioro 
species, together with small peaks assignable to the aqua adducts (<20%). No new 
peaks appeared in the spectrum after storage at ambient temperature in the dark for 2 
months, Figure 6.7. 
(B) 
I 	L - - I T L—J 
(A) 
	 Lij 
9 8 7 6 5 4 3 2 ppm 
Figure 6.7 Stability of [(ij 	(24) in isotonic saline solution. Low 
field region of the 'H NMR spectrum of 1 mM 24 in isotonic saline (150 mM NaCl) 
after (A) 10 min at 298 K, and (B) after storage at ambient temperature in the dark 
for 2 months. This solution contains Ca. 80% 24 and 20% aqua complex 24A and was 
stable over this period of time. Assignments: m methanol and d dioxane (reference). 
The effects of chloride concentrations typical of blood plasma (100 mM), cell 
cytoplasm (22.7 mM) and cell nucleus (4 mM) 2 ' on the speciation of 24 in aqueous 
solution were investigated. 1 H NMR spectra of 24 (50 tM) were recorded within 10 
min of sample preparation and after incubation at 310 K for 24 h. Based on 'H NMR 
peak integrals, complex 24 was found to be present only as the intact chloro complex 
at 100 mM [Cl] (pH* 7.0), as 45% hydrolysed complex 24A at 22.7 mM [Cl] (pH* 
7.1) and as 72% 24A at 4 mM [Cl] (pH* 6.8), see Figure 6.8 and Table 6.6. 
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Figure 6.8 Effect of various concentrations of NaC1 on the low field region of the 
600 MHz 'H NMR spectrum of a 50 p.M solution of [(11 6-p-cym)0s(pico)Cl] (24) in 
D20. The chloride concentrations were chosen so as to be close to those of blood 
plasma (100 mM), cell cytoplasm (22.7 mM) and cell nucleus (4 mM). At 100 mM 
NaCl, all of complex 24 is present as the intact chloro species, at 22.7 mM 45 % has 
hydrolyzed (highlighted by boxes), and at 4 mM this has increased to 72% 24A. 
Table 6.6 Speciation of osmium arene anticancer complex 24 [(r16-p-
cym)Os(pico)Cl] at chloride levels typical of blood plasma (100 mM), cell cytoplasm 
(22.7 mM) and the cell nucleus (4 mM) 
% Aqua complex 24A 
[Cl]/mM 	 50 p.M 24 
	
1 mM24 
l0 min (298K) 	24h(310K) 
	
10 mm (298 K) 
	
24 h (310 K) 










4 	 74 	 72 	 56 	 66 
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6.3.3 Kinetics of Hydrolysis 
The kinetics of hydrolysis for complexes 20-23 and 26 were too fast to measure by 
NMR. However, the formation of the aqua complexes of 24 and 25 were followed, 
based on integration of 'H NMR peaks in spectra recorded at various time intervals 
and temperatures. These experiments were carried out at acidic pH*  (ca. 2) so that 
deprotonation of the aqua complex as a secondary reaction did not occur. The 
hydrolysis data were fitted to pseudo-first order kinetics, Figure 6.9. At 298 K, the 
half-life for hydrolysis of the p-cymene complex 24 was 0.2 h, about 2.5 times 
shorter than that for the biphenyl complex 25 (Table 6.7). Arrhenius activation 
energies (En), activation enthalpies (AH) and activation entropies (AS) (Figure 









  CT 	 D 
0 	 10 1 (K) 	 0 	 3.410 1(K) 
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-rime /h Time /h 
Figure 6.9 Time dependence for formation of the aqua complex 24A/25A (based 
on 'H NMR peak integrals) during hydrolysis in acidic D20 (pH*  2) of (A) [(1 6-p-
cym)Os(pico)C1J (24) at 298 K (Y), 288 K (.), 285 K (A) and 278 K (.) and (B) 
[( 6-bip)Os(pico)C1] (25) at 298 K (V), 288 K (.), 285 K (U)  and 278 K (A). The 
insets show the Arrhenius plot, the slope of which gives the Arrhenius activation 
energies Ea of 91.5 and 93.1 kJ mol' for the hydrolysis of 24 and 25, respectively. 
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3.3 	3.4 	3.5 	3.6 
-8.51 	10 1/T(K) 
	21 
Figure 6.10 Eyring plot for the hydrolysis of [( 6-p-cym)Os(pico)Cl] 24 (.) and 
[( 6-bip)Os(pico)Cl] 25 (•) in acidic (pH*  2) D20. The slopes and intercepts give 
activation enthalpies (AH) of 89.1 and 90.7 kJ mol', and activation entropies (t\S) 
of -64.8 and -61.6 J K' mol' for the hydrolysis of complexes 24 and 25, 
respectively. 
Table 6.7 Rate data for the aquation of complexes 24 and 25 at varying temperatures 




kJ moF 1 JK' mor' 
278 0.243 ± 0.003 2.85 ± 0.03 
285 0.697±0.018 0.99±0.03 
24 
288 1.063 ± 0.035 0.65 ± 0.02 
91.5± 3.0 89.1±3.0 -64.8± 10.5 
298 3.491 ± 0.027 0.20 ± 0.01 
278 0.092 ± 0.001 7.51 ± 0.10 
285 0.211 ±0.003 3.29±0.04 
25 
288 0.339 ± 0.008 2.04 ± 0.05 
93.1±4.4 90.7±4.3 -61.6± 15.1 
298 1.346±0.053 0.52±0.02 - 
6.3.4 Variable Temperature Dynamic NMR 
1 H NMR spectra of aqueous solutions (1 mM, 5% MeOD-d4 /95% D20) of 
complexes 23, 24 and 26 (containing predominantly the aqua complexes 23A, 24A 
and 26A) at pH*  ca. 4 (so as to prevent deprotonation of the coordinated water) were 
recorded over the temperature range 275 K - 353 K. At lower temperatures (285 K), 
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four peaks for the p-cymene arene protons of the aqua complex 23A were resolved 
(doublets at 8 6.27 and 6 6.22, 8 5.98 and 8 5.96). These peaks broadened at 323 K 
(broad peak at 6 6.26, doublet at ö 6.01), but sharpened into two doublets (8 6.27 and 
6.03) at 343 K. The aqua complex 24A gave four sharp doublets (6 6.41, 8 6.38, 
6.17 and ö 6.10) at 293 K, which merged into two broad peaks (6 6.40 and ö 6.17) at 
353 K. 
(A) 	 + (B) 
>_.cT + (C) >çil + (D) >-cp?--- 	(E) 
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J\ 323K L 	 J323 
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Figure 6.11 Low field region (showing the p-cymene ring protons) of the 'H NMR 
spectra of solutions of the chioro complexes (A) [( 6-p-cym)Os(-a1a)Cl] (23), (B) 
[( 6-p-cym)Os(pico)CJ] (24) and (C) [(i 6-p-cym)Os(oxine)C1] (26), in D20 which 
predominantly contain the aqua adducts (23A, 24A and 26A), and (D) [(q 6-p-
cym)Os(pico)Cl] (24) and (E) [(i 6-p-cym)Os(oxine)Clj (26), in methanol-d4 at 
varying temperatures. Peaks for the hydroxo-bridged dimer 8 are present in aqueous 
solutions of complex 23, and peaks for the parent chloro compounds in aqueous 
solutions of 23 and 24 are indicated by +. 
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Peaks for the intact chioro complex 24 (accounting for Ca. 13% of the species in 
solution) showed a similar behaviour: doublets at 6 6.27, 6 6.00 and 6 5.98 at 293 K 
which merged into broad peaks at 6 6.27 and 6 6.00 at 353 K. 'H NMR spectra of the 
aqua complex 26A contained two p-cymene doublets (6 6.31, 6 6.09) at 298 K, one 
of which broadened on cooling to 283 K (broad peak 6 6.3 1, doublet 6 6.08) and 
resolved into broad peaks at 6 6.35 and 6 6.28, on cooling to 275 K (Figure 6.11). 
The rates of the dynamic chemical exchange processes (k u) which gave rise to 
these line shape changes, lifetimes of the contributing species (t a), and the gibbs free 
energy (AG) at the coalescence temperature (T a) were calculated. These range from 
kc = 47 s at Tc = 353 K for 24A, 57 s -1  at 323 K for 23A and 102 s at 283 K for 
26A (Table 6.8). 
Table 6.8 Rates of the dynamic processes observed for 23A, 24A and 26A in aqueous 
solutions (k)a,  the lifetimes of the species (t)'  and the gibbs free energy (AGja at the 
coalescence temperature (T a) 
To /K 	kIs' 	tv /ms 	AG/kJmol 1 
23A 	 1323 	57 	18 	69 
24A 	 1353 	47 	21 	76 
26A 	 1283 	102 	10 	58 
a Subject to large errors as based on the data obtained over the limited temperature 
range shown in Figure 6.11. 
Evidence for a similar dynamic process was also found from 'H NMR spectra 
of solutions of the intact chioro adducts 24 and 26 in methanol-d4 . These showed a 
similar temperature dependence with the four p-cymene peaks resolving out at lower 
temperatures, Figure 6.11 D and E. However, due to the temperature constraints of 
the solvent, fast exchange conditions were not fully achieved. 
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6.3.5 Cancer Cell Cytotoxicity. 
The cytotoxicity of complexes 20-26 towards human lung A549 and ovarian A2780 
cancer cell lines was investigated. Complexes 20-23 were non-toxic up to the highest 
test concentration of 50 jIM. The IC 50  (50% growth inhibitory activity) values are 
therefore likely to be > 100 riM, and, with this cut-off value, the complexes are 
deemed inactive. However, complexes 24-26 showed moderate to high activity 
(Figure 6.12 and Table 6.9) with 10 50  values of 4-60 jiM. Notable is the high activity 
of the biphenyl/picolinate complex 25 against both cell lines (IC50 8.0 and 4.2 
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Figure 6.12 Determination of cancer cell cytotoxicity. Effect of variation in the 
concentrations of [(ij  (24), [( 6-bip)Os(pico)Cl] (25) and [(p 6-p-
cym)Os(oxine)Cl] (26) on the survival of (A) human A549 lung cancer cells, and (B) 
human A2780 ovarian cancer cells, giving the IC 50 values in Table 6.9. 
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Table 6.9 In vitro growth inhibition of human 
A549 lung and A2780 ovarian cancer cells 
1050/ PM 	IC50! PM 
Compound 
A549 	A2780 
20 >100 >100 
21 >100 >100 
22 >100 >100 
23 >100 >100 
24 17 4.5 
25 8 4.2 
26 60 15.2 
RU26a 
- >100 
a. Ru analog of 26, [(r 6-p-cym)Ru(oxine)C1], Ref 36. 
6.3.6 Binding to Nucleobases, Possible Target Sites on DNA 
The reactions of the cytotoxic complex, [(r 6-p-cym)Os(pico)Cl] 24, with model 
nucleobases was investigated, as binding to DNA is often associated with the 
cytotoxic action of metal anticancer drugs.' 2,22 
In the 'H NMR spectrum of a solution containing 24 (1 mM) and 1 mol equiv 
9-ethylguanine (1320, pH*  7.68, 298 K), new peaks assignable to the 9EtG adduct 
24G appeared (Figure 6.13A), with an approximate half-time for reaction, based on 
peak integrals, of 3.5 h (Figure 6.1313). ESI-MS studies on this NMR sample gave a 
major peak at mlz 627.2, consistent with the presence Of [(116-p-
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Figure 6.13 (A) Low field region of the 'H NMR spectrum of an aqueous (020) 
solution of [(il 	24 (1 mM) and 1 mol equiv 9EtG after 45 h at 
298 K. Peaks assigned to the aqua complex, [(TI 	24A, H8 of 
free 9EtG H8-G and the 9EtG bound product [( 6-p-cym)09(pico)(9EtG)] 24G are 
indicated. (B) Time dependence, based on 'H NMR peak integrals, for formation of 
[( 6-p-cym)Os(pico)(9EtG)f (24G) in the above reaction. 
Complex 24G was synthesised, and the X-ray crystal structure of the PF 6 salt 
confirmed the binding of 9EtG by N7 (Figure 6.14A). An interesting feature of the 
structure is the hydrogen bonding between NH and NH 2 of 9EtG and the two 0 
atoms of the chelated picolinate on an adjacent molecule (N(73)H(73l)"0(92) 1.91 
A and N(l13)H(l 131)"0(82) 2.19 A) giving rise to chains in the crystal, Figure 
6.1413 and Table 63C. 
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Figure 6.14 (A) X-ray crystal structure and atom numbering scheme for the cation 
[( 6-p-cym)0s(pico)(9EtG)] (24G), short range interactions between chelated 
picolinate CH of the pyridine and 9EtG exocyclic oxygen, dictate the orientation of 
binding. (B) H-bonded dimers between the oxygen 092/082 of the chelated pico 
ligand and N  H (N73 H731 1) and C2NH2 (Nil 3H 113 1) of coordinated 9EtG from 
an adjacent molecule. (50% probability ellipsoids). Additional H atoms and the PF6 
counter ion have been omitted for clarity. 
Binding to N7 of 9EtG in 24G was further confirmed by a pH*  titration, 
monitored by 1 H NMR spectroscopy, over the pH*  range 3-12. Peaks assigned to 
species 24G shifted to high field with increasing PH*,  with an associated pKa* 
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Figure 6.15 Dependence of the 'H NMR chemical shift of (A) the H8 peak of 
bound 9EtG in [( 6-p-cym)Os(pico)(9EtG)] (24G), and (B) the H8 and H2 peaks of 
bound 9EtA in [(il  (24A7), on pH*.  Binding to the purine 
base is through N7 in both complexes, with pKa* values for Ni protonation of 8.97 
and 2.06 for 24G and 24A7, respectively. 
Addition of 1 mol equiv adenosine (Ado) to an aqueous solution of 24 (1 
mM,pH* 7.38, 298 K), gave rise to little product in the 'H NMR spectrum after 5 
mm, but after 24 h there were two new sets of peaks (38% major species 24Adol and 
21% minor species 24Ado2). ESI-MS studies on this NMR sample gave peaks at m/z 
+ 448.2 and 715.1, consistent with {(r 6  -p-cym)Os(pico)} ({24-Cl} +, calcd m/z 448.1) 
and [(il 	(24Ado, calcd m/z 715.2), respectively. 
Complex 24A7, the 9-ethyladenine (9EtA) analogue, was synthesised and the 
X-ray crystal structure of the PP6 salt showed the presence of N7-bound 9EtA, 
Figure 6.16A. Hydrogen bonds link independent coplanar 9EtA units in the crystal 
structure, N(51)H(51A) ... N(41) 2.11 A (Figure 6.16B). NH of 9EtA and the chelated 
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Figure 6.16 (A) X-ray crystal structure and atom numbering scheme for the cation 
[( 6-p-cym)Os(pico)(9EtA)} (24A7). Short range interactions between chelated 
picolinate oxygen and 9-ethyladenine NH2 are present, dictating the orientation of 
binding. The p-cymene arene in the crystal structure of 24A7PF6 0.5Et2O shows 
disorder over two positions (with ¼ occupancy of a diethyl ether molecule), but only 
one is shown here. (B) H-bonded dimers in the X-ray crystal structure of metal-
modified A:A homo base pairing between C2NH2 (N51H51 1) and NI (N41) of an 
adjacent molecule for [(il  (24A7) (50% probability 
ellipsoids). Additional H atoms, solvent molecule and the PF6 counter ion, have been 
omitted for clarity. 
The chemical shifts of the H8 and H2 singlets of 9EtA bound to Os in 
aqueous solutions of 24A7 shifted to high field with increase in PH*  over the range 1-
8, with an associated pI( of 2.06±0.02 (Figure 6.1 5B), assignable to NI protonation 
of N7-bound 9EtA. 
No new peaks appeared in the 'H NMR spectrum of 24 after addition of 
thymidine (Thy), over a period of 24 h (3 10 K). However, for cytidine (Cyt) a small 
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set of new peaks appeared accounting for < 10% of 
{ (





24 h at 310 K 
10 mm 
Figure 6.17 'H NMR spectra of 1: 1 solution of {( 6-p-cym)0s(pico)C1] 24 and (A) 
Cyt or (B) Thy after incubation for 10 min and 24 h at 310 K. After incubation for 24 
h, <10% of 24 reacted with Cyt, and Thy did not react at all. 
The addition of both 1 mol equiv 9EtG and 1 mol equiv 9EtA to 1 mM or 50 
l.tM equilibrium solutions of 24 (81% and 90% aqua adduct 24A, respectively) did 
not result in any new peaks after ca. 5 mm. However, after incubation at 310 K for 
24 h new peaks for 24G and 24A7 had appeared. Based on peak integrals (Figure 
6.18), the 1 mM solution of 24 contained 6.8% aqua adduct 24A, 80.7% of the 9EtG 
adduct 24G and 12.5% of the 9EtA adduct 24A7, a ratio of ca. 0.5:6:1, whereas the 
50 M solution of 24 contained 58.7% aqua adduct 24A, 32.9% 24G and 8.4% 
24A7, a ratio of ca. 7:4:1. 
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Figure 6.18 'H NMR spectra showing the arene CH region for 1: 1: 1 competition 
reactions of 24 with 9EtG and 9EtA in D20 at 1 mM and 50 p.M. (A) and (B) show 
the spectra obtained ca. 10 min after sample preparation, and (C) and (D) those 
obtained after incubation at 310 K for 24 h. 24 and 24A correspond to the intact 
chioro and aqua species, respectively, 24G to {( 6-p-cym)Os(pico)(9EtG)] and 
24A7 to [( 6-p-cym)Os(pico)(9EtA)]. 
Solutions of the 9EtG adduct 24G, [(ij 	in D20 at 
varying concentrations (2 mM - 20 p.M) were prepared and their 'NMR spectra 
recorded ca. 10 min after sample preparation, and after incubation at 310 K for 24 h, 
6 days and 13 days. No new peaks were present in the spectra recorded after 10 mm, 
but after 24 h minor new peaks (3% at 2 mM and 12% at 20 jiM) appeared, 
consistent with formation of aqua complex 24A and free 9EtG, see Figure 6.19A/C. 
After incubation of the samples for 6 and 13 days, these peaks increased in intensity. 
After incubation of the 20 p.M solution of 24G for 13 days at 310 K, 40% of the 
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intact complex was still present. Attempts to analyse the kinetics as a simple 
dissociation were unsuccessful, suggesting that equilibrium had not yet been reached 
under these conditions. Similarly the stability of 2 mM - 20 tM aqueous solutions of 
the 9EtA adduct 24A7, [(1 6-p-cym)Os(pico)(9EtA)f, were investigated by 'H NMR 
spectroscopy over a period of 24 h at 310 K. Again no new peaks were present in the 
spectra recorded after 10 mm, however after 24 h at 310 K, peaks assignable to free 
9EtA and the aqua osmium complex 24A were present and increased in relative 
proportion with decrease in Os concentration, Figure 6.1913/1). 
L 
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Figure 6.19 Low field 'H NMR spectra of 1 mM, 100 tM and 20 ptM aqueous 
solutions of (A) [(ij  (24G) and (B) [(r 6-p-
cym)Os(pico)(9EtA)] (24A7) directly after sample preparation, and (C) and (D) 
after incubation at 310 K for 24 h. Peaks for the free aqua adduct 24A are highlighted 
by boxes. Complex 24G remains mostly intact, whereas complex 24A7 dissociates 
almost completely after 24 h (for determination of stability constant, see Figure 
6.20). 
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An equilibrium binding constant of log K 3.95 was obtained from the slope of the 
plot of [24A7]/[free 9EtG] vs. [24A], based on peak integration, Figure 6.20. 
 
0 	100 	200 	300 	400 
[24A] / pM 
Figure 6.20 Plot of ftq6-p-cym)Os(pico)(9EtA)]t f[free 9EtA] versus the aqua adduct 
24A, [( 6-p-cym)Os(pico)(OD 2)], for determination of the apparent stability 
constant of [(i 6-p-cym)Os(pico)(9EtA)f (24A7) in D 20. Concentrations are based 
on 'H NMR peak integrals of spectra from varying concentrations of aqueous 24A7 
after incubation at 310 K for 24 h (see Figure 6.19). From the slope of the plot, a Log 
K value of 3.95 was obtained for the dissociation of [(1 6-p-cym)Os(pico)(9EtA)J 
24A7 into [(i 6-p-cym)0s(pico)(0D 2)] 24A and free 9EtA. 
6.4 Discussion 
The aim of this work was to investigate whether the aqueous chemistry of 
organometallic osmium(II) arene complexes can be fine-tuned so as to achieve 
cancer cell cytotoxicity and design potential osmium anticancer agents. In the 
previous chapters it was found that osmium(II) arene complexes containing 
ethylenediamine (en) as a N,N-chelating ligand hydrolyse slowly (ty, 6.4 h at 298 K 
and pH*  Ca. 7) whereas those with 13-diketonate 0,0-chelating ligands hydrolyse 
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rapidly and are deactivated by chelate ligand loss under biological test conditions. 19 
In this chapter complexes with mixed N,0-chelating ligands are investigated, and it 
is shown that the aqueous reactivity can be fine-tuned even within N,0-chelates by 
the choice of the types of N- and 0-donor groups. 
Chloride complexes 20-26 were synthesized containing primary amine and 
tertiary pyridine nitrogens as N-donors and carboxylato or aryloxides as 0-donors. 
They were expected to have the familiar half-sandwich, piano-stool structure, and 
this was verified by X-ray crystal structure determination for two of them, the p-
cymene/picolinate complex 24, and the p-cymene/hydroxyquinolate complex 26. The 
structures of Os" arene complexes are often similar to those of their Ru' 1 analogues. 
Both 26 and its Ru" analogue 14  form almost identical dimers in their crystal 
structures, and complex 24 is structurally very similar to the related Ru" complex, 
[(61,3,5C6Me3H3)Ru(pico)cl]•3 The Os-Cl bond length in 
26 (2.4235(7) A) is 
longer than that in 24 (2.4048(13) A), consistent with the increased charge at the Os" 
centre in 26 and the slower hydrolysis rate of 24. A similar difference in bond length 
and hydrolysis rate was noted for Os"/Ru" acetylacetonate and Os"/Ru" 
ethylenediamine half-sandwich complexes.' 9,23  The N,O-chelated complexes studied 
here are racemates due to the presence of a stereogenic osmium centre. 
6.4.1 Aqueous Solution Chemistry 
Aminoacidate complexes 2023 containing 5-membered chelate rings hydrolysed 
rapidly (ty, < mm) in agreement with a report for ftrì 6-benzene)Os(gly)Cl] (ty. 0.6 mm 
at 298 K),24 a characteristic shared by anionic 0,0-chelated Os" and Ru n arene 
complexes. 19,20,21  Substitution of the primary amine NH 2 donor by the it-acceptor 
pyridine (complexes 24-25) in N,0-chelated complexes, slows down the rate of 
hydrolysis, and replacement of the arene p-cymene (complex 24) by the more 
electron-deficient arene biphenyl 24  (complex 25) slows down the rate of hydrolysis 
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even further. The hydroxyquino late complex (26) also hydrolyses rapidly despite the 
presence of the it-acceptor pyridine N-donor. This can be attributed to the higher 
partial charge on the aryloxide 0-donor compared to the carboxylate group in 24 
where the charge is delocalised over two oxygens. The large negative activation 
entropies (ASs) obtained for the hydrolysis of 24 and 25, suggest that the mechanism 
involves an associative pathway. 
For all of the complexes studied, we observed slow exchange between the 
chioro and aqua species on the 'H NMR timescale, a characteristic of N,N-chelated 
complexes, but not 0,0-chelated f3-diketonate complexes. Hence it appears that N,0-
chelated complexes display aqueous chemistry behaviour intermediate between that 
of complexes containing neutral N,N- and anionic 0,0-chelating donors, and that, 
within the group of N,0-chelates, the choice of N- and 0-donor group can have a 
significant effect. 
The acidity of the aqua ligand in the aminoacidate complexes, 20A-23A, 
(pKa* 7.14-7.55) is intermediate between that of complexes containing the neutral 
N,N-chelating ethylenediamine (en), [(ij  (pKa* 6.37), and 
anionic 0,0-chelates such as acetylacetonate (acac), [( 6-p-cym)0s(acac)(0D 2 )] + 
(pKa* 7.84)) Introduction of the it-acceptor pyridine as the N-donor reduces the 
electron density on the metal, lowering the pKa*  of the coordinated water by 0.6 pKa* 
units, Table 6.4.25 
Due to the unsymmetrical nature of the chelating ligands, the osmium centre 
is chiral in all the complexes studied, as is evident from their aqueous 'H NMR 
spectra in which all of the protons of the coordinated arene are magnetically 
inequivalent. This is in contrast to the unsymmetrical 0,0-chelated maltolate 
complexes, for which averaging of proton environments is observed due to a 
dynamic (ring-opening) process which occurs at the metal centre, see Chapter 4. 20 
Complex 24 for example, in the aqueous solution gives four p-cymene 'H NMR 
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peaks, each peak showing the same pH* dependence, Figure 6.4A. However, 
complex 26 behaves differently during the pH*  titration. At acidic pH*  there are only 
two sharp doublets in the spectrum, these broaden as the pH*  is increased and resolve 
out into the expected four doublets, one for each arene ring proton, at basic pH* 
(Figure 6.413). This suggests that in acidic solutions the dynamic process involves 
rapid chelate ring opening via oxygen atom protonation, which slows down at basic 
pH*. 8-Hydroxyquinolate is a stronger base (pKa HQH 5.0±0.1)26 than 2-picolinate 
(pKa picoH 1.01)27  and the other carboxylate N,O-ligands investigated here, 
suggesting that it would be more readily protonated. This dynamic process was rapid 
for the maltolate complex {( 6-p-cym)Os(mal)(OD 2)], even at basic pH*  which is in 
keeping with the even higher basicity of maltolate (pKa malH 8.62).2028  The dynamic 
process was monitored for D20 solutions of 23, 24 and 26 at various temperatures. 
The exchange rates imply that ring-opening occurs most readily for the oxine 
complex 26, and least readily for the picolinate complex 24, which is again 
consistent with the acidity of the chelated oxygen atom (pKa of free 13-alanine is 
3.43 ). 29  Therefore, the more acidic ligands exhibit enhanced stability with respect to 
chelate protonation and ring-opening, which may also contribute to the higher 
stability of complexes with respect to dimer formation. 
It seems likely that the mechanism of hydroxo-bridged dimer formation 
initially involves breakage of the Os-O bond, assisted by protonation, followed by 
Os-N bond breakage. Dimer formation does not occur when the chelated ligand 
contains a pyridine N, despite the ready protonation of the coordinated oxygen in 
complex 26. Evidently the Os-N(pyridine) bond does not break under the conditions 
studied, preventing formation of the hydroxo-bridged dimer (8). Clearly the 
incorporation of a it—acceptor like pyridine is crucial for the overall stability of the 
complex, due to the strengthening of the metal-N bond formed. Complexes 
containing 6-membered aminoacidate chelate rings (complex 23) show less stability 
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with respect to dimer formation than their 5-membered analogues (complexes 20- 
22), a trend similar to that found previously for anionic 0,0-chelates as reported in 
Chapter 420 
At high chloride concentrations typical of blood plasma (100 mM) complex 
24 was present as the less reactive intact chloro species. At the lower chloride 
concentration of 4 mM (a typical nucleus concentration) 2 ' the complex is activated 
by hydrolysis, with 72% present as the reactive aqua species (24A). This suggests a 
possible mode of activation towards DNA binding. In addition, complex 24 was 
stable in isotonic saline solution when stored in the dark at ambient temperature for 
two months, making aqueous drug formulations feasible. 
6.4.2 Cytotoxicity 
Complexes containing aminoacidate chelates (20-23) hydrolysed rapidly, were 
unstable with respect to hydroxo-bridged dimer (8) formation, and inactive towards 
human ovarian and lung cancer cells. However, complexes 24-26 containing a 
pyridine as the N-donor atom which were stable at micromolar concentrations and 
reacted with purine nucleobases exhibit cytotoxic activity (IC 50 4-60 [LM, Table 6.9). 
Activity increases with a decrease in the rate of hydrolysis, and was greatest for 
complex 25 which exhibited the slowest kinetics. The rate of hydrolysis of 25 is 
comparable to the rate of hydrolysis of active ruthenium arene en complexes. 30  IC50 
values for 25 of 8 and 4.2 p.M for the A549 and A2780 cancer cell lines, respectively, 
are comparable to those of the anticancer drug carboplatin (IC 50 10 p.M and 6 p.M for 
A549 and A2780, respectively).3 1.32 
Figure 6.21 provides an overview of the relationships between cancer cell 
cytotoxicity, complex stability with respect to dimer formation, rates of hydrolysis 
and acidity of coordinated water. This work demonstrates how rational chemical 
design can be applied to osmium arene complexes resulting in specific windows of 
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reactivity, stability and cancer cell cytotoxicity. 
IC50 
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Figure 6.21 Bar charts illustrating the relationship between cytotoxicity towards 
human A2780 ovarian cancer cells, stability with respect to inert hydroxo-bridged 
dimer formation, rates of hydrolysis and acidity of aqua adduct for osmium arene 
complexes [(TI  containing different XY = N,N-, N,O- and 0,0-
chelating ligands. 
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6.4.3 Binding to Nucleobases 
Nuclear DNA is often believed to be the major target of metal-based anticancer 
complexes. 22  Osmium arene complexes, [(i
6  -arene)Os(XY)Cl] , containing a 
neutral N,N-chelate bind selectively to G type nucleobases and those containing an 
anionic 0,0-chelate have similar affinities for both G and A type nucleobases.' 9 ' 2° 
The competition reactions carried out with complex 24 show binding to both G and 
A, but with a strong preference for G. It is notable that even at micromolar 
concentrations, >40% of the osmium is bound to purine nucleobases. Intriguingly, 
the binding constant for 9EtA is only moderate (log K 3.95) and equilibrium for 
dissociation of 9EtA from [(il  (24A7) is reached within 
24 h of incubation (310 K). In contrast, dissociation of the 9EtG adduct [(r 6-p-
cym)Os(pico)(9EtG-N7)] (24G) at micromolar concentrations occurs relatively 
slowly and equilibrium is not reached even after incubation at 310 K for 13 days. 
Hence, once G adducts (on DNA, or RNA) are formed they are likely to persist. Such 
kinetic stability may also make G adducts less susceptible to repair compared to A 
adducts. Binding to the N7 of 9EtG or 9EtA acidifies the NI proton, which is 
consistent with metallation at the N7 site. 11,33,34  Little and no binding of [( 6 ..p6 
cym)Os(pico)Cl] to the pyrimidine bases, Cyt and Thy, was observed. The N3 
position is sterically crowded in both pyrimidine bases making it an unfavourable 
binding site, and at physiological pH N3 of Thy is protonated making it less available 
for binding (and involved in Watson-Crick H-bonding). 
A search of the Cambridge Database revealed no previously reported X-ray 
crystal structures of osmium complexes containing coordinated guanine or adenine 
nucleobases. However, the structure of [Os(9MeHyp)(NH 3) 5 ]Cl3 H20 (9MeHyp = 9-
methylhypoxanthine), which contains the purine base hypoxanthine (Hyp), has been 
reported .35  The X-ray structures of 24G and 24A7 confirmed the binding of 1 (116-p-
cym)Os(ico)} to the sterically non-hindered N7 site. In solution a minor product 
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(24Ado2; Ca. 20%) also formed with adenosine, and can be assigned to an NI-bound 
species. The Os-N7(nucleobase) bond lengths compare well with those reported for 
[Os(9MeHyp-N7)(NH 3 ) 5}Cl3 H20 (2.107 A), [(i 6-p-cym)Ru(gly)(9EtG-N7)] PF 6 
(2.136 A)36 and [(11 6-benzene)Ru(L-ala)(9EtA-N7)]Cl (2.112/5 A).37 Intriguingly the 
nucleobase functionality lies on opposite sides of the chelate for G and A bases. The 
exocyclic oxygen of 9EtG is on the N-chelated side of the picolinate ligand, and the 
NH2  of 9EtA is on the 0-chelated side (as is also the case for related ruthenium 
complexes), 36 '37  both forming favourable short-range interactions with the chelate 
(0 CH and NH 0, respectively). 
Homo base-pairing involving C6NH 2 N1 (C51NH2 ... N41) H-bonding, is 
observed between the metal-modified adenine fragments in the X-ray crystal 
structure of 24A7 (Figure 6.1613). This base-pairing is of the extended pairing 
scheme as the N7 position is blocked by the coordinated osmium. Non-Watson-Crick 
adenine homo base-pairing is not unusual, and is also present in the X-ray crystal 
structures of 2',3'-0-anhydroadenosine 38 and tetraaquo-(9-methyladenine) copper(II) 
sulphate monohydrate. 39 '4°  Evidence for such pairing has even been found in 
cytosine-rich DNA at low pH. 41 '42  Such binding to DNA might therefore result in 
mismatches in the base-pairing of adenine. The binding of cisplatin to DNA results 
in 25% of total lesions being ApG intrastrand adducts, and these are 5 times more 
mutagenic than the more common GpG adducts. 43 Therefore, such interactions 
resulting from A binding on DNA, could contribute to the anticancer activity of 
complex 24. 
6.5 Conclusions 
The goal of this chapter was to design osmium arene complexes which are cytotoxic 
towards cancer cells and therefore potential novel anticancer drugs. This has been 
achieved by employing chemical principles to tune the reactivity, aqueous chemistry 
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and stability of this class of complexes. 
Half-sandwich, piano stool Os" arene complexes of general formula [(p6. 
arene)Os(N,0)Cl], containing an anionic N,0-chelate, have been found to display 
chemical reactivity intermediate between those of the neutral N,N- and anionic 0,0-
chelated parent compounds. However, even within this group of N,0-chelates, the 
choice of the N- and 0-donors is crucial. The more acidic the chelated oxygen the 
less readily ring-opening occurs, and the less readily hydroxo-bridged dimers are 
formed. More critically, the introduction of a it-acceptor such as pyridine (as in 
complex 24 [(ij  minimizes chelate ring-opening through 
strengthening the Os-N bond. These factors appear to be crucial in maintaining 
stability with respect to formation of inert (biologically inactive) hydroxo-bridged 
dimers which can deactivate osmium arene complexes even at micromolar 
concentrations and in the presence of saline (0.1 M).' 9 '2° 
Complex 24 shows a strong preference for binding to G bases over A bases, 
with little or no reaction with pyrimidines. The X-ray crystal structures of the G and 
A adducts of complex 24 are, as far as I am aware, the first osmium G and A adducts 
to be reported. Reactivity towards DNA nucleobases, along with the aqueous 
chemistry and stability (at micromolar concentrations) make [( 6-p-cym)Os(pico)ClJ 
24, [( 6-bip)0s(pico)Cl] 25 and [( 6-p-cym)0s(oxine)Cl] 26 suitable candidates for 
further investigation as anticancer agents. These complexes exhibit activity against 
human A549 lung and A2780 ovarian cancer cells, comparable to that of carboplatin. 
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7.1 Conclusions 
When this work began not much was known about the aqueous chemistry of osmium 
arene complexes. The expected slower hydrolysis of osmium complexes, [(p6.. 
arene)0s(LL)ClJ, compared to their ruthenium analogues was observed (100 
times). However, the rates of hydrolysis are highly sensitive to the nature of the 
chelating ligand (LL), providing a huge window of reactivity in stark contrast to the 
inert reputation of osmium. Those containing an anionic 0,0-chelating ligand were 
found to hydrolyse rapidly (too fast to monitor by NMR), but these complexes were 
hydrolytically deactivated by formation of inert hydroxo-bridged dimers, [71 6 
arene)0s(i-01-1) 3 0s( 6-arene)] , at micromolar concentrations, even in the presence 
of saline. This was unexpected, and the formation of these dirners in the aqueous 
solution chemistry of both osmium and ruthenium arene complexes was established. 
In addition, water coordinated to osmium was found to be appreciably more acidic 
than when coordinated to its ruthenium analogue (ca. 1.5 pKa units), providing 
possible explanation for the more ready formation of hydroxo bridged dimers from 
osmium complexes. Again the choice of chelating ligand (LL) radically affects the 
acidity of the coordinated water, which spans a huge range from pKa 5.8 to 8.5. 
This thesis has been concerned with the rational design of osmium(II) arene 
complexes for use as anticancer agents, by tuning the chemical reactivity. Complexes 
are reported that display activity (IC 50 6-10 [tM, A549 cells) comparable to 
carboplatin, and are significantly more active than the only other reported osmium 
arene complex [(TI 6_arene)Os(pta)CI 2 1 (IC 50 1430 jiM, A549 cells)' where pta = 
phosphine 1,3,5-triazi-7-phosphatricyclo[3.3.1.I]decane. This has mainly been 
achieved by changing the nature of the chelating ligand, though further tuning by 
variations in the choice of arene (four different arenes were explored in this work) 
and the leaving group (in this thesis always chloride) are possible. Clearly these 
results warrant further investigation into the therapeutic benefits of osmium 
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complexes, which have till now been relatively neglected. The following section of 
this chapter explores future work that could be carried out on this project, in some 
cases based on preliminary results obtained in this thesis. 
7.2 Future Work 
7.2.1 Structural Variations to Picolinic Acid Backbone 
As described in Chapter 6, optimum reactivity, stability and ultimately cancer cell 
cytotoxicity, was achieved when the chelating ligand (LL) in [(71 6_arene)Os(LL)CI] n  
is picolinate (Figure 7.1). 
H0 N 0 
H m> H m 
H P  
Figure 7.1 Structure of the chelating ligand picolinate, where H 0, H01 and H 
correspond to the protons at the ortho, meta and para positions respectively. 
Substituting the ortho and para positions, the most sensitive to electronic effects, 2 
with electron donating and electron withdrawing groups would influence the amount 
of negative charge localised on the osmium, and, in turn, this would affect the rate of 
hydrolysis and the acidity of coordinated water. Based on the results obtained in 
Chapters 5 and 6 relating activity to reactivity (rates of hydrolysis), complexes 
containing electron withdrawing substituted chelates would be expected to display 
enhanced activity. 
7.2.2 0,0-Chelated Complexes 
In Chapter 4 the osmium(II) arene complex containing the 5-membered 0,0-chelate 
pyridonate (pyrid), was found to be significantly more stable than those containing 
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either the 5-membered maltolate or 6-membered acetylacetonate chelates, and 
subsequently showed moderate activity against the human A2780 ovarian cancer cell 
line (IC 50  ca. 30 jiM). Ruthenium complexes containing maltolate or acetylacetonate 
as a chelate were found to be more stable than their osmium analogues, therefore it is 
proposed that the ruthenium complex containing chelated pyridonate, [(p6 
arene)Ru(pyrid)CIJ, would display even greater stability and subsequently greater 
activity against cancer cells. 
Pyridinoate was initially used as a chelate for a different purpose. This work 
attempted to explore the possibility of using complexes of the type [(11 6 
arene)Os(O,O-chelate)Cl] as a drug delivery system. The complex containing the 
chelated ligand is relatively inactive. The free ligand, the release of which was 
studied in Chapter 4, is the active drug (pyrid is in clinical trials for the treatment of 
chronic iron overload 3).  On release of the active drug, the osmium may be excreted 
as the inert non-toxic hydroxo-bridged dimer, [(ij  
The release of other biologically relevant 0,0-chelators or fluorophores may be of 
interest. 
7.2.3 S-, P- or Se-Chelated Complexes 
This thesis has been concerned only with the investigation of chelating ligands 
containing nitrogen, oxygen or a combination of these. Other heteroatoms such as 
sulphur, selenium or phosphorus may be of interest. 4-7 
Initial results with sulphur showed that bifunctional complexes containing 
monodentate S-bound ligands like DMSO in [(i 6-arene)Os(SO(CH3)2-S)Cl2], were 
unstable in solution with respect to hydroxo-bridged dimer formation. However, 
results for the anionic complex containing the S,S-chelating ligand, [(-q 6 
arene)Os(dithio-S,5)Cl]Na where dithio = dithiotoluene, see Figure 7.2, were very 
exciting. 
228 





Figure 7.2 Diagram of the anionic osmium(II) arene complex containing the S,S-
chelate, dithiotoluene. 
This is the first anionic complex investigated in our laboratory. Unfortunately this 
dark red complex appeared to be completely insoluble. However, when tested both 
filtered and un-filtered (greater activity) solutions showed some activity against 
human A549 lung and A2780 ovarian cancer cells. For example a non-filtered 
solution (suspension) made up to be 50 tM resulted in only 34% cell survival when 
tested against the A549 cell line. This suggests that complexes containing S,S-
chelates and an overall negative charge with improved water solubility, have the 
potential to be highly active anticancer agents. 
The use of biologically-relevant ligands (or variations thereof), such as the 
dithiolene chelated to molybdenum in molybdopterin (Figure 7.3), may provide 




Figure 7.3 Molybdoterin is a cofactor found in a number of enzymes, for example 
aldehyde ferredoxin oxidoreductase, DMSO reductase, xanthine oxidase and sulphite 
oxidase. 
229 
Chapter 7 Conclusions & Future Work 
7.2.4 Cyclopentadienyl Osmium(II) Complexes 
In this thesis four arene ligands have been investigated; biphenyl, benzene, p-cymene 
and tetrahydroanthracene. The different arenes influence the overall reactivity of the 
complex, but these effects are relatively subtle. Therefore, it may be of interest to 
investigate osmium(II) complexes containing cyclopentadienyl (Cp) as the arene. 
There is substantial literature on this class of complexes . 8 ' ° A rate-enhancement of 
five orders of magnitude for ligand exchange was reported by Luginbuhl et al on 
substituting neutral benzene, [(TI  with anionic Cp, [(5 
Cp)Ru(CH 3 CN) 31t'' It seems prudent to attempt this initially for relatively 
stable/inert complexes containing bipyridine or phenanthroline ligands, to see if their 
reactivity can be enhanced sufficiently so as to be of some biological significance. 
7.2.5 DNA Binding Studies and Antimetastatic Potential 
In this thesis I have shown that active complexes bind to DNA nucleobases and 
therefore nuclear DNA may be a possible target and its damage responsible for the 
death of cancer cells. More extensive binding experiments are necessary, including 
DNA binding and ease of repair of DNA modified by osmium(II) arene complexes. 
However, the possibility of different biological targets should also be 
explored. In addition, toxic doses need to be established and these complexes should 
be screened for any antimetastatic (prevents the spread of secondary cancer) activity, 
as demonstrated by the ruthenium drug NAMI-A which has currently completed 
phase 1 clinical trials successfully. 
This work is currently being carried out by our collaborators. 
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7.2.6 Electron Microscopy 
One of the principal uses of osmium involves staining biological samples with the 
tetroxide, Os04 , for use in various forms of electron microscopy. Osmium is chosen 
as it is extremely electron dense. These procedures allow the heavy metal (osmium) 
to be fixed in the cell membrane or other parts of the cell structure. An example of 
osmium tetroxide staining using TEM (transmission electron microscopy) is shown 
in Figure 7.3. 
k.A.' 
•0' 





Figure 7.3 TEM image of cells from the fiat tongue of Platernypallidipectoris fixed 
with osmium tetroxide. Where s = nucleus and m = mitochondria. Figure reproduced 
from reference 12. 
It seems logical to exploit this feature and use it to determine where active 
osmium(I1) arene complexes are localising in the cell. This may provide insight into 
possible biological targets (e.g. nucleus, mitochondria). Unlike other techniques 
aimed to track a compounds distribution in the cell, like attaching a fluorophore to 
the complex, this technique does not alter the chemistry or biological activity of the 
complex being studied and is intrinsic to its natural properties. 
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